<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:NAOV="http://nanovibronix.com/20250930"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="naov-20250930.xsd" xlink:type="simple"/>
    <context id="From2025-01-01to2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-11-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2025-11-14</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2025-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_TechnologyBasedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CustomerListsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_OfficeEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_OfficeEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-14_custom_MergerAgreementMember_custom_PreFundedWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-14</instant>
        </period>
    </context>
    <context id="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="From2025-02-142025-02-14_custom_MergerAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-14</startDate>
            <endDate>2025-02-14</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_MergerAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ENvueMedicalHoldingsCorpMember_custom_CommonStockAndPreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:CommonStockAndPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ENvueMedicalHoldingsCorpMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ENvueMedicalHoldingsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember_us-gaap_TrademarksAndTradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember_custom_ProprietaryTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NAOV:ProprietaryTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember_us-gaap_CustomerRelationshipsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-03-132025-03-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2025-03-13</startDate>
            <endDate>2025-03-13</endDate>
        </period>
    </context>
    <context id="From2025-08-112025-08-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="AsOf2025-03-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2025-03-13</instant>
        </period>
    </context>
    <context id="AsOf2025-08-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2025-08-11</instant>
        </period>
    </context>
    <context id="From2025-05-152025-05-15_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-15</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-15_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-15</instant>
        </period>
    </context>
    <context id="From2025-05-152025-05-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2025-05-15</startDate>
            <endDate>2025-05-15</endDate>
        </period>
    </context>
    <context id="From2025-05-162025-07-02_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-16</startDate>
            <endDate>2025-07-02</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-02_us-gaap_SeriesGPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-02</instant>
        </period>
    </context>
    <context id="From2025-05-162025-07-02_us-gaap_SeriesGPreferredStockMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-16</startDate>
            <endDate>2025-07-02</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-14</instant>
        </period>
    </context>
    <context id="AsOf2025-02-14_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-14</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_SeriesXPreferredStockMember_custom_SeriesXAmendmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SeriesXAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_SeriesXPreferredStockMember_custom_SeriesXAmendmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SeriesXAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-05-12_srt_MinimumMember_custom_SeriesXPreferredStockMember_custom_SeriesXAmendmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SeriesXAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="AsOf2025-05-12_srt_MaximumMember_custom_SeriesXPreferredStockMember_custom_SeriesXAmendmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SeriesXAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="From2025-05-122025-05-12_custom_SeriesXPreferredStockMember_custom_SeriesXAmendmentAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SeriesXAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-12</startDate>
            <endDate>2025-05-12</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-22_custom_JulyPurchaseAgreementMember_custom_SeriesXPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="From2025-07-222025-07-22_custom_JulyPurchaseAgreementMember_custom_SeriesXPreferredStockMember_custom_JulyPrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NAOV:SeriesXPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">NAOV:JulyPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-18_us-gaap_SeriesHPreferredStockMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:JulyTwoThousandTwentyFivePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="AsOf2025-07-18_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:JulyTwoThousandTwentyFivePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="From2025-07-182025-07-18_us-gaap_SeriesHPreferredStockMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:JulyTwoThousandTwentyFivePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-18</startDate>
            <endDate>2025-07-18</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-18_us-gaap_WarrantMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:JulyTwoThousandTwentyFivePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-18</instant>
        </period>
    </context>
    <context id="From2025-07-222025-07-22_custom_JulyTwoThousandTwentyFivePrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">NAOV:JulyTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="From2025-07-222025-07-22_custom_JulyTwoThousandTwentyFivePrivatePlacementMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">NAOV:JulyTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_JulyTwoThousandTwentyFivePrivatePlacementMember_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">NAOV:JulyTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_JulyTwoThousandTwentyFivePrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">NAOV:JulyTwoThousandTwentyFivePrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-222025-07-22_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-22</startDate>
            <endDate>2025-07-22</endDate>
        </period>
    </context>
    <context id="AsOf2025-07-22_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-22</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_SeriesHPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-09-162025-09-16_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-16</startDate>
            <endDate>2025-09-16</endDate>
        </period>
    </context>
    <context id="From2025-09-162025-09-16_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-16</startDate>
            <endDate>2025-09-16</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-16_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-16</instant>
        </period>
    </context>
    <context id="AsOf2025-09-16_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PrefundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-16</instant>
        </period>
    </context>
    <context id="From2025-09-162025-09-16_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-16</startDate>
            <endDate>2025-09-16</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_StockOptionMember_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NAOV:TwoThousandAndTwentyFourLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2025-03-14_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NAOV:TwoThousandAndTwentyFourLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-14</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NAOV:TwoThousandAndTwentyFourLongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_SeriesA1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:SeriesA1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_SeriesA2WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:SeriesA2WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-30</instant>
        </period>
    </context>
    <context id="From2025-01-072025-01-07_us-gaap_CommonStockMember_custom_SecuritiesExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-07</startDate>
            <endDate>2025-01-07</endDate>
        </period>
    </context>
    <context id="AsOf2025-01-07_custom_PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-07</instant>
        </period>
    </context>
    <context id="AsOf2025-01-07_custom_PreFundedWarrantsMember_custom_SecuritiesExchangeAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-07</instant>
        </period>
    </context>
    <context id="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_SeriesA1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:SeriesA1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-07</instant>
        </period>
    </context>
    <context id="From2025-01-072025-01-07_custom_SecuritiesExchangeAgreementMember_custom_SeriesA1WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">NAOV:SeriesA1WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:SecuritiesExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-07</startDate>
            <endDate>2025-01-07</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-24_custom_PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-24</instant>
        </period>
    </context>
    <context id="From2025-01-012025-01-01_custom_PrefundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:PrefundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-01-01_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2024-01-012024-12-31_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_MayTwoThousandTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NAOV:MayTwoThousandTwentyFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_RepresentativeWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NAOV:RepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NAOV:MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NAOV:MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NAOV:MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NAOV:MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_JulyTwoThousandTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NAOV:JulyTwoThousandTwentyFiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_JulyTwoThousandTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NAOV:JulyTwoThousandTwentyFiveWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_JulyTwoThousandTwentyFiveWarrantsMember_us-gaap_MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NAOV:JulyTwoThousandTwentyFiveWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_JulyTwoThousandTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NAOV:JulyTwoThousandTwentyFiveWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_JulyTwoThousandTwentyFiveWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NAOV:JulyTwoThousandTwentyFiveWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_OtherIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_OtherIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExercisePriceMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExercisePriceMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-02-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <instant>2025-02-13</instant>
        </period>
    </context>
    <context id="AsOf2025-03-26_custom_ENvueMedicalHoldingsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-26</instant>
        </period>
    </context>
    <context id="AsOf2025-02-06_custom_ENvueMedicalHoldingsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-06</instant>
        </period>
    </context>
    <context id="AsOf2025-03-04_custom_ENvueMedicalHoldingsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-04</instant>
        </period>
    </context>
    <context id="AsOf2025-03-26_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-26</instant>
        </period>
    </context>
    <context id="AsOf2025-01-17_custom_ENvueConsolidatedSecuredNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NAOV:ENvueConsolidatedSecuredNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-17</instant>
        </period>
    </context>
    <context id="From2025-12-312025-12-31_custom_ENvueConsolidatedSecuredNoteMember_srt_ScenarioForecastMember_custom_ENvueMedicalHoldingsCorpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">NAOV:ENvueMedicalHoldingsCorpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NAOV:ENvueConsolidatedSecuredNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2025-04-11_custom_AprilTwoThousandTwentyFivePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NAOV:AprilTwoThousandTwentyFivePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-11</instant>
        </period>
    </context>
    <context id="From2025-04-112025-04-11_custom_AprilTwoThousandTwentyFivePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NAOV:AprilTwoThousandTwentyFivePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-11</startDate>
            <endDate>2025-04-11</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NAOV:StockOptionsEmployeeAndNonEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_WarrantMember2482609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NAOV:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_NanoVibronixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:NanoVibronixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_custom_EnvueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:EnvueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_NanoVibronixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:NanoVibronixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_custom_EnvueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:EnvueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_NanoVibronixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:NanoVibronixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_EnvueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:EnvueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_NanoVibronixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:NanoVibronixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_EnvueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:EnvueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_NanoVibronixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:NanoVibronixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_EnvueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:EnvueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_NanoVibronixMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:NanoVibronixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_EnvueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">NAOV:EnvueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_AustraliaNewZealandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:AustraliaNewZealandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_AustraliaNewZealandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:AustraliaNewZealandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_AustraliaNewZealandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:AustraliaNewZealandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_AustraliaNewZealandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:AustraliaNewZealandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-012025-09-30_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-07-012024-09-30_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_OtherCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NAOV:OtherCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="From2021-02-252021-02-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-02-26</endDate>
        </period>
    </context>
    <context id="From2022-03-142022-03-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
        </entity>
        <period>
            <startDate>2022-03-14</startDate>
            <endDate>2022-03-15</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_ArbitratorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:ArbitratorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2025-01-012025-09-30_custom_PiersonFerdinandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PiersonFerdinandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="From2024-01-012024-09-30_custom_PiersonFerdinandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NAOV:PiersonFerdinandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="From2025-07-182025-07-18_us-gaap_SeriesHPreferredStockMember_srt_MaximumMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001326706</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesHPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NAOV:JulyTwoThousandTwentyFivePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-18</startDate>
            <endDate>2025-07-18</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Integer">
        <measure>NAOV:Integer</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2025-01-01to2025-09-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2025-01-01to2025-09-30" id="Fact000004">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2025-01-01to2025-09-30" id="Fact000005">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="From2025-01-01to2025-09-30" id="Fact000006">0001326706</dei:EntityCentralIndexKey>
    <us-gaap:RestrictedCash
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0050"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0071"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0083"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0104"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:TrancheFinancingLiabilityCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0107"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:WarrantyLiabilityCurrent
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0110"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl0133"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl0134"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0139"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesCPreferredStockMember"
      id="xdx2ixbrl0140"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0158"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0177"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0178"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2025-09-30_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-12-31_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0197"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DividendsPreferredStockStockOne
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DividendsPreferredStockStockOne
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividend
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividend
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DividendsPreferredStockStockTwo
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DividendsPreferredStockStockTwo
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0405"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0424"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0434"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0444"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0449"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0455"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0457"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0458"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0460"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0462"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0464"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0465"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0466"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0467"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0469"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0475"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0476"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0487"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0494"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0502"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0504"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0505"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0528"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0529"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0536"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0537"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0538"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0541"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0542"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0543"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0544"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0554"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0557"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0568"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringThePeriodValueWarrantExchangeAgreement
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringThePeriodValueWarrantExchangeAgreement
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringThePeriodValueWarrantExchangeAgreement
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringThePeriodValueWarrantExchangeAgreement
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0575"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringThePeriodValueWarrantExchangeAgreement
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0576"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringThePeriodValueWarrantExchangeAgreement
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0577"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringThePeriodValueWarrantExchangeAgreement
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0578"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringThePeriodValueWarrantExchangeAgreement
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0579"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0584"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0585"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0588"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0592"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0593"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0594"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0595"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0596"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0597"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0598"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0603"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0604"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0605"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0606"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0608"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0609"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0613"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0614"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0615"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0616"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0618"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0620"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0623"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0624"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0627"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0628"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0633"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0634"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0635"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0637"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0639"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0641"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0642"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0643"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0644"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0647"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0651"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0652"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0653"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0656"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0658"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0660"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0661"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0662"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0663"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0664"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0665"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0666"
      unitRef="Shares"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuesReverseStockSplits
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0667"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0670"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0672"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0673"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0676"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0679"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0680"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0682"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0683"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0684"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0688"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0689"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0702"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0703"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0710"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0712"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0714"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0718"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0719"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0720"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0721"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0723"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0724"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0727"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0728"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0729"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0730"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0731"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0733"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0736"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0737"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0738"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0740"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0741"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0742"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0747"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0748"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0749"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0750"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0751"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0752"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0756"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0757"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0758"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0765"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0767"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0769"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0773"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0774"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0775"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0782"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0784"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0786"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0790"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0791"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0792"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0799"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0801"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0803"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0807"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0808"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0809"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0810"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0812"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0813"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0816"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0817"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0818"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0820"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0821"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0822"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0827"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0828"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0829"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0830"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0831"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0833"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0836"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0837"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0838"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0839"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0840"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0841"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0845"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0846"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0847"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0854"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0856"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0858"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0862"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0863"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0864"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      id="xdx2ixbrl0871"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      id="xdx2ixbrl0873"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      id="xdx2ixbrl0875"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2025-01-01to2025-09-30"
      id="xdx2ixbrl0892"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:ChangeInFairValueOfWarrantLiability
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0899"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:ProfessionalFeesAllocatedToWarrantLiability
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0902"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0926"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0938"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0950"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0953"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:ProceedsFromTrancheFinancing
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0956"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:ProceedsFromIssuanceOfNotesPayableToRelatedParty
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0959"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0962"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0965"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl0968"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RestrictedCash
      contextRef="AsOf2024-09-30"
      id="xdx2ixbrl0995"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaidNet
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl1004"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration contextRef="AsOf2025-09-30" id="xdx2ixbrl1068">http://fasb.org/us-gaap/2025#LeaseholdImprovementsMember</us-gaap:PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_StockOptionMember"
      id="xdx2ixbrl1317"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_StockOptionMember"
      id="xdx2ixbrl1319"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2025-01-012025-09-30_us-gaap_StockOptionMember"
      id="xdx2ixbrl1345"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-09-30_us-gaap_StockOptionMember"
      id="xdx2ixbrl1347"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_StockOptionMember"
      id="xdx2ixbrl1349"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-09-30_us-gaap_StockOptionMember"
      id="xdx2ixbrl1351"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2024-12-31_us-gaap_WarrantMember"
      id="xdx2ixbrl1455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebt
      contextRef="AsOf2024-12-31"
      id="xdx2ixbrl1487"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebt
      contextRef="AsOf2025-09-30"
      id="xdx2ixbrl1495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl1535"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl1537"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DividendsPreferredStockStockOne
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl1540"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DividendsPreferredStockStockOne
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl1542"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividend
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl1545"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DeemedDividend
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl1547"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DividendsPreferredStockStockTwo
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl1550"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:DividendsPreferredStockStockTwo
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl1552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2025-07-012025-09-30"
      id="xdx2ixbrl1554"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2024-07-012024-09-30"
      id="xdx2ixbrl1555"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2024-01-012024-09-30"
      id="xdx2ixbrl1557"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2025-09-30_custom_NanoVibronixMember"
      id="xdx2ixbrl1581"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1591"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2024-12-31_custom_NanoVibronixMember"
      id="xdx2ixbrl1595"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2024-12-31_custom_EnvueMember"
      id="xdx2ixbrl1597"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Goodwill
      contextRef="AsOf2024-12-31_us-gaap_CorporateMember"
      id="xdx2ixbrl1599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_EnvueMember"
      id="xdx2ixbrl1603"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_us-gaap_CorporateMember"
      id="xdx2ixbrl1605"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1616"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-012025-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1640"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1641"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1645"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1646"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1650"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1651"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1655"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1656"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1661"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1665"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1666"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2025-07-012025-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1671"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1676"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-07-012025-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2024-07-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1700"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="From2024-07-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1705"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1710"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1711"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-07-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1715"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-07-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1716"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1720"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1721"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30_custom_EnvueMember"
      id="xdx2ixbrl1725"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_CorporateMember"
      id="xdx2ixbrl1726"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_OtherCountryMember"
      id="xdx2ixbrl1746"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:WarrantLiabilityFairValueDisclosure
      contextRef="AsOf2024-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1772"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:WarrantLiabilityFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1782"
      unitRef="USD"
      xsi:nil="true"/>
    <NAOV:WarrantLiabilityFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1783"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2025-01-01to2025-09-30" id="Fact000014">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2025-01-01to2025-09-30" id="Fact000015">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2025-01-01to2025-09-30" id="Fact000016">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2025-01-01to2025-09-30" id="Fact000017">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2025-01-01to2025-09-30" id="Fact000018">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2025-01-01to2025-09-30" id="Fact000019">001-36445</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2025-01-01to2025-09-30" id="Fact000020">NanoVibronix, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2025-01-01to2025-09-30" id="Fact000021">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2025-01-01to2025-09-30" id="Fact000022">01-0801232</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2025-01-01to2025-09-30" id="Fact000023">969     Pruitt Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2025-01-01to2025-09-30" id="Fact000024">Tyler</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2025-01-01to2025-09-30" id="Fact000025">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2025-01-01to2025-09-30" id="Fact000026">77569</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2025-01-01to2025-09-30" id="Fact000027">(914)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2025-01-01to2025-09-30" id="Fact000028">233-3004</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2025-01-01to2025-09-30" id="Fact000029">Common     stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2025-01-01to2025-09-30" id="Fact000030">NAOV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2025-01-01to2025-09-30" id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2025-01-01to2025-09-30" id="Fact000032">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2025-01-01to2025-09-30" id="Fact000033">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2025-01-01to2025-09-30" id="Fact000034">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2025-01-01to2025-09-30" id="Fact000035">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2025-01-01to2025-09-30" id="Fact000036">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2025-01-01to2025-09-30" id="Fact000037">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2025-11-14"
      decimals="INF"
      id="Fact000038"
      unitRef="Shares">1088176</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000046"
      unitRef="USD">6950000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000047"
      unitRef="USD">752000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000049"
      unitRef="USD">30000</us-gaap:RestrictedCash>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000052"
      unitRef="USD">252000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000053"
      unitRef="USD">98000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000055"
      unitRef="USD">540000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000056"
      unitRef="USD">290000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000058"
      unitRef="USD">2243000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000059"
      unitRef="USD">2191000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000061"
      unitRef="USD">10015000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000062"
      unitRef="USD">3331000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000067"
      unitRef="USD">124000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000068"
      unitRef="USD">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AccountsReceivableNetNoncurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000070"
      unitRef="USD">23000</us-gaap:AccountsReceivableNetNoncurrent>
    <NAOV:SeveranceAssetsNoncurent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000073"
      unitRef="USD">190000</NAOV:SeveranceAssetsNoncurent>
    <NAOV:SeveranceAssetsNoncurent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000074"
      unitRef="USD">173000</NAOV:SeveranceAssetsNoncurent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000076"
      unitRef="USD">125000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000077"
      unitRef="USD">116000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000079"
      unitRef="USD">5275000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000082"
      unitRef="USD">38631000</us-gaap:Goodwill>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000085"
      unitRef="USD">44368000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000086"
      unitRef="USD">298000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000088"
      unitRef="USD">54383000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000089"
      unitRef="USD">3629000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000097"
      unitRef="USD">492000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000098"
      unitRef="USD">47000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000100"
      unitRef="USD">4267000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000101"
      unitRef="USD">2608000</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:LoansPayableCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000103"
      unitRef="USD">1043000</us-gaap:LoansPayableCurrent>
    <NAOV:TrancheFinancingLiabilityCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000106"
      unitRef="USD">2000000</NAOV:TrancheFinancingLiabilityCurrent>
    <NAOV:WarrantyLiabilityCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000109"
      unitRef="USD">3730000</NAOV:WarrantyLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000113"
      unitRef="USD">15000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000115"
      unitRef="USD">112000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000116"
      unitRef="USD">52000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000118"
      unitRef="USD">11644000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000119"
      unitRef="USD">2722000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000124"
      unitRef="USD">260000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000125"
      unitRef="USD">216000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000127"
      unitRef="USD">15000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000128"
      unitRef="USD">64000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000130"
      unitRef="USD">11919000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000131"
      unitRef="USD">3002000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000142"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000144"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000146"
      unitRef="Shares">400000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000148"
      unitRef="Shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000150"
      unitRef="Shares">820</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000152"
      unitRef="Shares">820</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000154"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000156"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000161"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000163"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000165"
      unitRef="Shares">62220</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000167"
      unitRef="Shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000169"
      unitRef="Shares">53100</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000171"
      unitRef="Shares">53100</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000173"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000175"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000180"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000182"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-09-30_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000184"
      unitRef="Shares">11000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-12-31_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000186"
      unitRef="Shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000188"
      unitRef="Shares">8889</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000190"
      unitRef="Shares">8889</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-12-31_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000192"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000194"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000202"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000204"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000206"
      unitRef="Shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000208"
      unitRef="Shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000210"
      unitRef="Shares">1011086</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact000212"
      unitRef="Shares">1011086</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000214"
      unitRef="Shares">37894</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-12-31"
      decimals="INF"
      id="Fact000216"
      unitRef="Shares">37894</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000199"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000200"
      unitRef="USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000218"
      unitRef="USD">119408000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000219"
      unitRef="USD">70507000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000221"
      unitRef="USD">-87000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000222"
      unitRef="USD">-80000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000224"
      unitRef="USD">-76858000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000225"
      unitRef="USD">-69801000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000227"
      unitRef="USD">42464000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000228"
      unitRef="USD">627000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000230"
      unitRef="USD">54383000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000231"
      unitRef="USD">3629000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000234"
      unitRef="USD">722000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000235"
      unitRef="USD">376000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000236"
      unitRef="USD">2241000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000237"
      unitRef="USD">2114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000239"
      unitRef="USD">533000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000240"
      unitRef="USD">243000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000241"
      unitRef="USD">1718000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000242"
      unitRef="USD">889000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000244"
      unitRef="USD">189000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000245"
      unitRef="USD">133000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000246"
      unitRef="USD">523000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000247"
      unitRef="USD">1225000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000254"
      unitRef="USD">221000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000255"
      unitRef="USD">249000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000256"
      unitRef="USD">1723000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000257"
      unitRef="USD">557000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000259"
      unitRef="USD">812000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000260"
      unitRef="USD">181000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000261"
      unitRef="USD">1878000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000262"
      unitRef="USD">545000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000264"
      unitRef="USD">1403000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000265"
      unitRef="USD">673000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000266"
      unitRef="USD">4997000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000267"
      unitRef="USD">2335000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000269"
      unitRef="USD">2436000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000270"
      unitRef="USD">1103000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000271"
      unitRef="USD">8598000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000272"
      unitRef="USD">3437000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000274"
      unitRef="USD">-2247000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000275"
      unitRef="USD">-970000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000276"
      unitRef="USD">-8075000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000277"
      unitRef="USD">-2212000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000279"
      unitRef="USD">53000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000280"
      unitRef="USD">33000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000281"
      unitRef="USD">250000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000282"
      unitRef="USD">101000</us-gaap:InterestExpenseNonoperating>
    <NAOV:FinancialIncomeExpensesNet
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000284"
      unitRef="USD">2845000</NAOV:FinancialIncomeExpensesNet>
    <NAOV:FinancialIncomeExpensesNet
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000285"
      unitRef="USD">8000</NAOV:FinancialIncomeExpensesNet>
    <NAOV:FinancialIncomeExpensesNet
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000286"
      unitRef="USD">3104000</NAOV:FinancialIncomeExpensesNet>
    <NAOV:FinancialIncomeExpensesNet
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000287"
      unitRef="USD">53000</NAOV:FinancialIncomeExpensesNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000289"
      unitRef="USD">545000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000290"
      unitRef="USD">-995000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000291"
      unitRef="USD">-5221000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000292"
      unitRef="USD">-2260000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000294"
      unitRef="USD">35000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000295"
      unitRef="USD">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000296"
      unitRef="USD">112000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000297"
      unitRef="USD">14000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000299"
      unitRef="USD">510000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000300"
      unitRef="USD">-998000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000301"
      unitRef="USD">-5333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000302"
      unitRef="USD">-2274000</us-gaap:NetIncomeLoss>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000309"
      unitRef="USD">758000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000311"
      unitRef="USD">1102000</us-gaap:DividendsPreferredStockStock>
    <NAOV:DividendsPreferredStockStockOne
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000314"
      unitRef="USD">223000</NAOV:DividendsPreferredStockStockOne>
    <NAOV:DividendsPreferredStockStockOne
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000316"
      unitRef="USD">223000</NAOV:DividendsPreferredStockStockOne>
    <NAOV:DeemedDividend
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000319"
      unitRef="USD">399000</NAOV:DeemedDividend>
    <NAOV:DeemedDividend
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000321"
      unitRef="USD">399000</NAOV:DeemedDividend>
    <NAOV:DividendsPreferredStockStockTwo
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000324"
      unitRef="USD">-90000</NAOV:DividendsPreferredStockStockTwo>
    <NAOV:DividendsPreferredStockStockTwo
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000326"
      unitRef="USD">-90000</NAOV:DividendsPreferredStockStockTwo>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000331"
      unitRef="USD">-3815000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000334"
      unitRef="USD">-780000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000335"
      unitRef="USD">-998000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000336"
      unitRef="USD">-3152000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000337"
      unitRef="USD">-2274000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000339"
      unitRef="USDPShares">-0.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000341"
      unitRef="USDPShares">-0.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000343"
      unitRef="USDPShares">-3.56</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000345"
      unitRef="USDPShares">-3.56</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000347"
      unitRef="USDPShares">-6.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000349"
      unitRef="USDPShares">-6.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000351"
      unitRef="USDPShares">-8.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000353"
      unitRef="USDPShares">-8.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000355"
      unitRef="Shares">858434</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-07-012025-09-30"
      decimals="INF"
      id="Fact000357"
      unitRef="Shares">858434</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000359"
      unitRef="Shares">280318</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-07-012024-09-30"
      decimals="INF"
      id="Fact000361"
      unitRef="Shares">280318</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000363"
      unitRef="Shares">470940</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact000365"
      unitRef="Shares">470940</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000367"
      unitRef="Shares">271284</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact000369"
      unitRef="Shares">271284</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000376"
      unitRef="USD">510000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000377"
      unitRef="USD">-998000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000378"
      unitRef="USD">-5333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000379"
      unitRef="USD">-2274000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000381"
      unitRef="USD">-2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000382"
      unitRef="USD">-3000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000383"
      unitRef="USD">-7000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000384"
      unitRef="USD">-8000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000386"
      unitRef="USD">508000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000387"
      unitRef="USD">-1001000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000388"
      unitRef="USD">-5340000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000389"
      unitRef="USD">-2282000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000401"
      unitRef="Shares">6332</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000403"
      unitRef="Shares">61346</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000407"
      unitRef="Shares">787381</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000395"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000396"
      unitRef="USD">116549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000397"
      unitRef="USD">-85000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000398"
      unitRef="USD">-75988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-06-30"
      decimals="-3"
      id="Fact000399"
      unitRef="USD">40477000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000418"
      unitRef="Shares">74114</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000413"
      unitRef="USD">1878000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000416"
      unitRef="USD">1878000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000429"
      unitRef="Shares">140000</NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000440"
      unitRef="Shares">-5512</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-07-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000442"
      unitRef="Shares">9591</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000453"
      unitRef="Shares">-8246</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000448"
      unitRef="USD">5000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000451"
      unitRef="USD">5000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000459"
      unitRef="USD">758000</NAOV:StockIssuedDuringPeriodValueStockDividends>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000461"
      unitRef="USD">-758000</NAOV:StockIssuedDuringPeriodValueStockDividends>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000468"
      unitRef="USD">223000</NAOV:StockIssuedDuringPeriodValueStockDividendsOne>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000470"
      unitRef="USD">-223000</NAOV:StockIssuedDuringPeriodValueStockDividendsOne>
    <NAOV:StockIssuedDuringPeriodSharesIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000482"
      unitRef="Shares">8889</NAOV:StockIssuedDuringPeriodSharesIIssuanceOfSeriesHPreferredStock>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000477"
      unitRef="USD">4601000</NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000480"
      unitRef="USD">4601000</NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-07-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000488"
      unitRef="USD">399000</NAOV:DeemedDividendForDownRoundOfShares>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000490"
      unitRef="USD">-399000</NAOV:DeemedDividendForDownRoundOfShares>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000498"
      unitRef="USD">-2000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000500"
      unitRef="USD">-2000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000508"
      unitRef="USD">510000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact000509"
      unitRef="USD">510000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000520"
      unitRef="Shares">820</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000522"
      unitRef="Shares">53100</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000524"
      unitRef="Shares">8889</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000526"
      unitRef="Shares">1011086</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000514"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000515"
      unitRef="USD">119408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000516"
      unitRef="USD">-87000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000517"
      unitRef="USD">-76858000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000518"
      unitRef="USD">42464000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000539"
      unitRef="Shares">37894</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000531"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000532"
      unitRef="USD">70507000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000533"
      unitRef="USD">-80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000534"
      unitRef="USD">-69801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000535"
      unitRef="USD">627000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000549"
      unitRef="Shares">61346</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000550"
      unitRef="Shares">3318</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000545"
      unitRef="USD">41864000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000548"
      unitRef="USD">41864000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <NAOV:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000560"
      unitRef="Shares">5000</NAOV:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <NAOV:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000556"
      unitRef="USD">102000</NAOV:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <NAOV:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000559"
      unitRef="USD">102000</NAOV:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000570"
      unitRef="Shares">170573</NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised>
    <NAOV:StockIssuedDuringThePeriodSharesWarrantExchangeAgreement
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000580"
      unitRef="USD">4150</NAOV:StockIssuedDuringThePeriodSharesWarrantExchangeAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000590"
      unitRef="Shares">400000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000586"
      unitRef="USD">3732000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000589"
      unitRef="USD">3732000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000600"
      unitRef="Shares">-399180</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000601"
      unitRef="Shares">709419</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000611"
      unitRef="Shares">-8246</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000607"
      unitRef="USD">5000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000610"
      unitRef="USD">5000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000617"
      unitRef="USD">1102000</NAOV:StockIssuedDuringPeriodValueStockDividends>
    <NAOV:StockIssuedDuringPeriodValueStockDividends
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000619"
      unitRef="USD">-1102000</NAOV:StockIssuedDuringPeriodValueStockDividends>
    <NAOV:StockIssuedDuringPeriodSharesIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000630"
      unitRef="Shares">8889</NAOV:StockIssuedDuringPeriodSharesIIssuanceOfSeriesHPreferredStock>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000626"
      unitRef="USD">4601000</NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock>
    <NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000629"
      unitRef="USD">4601000</NAOV:StockIssuedDuringPeriodValueIIssuanceOfSeriesHPreferredStock>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000636"
      unitRef="USD">223000</NAOV:StockIssuedDuringPeriodValueStockDividendsOne>
    <NAOV:StockIssuedDuringPeriodValueStockDividendsOne
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000638"
      unitRef="USD">-223000</NAOV:StockIssuedDuringPeriodValueStockDividendsOne>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000649"
      unitRef="Shares">74114</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000645"
      unitRef="USD">1878000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000648"
      unitRef="USD">1878000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-01-012025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000655"
      unitRef="USD">399000</NAOV:DeemedDividendForDownRoundOfShares>
    <NAOV:DeemedDividendForDownRoundOfShares
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000657"
      unitRef="USD">-399000</NAOV:DeemedDividendForDownRoundOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="From2025-01-012025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000668"
      unitRef="Shares">6618</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-01-012025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000675"
      unitRef="USD">-7000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000677"
      unitRef="USD">-7000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000685"
      unitRef="USD">-5333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000686"
      unitRef="USD">-5333000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact000696"
      unitRef="Shares">820</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact000697"
      unitRef="Shares">53100</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_PreferredStockMember_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact000698"
      unitRef="Shares">8889</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000699"
      unitRef="Shares">1011086</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000691"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000692"
      unitRef="USD">119408000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000693"
      unitRef="USD">-87000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000694"
      unitRef="USD">-76858000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000695"
      unitRef="USD">42464000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000716"
      unitRef="Shares">18603</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000704"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000705"
      unitRef="USD">70151000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000706"
      unitRef="USD">-67000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000707"
      unitRef="USD">-66096000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000708"
      unitRef="USD">3988000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000722"
      unitRef="USD">165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000725"
      unitRef="USD">165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-01-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000732"
      unitRef="USD">-8000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000734"
      unitRef="USD">-8000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000745"
      unitRef="Shares">9045</NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000739"
      unitRef="USD">1000</NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000743"
      unitRef="USD">1000</NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000753"
      unitRef="USD">-2274000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000754"
      unitRef="USD">-2274000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000771"
      unitRef="Shares">27648</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000759"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000760"
      unitRef="USD">70316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000761"
      unitRef="USD">-75000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000762"
      unitRef="USD">-68370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000763"
      unitRef="USD">1872000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000788"
      unitRef="Shares">25312</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000776"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000777"
      unitRef="USD">70286000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000778"
      unitRef="USD">-73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000779"
      unitRef="USD">-67372000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="-3"
      id="Fact000780"
      unitRef="USD">2841000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000805"
      unitRef="Shares">25312</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000793"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000794"
      unitRef="USD">70286000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000795"
      unitRef="USD">-73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000796"
      unitRef="USD">-67372000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="-3"
      id="Fact000797"
      unitRef="USD">2841000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000811"
      unitRef="USD">30000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000814"
      unitRef="USD">30000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000825"
      unitRef="Shares">2336</NAOV:StockIssuedDuringPeriodSharesPrefundedWarrantsExercised>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-07-012024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000819"
      unitRef="USD">1000</NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised>
    <NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000823"
      unitRef="USD">1000</NAOV:StockIssuedDuringPeriodValuePrefundedWarrantsExercised>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-07-012024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000832"
      unitRef="USD">-2000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000834"
      unitRef="USD">-2000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000842"
      unitRef="USD">-998000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact000843"
      unitRef="USD">-998000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000860"
      unitRef="Shares">27648</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000848"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000849"
      unitRef="USD">70316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000850"
      unitRef="USD">-75000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000851"
      unitRef="USD">-68370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000852"
      unitRef="USD">1872000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000877"
      unitRef="Shares">27648</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_CommonStockMember"
      decimals="-3"
      id="Fact000865"
      unitRef="USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact000866"
      unitRef="USD">70316000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact000867"
      unitRef="USD">-75000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="Fact000868"
      unitRef="USD">-68370000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000869"
      unitRef="USD">1872000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000883"
      unitRef="USD">-5333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000884"
      unitRef="USD">-2274000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000889"
      unitRef="USD">639000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000890"
      unitRef="USD">1000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000893"
      unitRef="USD">165000</us-gaap:ShareBasedCompensation>
    <NAOV:NoncashInterestExpense
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000895"
      unitRef="USD">202000</NAOV:NoncashInterestExpense>
    <NAOV:NoncashInterestExpense
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000896"
      unitRef="USD">100000</NAOV:NoncashInterestExpense>
    <NAOV:ChangeInFairValueOfWarrantLiability
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000898"
      unitRef="USD">4613000</NAOV:ChangeInFairValueOfWarrantLiability>
    <NAOV:ProfessionalFeesAllocatedToWarrantLiability
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000901"
      unitRef="USD">1420000</NAOV:ProfessionalFeesAllocatedToWarrantLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000907"
      unitRef="USD">122000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000908"
      unitRef="USD">261000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000910"
      unitRef="USD">245000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000911"
      unitRef="USD">88000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000913"
      unitRef="USD">-343000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000914"
      unitRef="USD">-482000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000916"
      unitRef="USD">320000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000917"
      unitRef="USD">-113000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000919"
      unitRef="USD">683000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000920"
      unitRef="USD">54000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000922"
      unitRef="USD">-15000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000923"
      unitRef="USD">-34000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000925"
      unitRef="USD">-2000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <NAOV:IncreaseDecreaseInAccruedSeverancePayNet
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000928"
      unitRef="USD">27000</NAOV:IncreaseDecreaseInAccruedSeverancePayNet>
    <NAOV:IncreaseDecreaseInAccruedSeverancePayNet
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000929"
      unitRef="USD">-1000</NAOV:IncreaseDecreaseInAccruedSeverancePayNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000931"
      unitRef="USD">-6696000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000932"
      unitRef="USD">-1968000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000937"
      unitRef="USD">148000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000940"
      unitRef="USD">37000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000941"
      unitRef="USD">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000943"
      unitRef="USD">111000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000944"
      unitRef="USD">-3000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000949"
      unitRef="USD">17135000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000952"
      unitRef="USD">5000000</us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock>
    <NAOV:ProceedsFromTrancheFinancing
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000955"
      unitRef="USD">2000000</NAOV:ProceedsFromTrancheFinancing>
    <NAOV:ProceedsFromIssuanceOfNotesPayableToRelatedParty
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000958"
      unitRef="USD">1300000</NAOV:ProceedsFromIssuanceOfNotesPayableToRelatedParty>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000961"
      unitRef="USD">1300000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000964"
      unitRef="USD">1777000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000967"
      unitRef="USD">360000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000970"
      unitRef="USD">102000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000971"
      unitRef="USD">1000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000973"
      unitRef="USD">12820000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000974"
      unitRef="USD">1000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000976"
      unitRef="USD">-7000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000977"
      unitRef="USD">-8000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact000979"
      unitRef="USD">6228000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact000980"
      unitRef="USD">-1978000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact000982"
      unitRef="USD">752000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-12-31"
      decimals="-3"
      id="Fact000983"
      unitRef="USD">3283000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000985"
      unitRef="USD">6980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000986"
      unitRef="USD">1305000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000991"
      unitRef="USD">6950000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000992"
      unitRef="USD">1305000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000994"
      unitRef="USD">30000</us-gaap:RestrictedCash>
    <NAOV:CashAndCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact000997"
      unitRef="USD">6980000</NAOV:CashAndCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <NAOV:CashAndCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-09-30"
      decimals="-3"
      id="Fact000998"
      unitRef="USD">1305000</NAOV:CashAndCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001003"
      unitRef="USD">25000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001006"
      unitRef="USD">20000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact001007"
      unitRef="USD">4000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:NatureOfOperations contextRef="From2025-01-01to2025-09-30" id="Fact001009">&lt;p id="xdx_802_eus-gaap--NatureOfOperations_zzfLFjNHh7j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
1 - &lt;span id="xdx_82B_zjJ4EEoVuEY4"&gt;DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;NanoVibronix,
Inc. (the &#x201c;Company&#x201d;), a Delaware corporation, commenced operations on October 20, 2003, and is a medical device company focusing
on non-invasive biological response-activating devices that target wound healing and pain therapy and can be administered at home, without
the assistance of medical professionals.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s principal research and development activities are conducted in Israel through its wholly-owned subsidiary, NanoVibronix
Ltd., a company registered in Israel, which commenced operations in October 2003.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2025, pursuant to the terms of that certain Agreement and Plan of Merger, dated as of February 14, 2025 (the &#x201c;Merger
Agreement&#x201d;), by and among NanoVibronix, Inc. (the &#x201c;Company&#x201d;), NVEH Merger Sub, Inc., a Delaware corporation and a wholly-owned
subsidiary of NVEH Merger Sub I, Inc. (&#x201c;First Merger Sub&#x201d;), NVEH Merger Sub II, LLC, a Delaware limited liability company
and a wholly-owned subsidiary of the Company (&#x201c;Second Merger Sub&#x201d;), and Predecessor ENvue, the Company and Predecessor ENvue
effected (i) a merger of First Merger Sub with and into Predecessor ENvue, with the First Merger Sub ceasing to exist and Predecessor
ENvue becoming a wholly-owned subsidiary the Company and (ii) the merger of Predecessor ENvue with and into Second Merger Sub (the &#x201c;Second
Merger&#x201d; and, together with the First Merger, the &#x201c;ENvue Merger&#x201d;), with Second Merger Sub being the surviving entity
of the Second Merger (&#x201c;Surviving Entity&#x201d;). At the effective time of the Second Merger, the certificate of formation of the
Surviving Entity was amended and restated to, among other things, to change the name of the Surviving Entity to &#x201c;ENvue Medical
Holdings LLC.&#x201d; See Note 4 &#x2013; Merger.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ENvue
Medical Holdings LLC (previously: Envizion Medical Holding Corp.) (hereinafter: &#x201c;ENvue&lt;b&gt;&#x201d;&lt;/b&gt;) is a Delaware corporation
incorporated June 5, 2024. ENvue has two wholly owned subsidiaries: ENvue Medical (USA) Inc. (previously: Envizion Medical (USA) Inc.)
and ENvue Medical Ltd. (previously: Envizion Medical Israel Ltd.).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ENvue
is engaged in research, development, marketing, and sale of medical equipment in the field of enteral feeding and are in the initial
stage of commercializing its products.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NatureOfOperations>
    <NAOV:LiquidityAndPlanOfOperationsTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001011">&lt;p id="xdx_80C_ecustom--LiquidityAndPlanOfOperationsTextBlock_zHwBGWsimjC3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
2 - &lt;span id="xdx_829_zG5uy5Kj3baa"&gt;LIQUIDITY AND PLAN OF OPERATIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, the Company has incurred recurring losses and negative cash flows from operations and has an accumulated deficit
of $&lt;span id="xdx_908_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn3n3_di_c20250930_zNkfdjck8eve" title="Accumulated deficit"&gt;76,858&lt;/span&gt;. For the nine-month period ended September 30, 2025, the Company used approximately $&lt;span id="xdx_90C_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20250101__20250930_zHHisypfvYw4" title="Cash in operations"&gt;6,696&lt;/span&gt; of cash in operations. The Company
expects to incur future net losses and its transition to profitability is dependent upon, among other things, the achievement of a level
of revenues adequate to support the cost structure. Until the Company achieves profitability or generates positive cash flows, it will
continue to be dependent on raising additional funds to fund its operations. The Company intends to fund its future operations through
cash on hand, additional private and/or public offerings of debt or equity securities or a combination of the foregoing. There are no
assurances, however, that the Company will be able to obtain an adequate level of financial resources that are required to fund its operation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for twelve months from the date of
issuance of these interim condensed consolidated financial statements. The accompanying condensed interim consolidated financial statements
do not include any adjustments to reflect the possible future effects on recoverability and classification of assets or the amounts and
classification of liabilities that may result from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NAOV:LiquidityAndPlanOfOperationsTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001013"
      unitRef="USD">-76858000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001015"
      unitRef="USD">-6696000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001017">&lt;p id="xdx_80E_eus-gaap--SignificantAccountingPoliciesTextBlock_zhm1Ek6Qsq37" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
3 - &lt;span id="xdx_822_z4T1WaT0reBh"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zLiQV6UD2zpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of presentation and principles of consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts
and transactions have been eliminated in consolidation. The Company&#x2019;s condensed consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for the interim
financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying
unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary
to state fairly the financial position and results of operations of the Company. These condensed consolidated financial statements and
notes thereto are unaudited and should be read in conjunction with the Company&#x2019;s audited financial statements for the year ended
December 31, 2024, as found in the Company&#x2019;s Annual Report on Form 10-K, as amended, initially filed with the Securities and Exchange
Commission (the &#x201c;SEC&#x201d;) on March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
balance sheet for December 31, 2024, was derived from the Company&#x2019;s audited financial statements for the year ended December 31,
2024. The results of operations for the periods presented are not necessarily indicative of results that could be expected for the entire
fiscal year. Certain information and footnote disclosures normally included in the consolidated financial statements in accordance with
U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC for interim reporting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including
ENvue as of the date of the ENvue Merger. Intercompany accounts and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zR8ZUxLeIwU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zwr9YrIEOhRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
currency translation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
currency of the primary economic environment in which the operations of the Company and certain subsidiaries are conducted is the U.S.
dollar; thus, the dollar is the functional currency of the Company and certain subsidiaries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and certain subsidiaries&#x2019; transactions and balances denominated in dollars are presented at their original amounts. Non-dollar
transactions and balances have been remeasured to dollars in accordance with ASC 830, &#x201c;Foreign Currency Matters&#x201d;. All transaction
gains and losses from remeasurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements
of operations as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain subsidiaries whose functional currency has been determined to be a non-dollar currency, assets and liabilities are translated
at period-end exchange rates and statement of operations items are translated at average exchange rates prevailing during the period.
Such translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss) in shareholders&#x2019;
equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zjCiHfNDMW44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash
and cash equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of cash on hand and highly liquid investments with original maturities of three months or less, at the date
of purchase.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zEyabTYLhJD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Concentration
of credit risk &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, trade receivables,
and other accounts receivable. The Company holds cash in various banking institutions. Such funds are insured by the Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) up to $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20250930__srt--RangeAxis__srt--MaximumMember_zmnYpNaXzWbi" title="Cash FDIC, insured amount"&gt;250&lt;/span&gt;. Cash balances could exceed insured amounts at any given time. Generally, these investments may be redeemed upon demand and the Company believes that the financial institutions
that hold the Company's cash deposits are financially sound and, accordingly, bear minimal risk. As of September
30, 2025, the Company had cash in excess of the FDIC insured amount totaling $&lt;span id="xdx_90C_eus-gaap--Cash_iI_pn3n3_c20250930_zTm1ScELaSGf" title="Cash uninsured amount"&gt;6,525&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zn6SShIgGgpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Trade
receivables&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s trade receivable balance consists of amounts due from its customers. The Current Expected Credit Losses (&#x201c;CECL&#x201d;)
impairment model requires an estimate of expected credit losses, measured over the contractual life of an instrument, which considers
forecasts of future economic conditions in addition to information about past events and current conditions. Based on this model, the
Company considers many factors, including the age of the balance, collection history, and current economic trends. Credit losses are
written off after all collection efforts have ceased. Allowances for credit losses are recorded as a direct reduction from an asset&#x2019;s
amortized cost basis. Credit losses and recoveries are recorded in selling, general and administrative expenses in the consolidated statements
of operations. Recoveries of financial assets previously written off are recorded when received. As of September 30, 2025, the credit
losses allowance was immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z15ohwyo3Ywh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Earnings
per share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes net loss per share using the two-class method required for participating securities. The two-class method requires
income available to common stockholders for the period to be allocated between shares of Common Stock and participating securities
based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company&#x2019;s
Series X Preferred Shares and Series H Preferred shares would be entitled to dividends that would be distributed to the holders of
Common Stock, based on the conversion ratio, assuming conversion of all Convertible Series X Preferred Shares and Series H Preferred
shares into shares of Common Stock. The Company does not allocate losses to these participating securities as they do not share in
the Company&#x2019;s losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s basic net loss per share is calculated by dividing net loss attributable to common and preferred stockholders by the
weighted-average number of shares, which include prefunded warrants, without consideration of potentially dilutive securities. The diluted
net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury
share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss
per share in periods when the effects of potentially dilutive shares of Common Stock are anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zf1OThWxFWz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the &#x201c;first-in,
first-out&#x201d; method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates
the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation,
provisions are made when required to write-down inventory to its net market value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zevs2TaCyNO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
has been recorded as a result of the acquisition. Goodwill represents the excess of the purchase price in a business combination over
the fair value of identifiable tangible and intangible assets acquired. Goodwill is not amortized but rather is subject to an impairment
test.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
No. 350, &#x201c;Intangibles - Goodwill and other&#x201d; (&#x201c;ASC No. 350&#x201d;) requires goodwill to be tested for impairment at
the reporting unit level at least annually or between annual tests in certain circumstances and written down when impaired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
No. 350 allows an entity to first assess qualitative factors to determine whether it is necessary to perform the quantitative goodwill
impairment test. If the qualitative assessment does not result in a more likely than not indication of impairment, no further impairment
testing is required. If it does result in a more likely than not indication of impairment, the quantitative goodwill impairment test
is performed. Alternatively, ASC No. 350 permits an entity to bypass the qualitative assessment for any reporting unit and proceed directly
to perform the quantitative goodwill impairment test. The Company performs the quantitative goodwill impairment test during the fourth
quarter of each fiscal year, or more frequently if impairment indicators are present and compares the fair value of the reporting unit
with its carrying value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2025 and 2024, &lt;span id="xdx_903_eus-gaap--GoodwillImpairmentLoss_pn3n3_do_c20250101__20250930_zO3KDQ1UD8f4" title="Goodwill impairment"&gt;&lt;span id="xdx_90B_eus-gaap--GoodwillImpairmentLoss_pn3n3_do_c20240101__20240930_zrLRo60lnEm" title="Goodwill impairment"&gt;no&lt;/span&gt;&lt;/span&gt; impairment was recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_znhqNJf62L6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives, which
is &lt;span id="xdx_908_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_zHmFXUYYG4gf" title="Acquired estimated useful lives"&gt;5&lt;/span&gt; &#x2013; &lt;span id="xdx_90B_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zJHSLnIYx0E5" title="Acquired estimated useful lives"&gt;7&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zeDL1ibzQ7z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives of the Company&#x2019;s intangible assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B6_zmqGirkfDx9a" style="display: none"&gt;SCHEDULE
OF INTANGIBLE ASSETS ESTIMATED USEFUL LIVES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Intangible Assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Tradename and trademarks&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z1mZ6mNDzrm6" title="Intangible assets estimated useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zjYo3jL3DS15" title="Intangible assets estimated useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer list&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerListsMember_zCrx0h2UUOzc" title="Intangible assets estimated useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zsRY2AWv0zti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zz61XuURaS58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Property
and equipment, net&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zupeJjcpHDl2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives of the Company&#x2019;s property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BC_z9kpncmxnod8" style="display: none"&gt;SCHEDULE
OF USEFUL LIVES OF THE COMPANY&#x2019;S PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Computers and peripheral equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zv6x20RY0Mj4" title="Estimated useful life"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zanrc1xvanPf" title="Estimated useful life"&gt;5&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_ze8dXDvWdAn" title="Estimated useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20250930_zQxMLDjHg8F" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23LeaseholdImprovementsMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1068"&gt;The shorter of term of the lease or the useful life of the asset&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zAsTAWI0K2h5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z57YghytELv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
long-lived assets of the Company, including finite-lived intangible assets, are reviewed for impairment in accordance with ASC No. 360,
&#x201c;Property, Plant and Equipment&#x201d;, whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset
to the future undiscounted cash flows expected to be generated by the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of
the assets exceeds the fair value of the assets. During the three and nine months ended September 30, 2025 and 2024, &lt;span id="xdx_904_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_do_c20250701__20250930_zKyHu5Dv32w8" title="Impairment of long lived assets"&gt;&lt;span id="xdx_908_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_do_c20250101__20250930_z58c0BqGtNXa" title="Impairment of long lived assets"&gt;&lt;span id="xdx_90E_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_do_c20240701__20240930_zl7BEbqK85pl" title="Impairment of long lived assets"&gt;&lt;span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_do_c20240101__20240930_zeHhL8aMoIs1" title="Impairment of long lived assets"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; impairment was
recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--WarrantsPolicyTextBlock_z5fELiGYlOJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments,
meet the definition of a liability under ASC 480, and meet all of the requirements for equity classification, including whether the warrants
are indexed to the Company&#x2019;s own common stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d;
in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires
the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period end date while
the warrants are outstanding. Warrants that meet all the criteria for equity classification, are required to be recorded as a component
of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities
at their initial fair value on the date of issuance and remeasured to fair value at each balance sheet date thereafter. The liability-classified
warrants are recorded under non-current liabilities. Changes in the estimated fair value of the warrants are recognized in Financial
expenses or income in the unaudited interim condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued warrants in connection with the Series G Preferred financing and Series H Preferred financing, which were recorded as
liabilities. The rest of the Company&#x2019;s outstanding warrants are equity classified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_ecustom--AccruedSeverancePayPolicyTextBlock_z8oYmgDVav89" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accrued
severance pay&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based
on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large
part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies.
The value of these deposits and policies is recorded as an asset in the Company&#x2019;s balance sheet. Accrued severance pay liability
on September 30, 2025, and December 31, 2024, was $&lt;span id="xdx_907_ecustom--AccruedSeverancePayLiability_pn3n3_c20250101__20250930_zbbcb1wQGDA2" title="Accrued severance pay liability"&gt;260&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--AccruedSeverancePayLiability_pn3n3_c20240101__20241231_zQ0y35yMDaZd" title="Accrued severance pay liability"&gt;216&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_z6xuZ0tNRhPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its leases in accordance with ASU 2016-02, &#x201c;Leases&#x201d; (Topic 842). This topic requires that a lessee recognize
the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the
consolidated balance sheet for all leases with a term longer than 12 months and classifies them as operating leases. For leases with
a term of 12 months or less, the Company elects not to recognize lease assets and lease liabilities on those leases. Lease liabilities
have been measured by the present value of the Company&#x2019;s remaining lease payments over the lease term using our incremental borrowing
rates or implicit rates, when readily determined.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may sell its insertion systems to customers through bundled lease arrangements which typically include insertion systems and
nasoenteral tubes. Revenues under these bundled lease arrangements are allocated considering the relative standalone selling prices of
the lease and non-lease components included in the bundled arrangement. The primary accounting provision the Company uses to classify
transactions as sales-type or operating leases is whether the lease transfers ownership of the underlying asset to the lessee by the
end of the lease term. Systems included in arrangements meeting this condition are accounted for as sales-type leases and revenue is
recognized at lease commencement. When leases are determined to be operating leases, revenue is recognized over the term of the lease.
For the nine-month period ended September 30, 2025, there were no operating leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from sales-type leases is presented on a gross basis when the Company enters into a lease to realize value from a product that it would
otherwise sell in its ordinary course of business&#x2014;see revenue recognition policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
income for the nine-month period ended September 30, 2025 was immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the commencement date of sales-type leases for the nine-month period ended September 30, 2025, the Company recognized $&lt;span id="xdx_908_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20250101__20250930_z4w9ioKeV08e" title="Sales-type lease revenue"&gt;43&lt;/span&gt;&#160;of revenue.
At the commencement date of sales-type leases nine-month period ended September 30, 2025, the Company recognized $&lt;span id="xdx_903_eus-gaap--CostOfGoodsSoldSalesTypeLease_pn3n3_c20250101__20250930_zDJjd2IO14cf" title="Sales-type lease. cost of revenue"&gt;36&lt;/span&gt;&#160;cost of revenue.
The Company&#x2019;s short -term net investment in a lease receivable as of September 30, 2025 was $&lt;span id="xdx_906_eus-gaap--SalesTypeLeaseLeaseReceivable_iI_pn3n3_c20250930_zceBCi8nzToi" title="Sales-type lease. lease receivable"&gt;20&lt;/span&gt;&#160;and is presented within trade
receivables in the interim consolidated balance sheets. The Company&#x2019;s long -term net investment in a lease receivable as of September
30, 2025 was $&lt;span id="xdx_907_ecustom--SalesTypeLeaseLeaseReceivableNoncurrent_iI_pn3n3_c20250930_zq1oAPtIUIAc" title="Sales-type lease. lease receivable"&gt;23&lt;/span&gt; and is presented within long-term trade receivables in the interim consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zICJTWjYLx0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
from product and services are recognized in accordance with ASC 606 &#x201c;Revenue Recognition.&#x201d; Five basic steps must be followed
before revenue can be recognized: (1) Identifying the contract(s) with a customer that create(s) enforceable rights and obligations;
(2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining
the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring
promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which
requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling
prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance
obligation by transferring a promised good or service to a customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company generates revenue from sales of products and services. Revenues from product sales is recorded at
the net sales price, or &#x201c;transaction price,&#x201d; which includes estimates of variable consideration that result from discounts
as well as allowances for returns. Revenue from product sales is recognized at a point in time when control of the product is transferred,
which is generally upon shipment to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
its ENvue sales, the Company regularly sells its Systems and Nasoenteral tubes on a stand-alone basis and therefore concludes these products
are separate performance obligations. Revenue from product sales is recognized at a point in time when control of the product is transferred,
which is generally upon shipment to the customer. Revenue from training services is recognized over time, while the Company provides
the services, which are usually completed in under a week.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also concluded that training services are capable of being distinct and separately identifiable and therefore should be accounted
for as a separate performance obligation. When a contract includes one of these products or services, the entire transaction price is
allocated to that product or service. When a contract includes a combination of products and services, the transaction price is allocated
to each performance obligation on a stand-alone selling price basis. The stand-alone selling prices are generally determined based on
the prices at which the Company separately sells the products and services. The Company&#x2019;s contracts with its ENvue customers generally
do not include rights of return.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Revenue from sales-type leases is presented
on a gross basis when the Company enters into a lease to realize value from a product that it would otherwise sell in its ordinary course
of business&#x2014;see lease policy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The payments are typically due between 30 and 60 days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applied the practical expedient in ASC 606 and did not evaluate payment terms of one year or less for the existence of a significant
financing component. The related revenue is recognized net of any taxes collected from customers which are subsequently remitted to governmental
entities (e.g., sales tax and other indirect taxes). The Company elected to not disclose information about the remaining performance
obligations that have original expected durations of one year or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
some of its contracts, the Company provides assurance type warranty services to its customers, in accordance with legal provisions or
industry standards to ensure the quality of the products. As such, the Company recognizes a provision for warranties in its financial
statements as applicable. As of September 30, 2025, the Company&#x2019;s provision for warranty amounted to $&lt;span id="xdx_907_ecustom--ProvisionForWarranty_iI_pn3n3_c20250930_z2MAgafOopz2" title="Provision for warranty"&gt;75&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--DebtPolicyTextBlock_zlGru4hipGn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Convertible
Debenture&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
permitted under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic
825, &lt;i&gt;Financial Instruments&lt;/i&gt; (&#x201c;ASC 825&#x201d;), the Company elects to account for its Debenture (as defined below), which
meets the required criteria, at fair value at inception and at each subsequent reporting date. Subsequent changes in fair value are recorded
as a component of non-operating loss in the consolidated statements of operations, except for adjustments related to instrument specific
credit risk, which are recorded as other comprehensive income. This election is made on an instrument-by-instrument basis as permitted
under ASC 825. As a result of electing the fair value option, direct costs and fees related to the Debenture are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of the Debenture using a Monte Carlo simulation model, which uses as inputs the fair value of our common
stock and estimates for the equity volatility and volume volatility of our common stock, the time to expiration of the Debenture, the
risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, we estimate our
expected future volatility based on the actual volatility of our common stock and historical volatility of our common stock utilizing
a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration
to the voluntary, mandatory and potential accelerated redemption scenarios. The risk-free interest rate is determined by reference to
the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability
of default is estimated using our financial information to calculate a default risk specific to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s convertible debenture was repaid in May 2025. During the nine-month period ended September 30, 2025, the Company recorded
fair value adjustment of $&lt;span id="xdx_90F_ecustom--RepaymentOfIssuanceOfDebt_pn3n3_c20250101__20250930_zrjLDJn39tLl" title="Repayment of issuance of debt"&gt;23&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ConsolidationVariableInterestEntityPolicy_zQgzSQKFOG51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Variable
interest entities &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its variable interests in variable interest entities (&#x201c;VIEs&#x201d;), and consolidates VIEs when the Company is
the primary beneficiary. The Company determines whether it is the primary beneficiary of a VIE based on its assessment of whether the
Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance and
(ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant
to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary
conclusion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--BusinessCombinationsPolicy_zmXjSxLYQX07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Business
combination&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the provisions of ASC 805, &#x201c;Business Combination&#x201d; and allocates the fair value of purchase consideration
to the tangible assets acquired, liabilities assumed, and intangible assets acquired based on their estimated fair values. The excess
of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill.
Goodwill generated from a business combination is primarily attributable to synergies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially
with respect to intangible assets. Significant estimates in valuing certain intangible assets include but are not limited to future expected
cash flows from acquired technology and acquired customer relationships from a market participant perspective, useful lives and discount
rates. Management&#x2019;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain
and unpredictable and, as a result, actual results may differ from estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition-related
expenses are recognized separately from the business combination and are expensed as incurred (see also Note 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHx6IUPtqGLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
issued accounting standards&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standard Board (&#x201c;FASB&#x201d;) issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740), Improvements
to Income Tax Disclosures&lt;/i&gt;, which requires disaggregated information about the effective tax rate reconciliation as well as information
on income taxes paid. The guidance is effective for the Company for annual periods beginning January 1, 2025. The Company is currently
evaluating the impact on its financial statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure
(Subtopic 220-40), Disaggregation of Income Statement Expenses&lt;/i&gt;, which requires disclosure of disaggregated information about certain
expense captions presented in the Consolidated Statements of Operations as well as disclosure about selling expense. The guidance will
be effective for the Company for annual periods beginning January 1, 2027 and interim periods beginning January 1, 2028, with early adoption
permitted. It could be applied either prospectively or retrospectively. The Company is currently evaluating the impact on its financial
statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2025, the FASB issued Accounting Standards Update No. 2025-05, &#x201c;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement
of Credit Losses for Accounts Receivable and Contract Assets&#x201d; (&#x201c;ASU 2025-05&#x201d;), which provides a practical expedient
for estimating expected credit losses for current accounts receivable and current contract assets. ASU 2025-05 will be effective for
annual periods beginning after December 15, 2025 and interim periods within those annual reporting periods and should be applied prospectively.
The Company is currently evaluating the impact of ASU 2025-05 on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001019">&lt;p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zLiQV6UD2zpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Basis
of presentation and principles of consolidation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts
and transactions have been eliminated in consolidation. The Company&#x2019;s condensed consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) for the interim
financial information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the accompanying
unaudited interim consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary
to state fairly the financial position and results of operations of the Company. These condensed consolidated financial statements and
notes thereto are unaudited and should be read in conjunction with the Company&#x2019;s audited financial statements for the year ended
December 31, 2024, as found in the Company&#x2019;s Annual Report on Form 10-K, as amended, initially filed with the Securities and Exchange
Commission (the &#x201c;SEC&#x201d;) on March 31, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
balance sheet for December 31, 2024, was derived from the Company&#x2019;s audited financial statements for the year ended December 31,
2024. The results of operations for the periods presented are not necessarily indicative of results that could be expected for the entire
fiscal year. Certain information and footnote disclosures normally included in the consolidated financial statements in accordance with
U.S. GAAP have been omitted in accordance with the rules and regulations of the SEC for interim reporting.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, including
ENvue as of the date of the ENvue Merger. Intercompany accounts and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2025-01-01to2025-09-30" id="Fact001021">&lt;p id="xdx_84D_eus-gaap--UseOfEstimates_zR8ZUxLeIwU1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Use
of estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and
assumptions. The Company believes that the estimates, judgments and assumptions used are reasonable based upon information available
at the time they are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during
the reporting period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001023">&lt;p id="xdx_84F_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zwr9YrIEOhRb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Foreign
currency translation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
currency of the primary economic environment in which the operations of the Company and certain subsidiaries are conducted is the U.S.
dollar; thus, the dollar is the functional currency of the Company and certain subsidiaries.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company and certain subsidiaries&#x2019; transactions and balances denominated in dollars are presented at their original amounts. Non-dollar
transactions and balances have been remeasured to dollars in accordance with ASC 830, &#x201c;Foreign Currency Matters&#x201d;. All transaction
gains and losses from remeasurement of monetary balance sheet items denominated in non-dollar currencies are reflected in the statements
of operations as financial income or expenses, as appropriate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
certain subsidiaries whose functional currency has been determined to be a non-dollar currency, assets and liabilities are translated
at period-end exchange rates and statement of operations items are translated at average exchange rates prevailing during the period.
Such translation adjustments are recorded as a separate component of accumulated other comprehensive income (loss) in shareholders&#x2019;
equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001025">&lt;p id="xdx_84A_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zjCiHfNDMW44" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Cash
and cash equivalents&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash
and cash equivalents consist of cash on hand and highly liquid investments with original maturities of three months or less, at the date
of purchase.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2025-01-01to2025-09-30" id="Fact001027">&lt;p id="xdx_846_eus-gaap--ConcentrationRiskCreditRisk_zEyabTYLhJD8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Concentration
of credit risk &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Financial
instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, trade receivables,
and other accounts receivable. The Company holds cash in various banking institutions. Such funds are insured by the Federal Deposit
Insurance Corporation (&#x201c;FDIC&#x201d;) up to $&lt;span id="xdx_90F_eus-gaap--CashFDICInsuredAmount_iI_pn3n3_c20250930__srt--RangeAxis__srt--MaximumMember_zmnYpNaXzWbi" title="Cash FDIC, insured amount"&gt;250&lt;/span&gt;. Cash balances could exceed insured amounts at any given time. Generally, these investments may be redeemed upon demand and the Company believes that the financial institutions
that hold the Company's cash deposits are financially sound and, accordingly, bear minimal risk. As of September
30, 2025, the Company had cash in excess of the FDIC insured amount totaling $&lt;span id="xdx_90C_eus-gaap--Cash_iI_pn3n3_c20250930_zTm1ScELaSGf" title="Cash uninsured amount"&gt;6,525&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2025-09-30_srt_MaximumMember"
      decimals="-3"
      id="Fact001029"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:Cash
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001031"
      unitRef="USD">6525000</us-gaap:Cash>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2025-01-01to2025-09-30" id="Fact001033">&lt;p id="xdx_847_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zn6SShIgGgpi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Trade
receivables&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s trade receivable balance consists of amounts due from its customers. The Current Expected Credit Losses (&#x201c;CECL&#x201d;)
impairment model requires an estimate of expected credit losses, measured over the contractual life of an instrument, which considers
forecasts of future economic conditions in addition to information about past events and current conditions. Based on this model, the
Company considers many factors, including the age of the balance, collection history, and current economic trends. Credit losses are
written off after all collection efforts have ceased. Allowances for credit losses are recorded as a direct reduction from an asset&#x2019;s
amortized cost basis. Credit losses and recoveries are recorded in selling, general and administrative expenses in the consolidated statements
of operations. Recoveries of financial assets previously written off are recorded when received. As of September 30, 2025, the credit
losses allowance was immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001035">&lt;p id="xdx_845_eus-gaap--EarningsPerSharePolicyTextBlock_z15ohwyo3Ywh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Earnings
per share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company computes net loss per share using the two-class method required for participating securities. The two-class method requires
income available to common stockholders for the period to be allocated between shares of Common Stock and participating securities
based upon their respective rights to receive dividends as if all income for the period had been distributed. The Company&#x2019;s
Series X Preferred Shares and Series H Preferred shares would be entitled to dividends that would be distributed to the holders of
Common Stock, based on the conversion ratio, assuming conversion of all Convertible Series X Preferred Shares and Series H Preferred
shares into shares of Common Stock. The Company does not allocate losses to these participating securities as they do not share in
the Company&#x2019;s losses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s basic net loss per share is calculated by dividing net loss attributable to common and preferred stockholders by the
weighted-average number of shares, which include prefunded warrants, without consideration of potentially dilutive securities. The diluted
net loss per share is calculated by giving effect to all potentially dilutive securities outstanding for the period using the treasury
share method or the if-converted method based on the nature of such securities. Diluted net loss per share is the same as basic net loss
per share in periods when the effects of potentially dilutive shares of Common Stock are anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001037">&lt;p id="xdx_848_eus-gaap--InventoryPolicyTextBlock_zf1OThWxFWz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Inventory&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are stated at the lower of cost or net realizable value. Net realizable value is the estimated selling prices in the ordinary course
of business, less reasonably predictable costs of completion, disposal, and transportation. Cost is determined using the &#x201c;first-in,
first-out&#x201d; method.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
write-offs are provided to cover risks arising from slow-moving items or technological obsolescence. The Company periodically evaluates
the quantities on hand relative to current and historical selling prices and historical and projected sales volume. Based on this evaluation,
provisions are made when required to write-down inventory to its net market value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2025-01-01to2025-09-30" id="Fact001039">&lt;p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zevs2TaCyNO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Goodwill&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goodwill
has been recorded as a result of the acquisition. Goodwill represents the excess of the purchase price in a business combination over
the fair value of identifiable tangible and intangible assets acquired. Goodwill is not amortized but rather is subject to an impairment
test.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
No. 350, &#x201c;Intangibles - Goodwill and other&#x201d; (&#x201c;ASC No. 350&#x201d;) requires goodwill to be tested for impairment at
the reporting unit level at least annually or between annual tests in certain circumstances and written down when impaired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;ASC
No. 350 allows an entity to first assess qualitative factors to determine whether it is necessary to perform the quantitative goodwill
impairment test. If the qualitative assessment does not result in a more likely than not indication of impairment, no further impairment
testing is required. If it does result in a more likely than not indication of impairment, the quantitative goodwill impairment test
is performed. Alternatively, ASC No. 350 permits an entity to bypass the qualitative assessment for any reporting unit and proceed directly
to perform the quantitative goodwill impairment test. The Company performs the quantitative goodwill impairment test during the fourth
quarter of each fiscal year, or more frequently if impairment indicators are present and compares the fair value of the reporting unit
with its carrying value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the nine months ended September 30, 2025 and 2024, &lt;span id="xdx_903_eus-gaap--GoodwillImpairmentLoss_pn3n3_do_c20250101__20250930_zO3KDQ1UD8f4" title="Goodwill impairment"&gt;&lt;span id="xdx_90B_eus-gaap--GoodwillImpairmentLoss_pn3n3_do_c20240101__20240930_zrLRo60lnEm" title="Goodwill impairment"&gt;no&lt;/span&gt;&lt;/span&gt; impairment was recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001041"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact001043"
      unitRef="USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="From2025-01-01to2025-09-30" id="Fact001045">&lt;p id="xdx_84E_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_znhqNJf62L6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Intangible
Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash
flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives, which
is &lt;span id="xdx_908_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250101__20250930__srt--RangeAxis__srt--MinimumMember_zHmFXUYYG4gf" title="Acquired estimated useful lives"&gt;5&lt;/span&gt; &#x2013; &lt;span id="xdx_90B_eus-gaap--AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_dtY_c20250101__20250930__srt--RangeAxis__srt--MaximumMember_zJHSLnIYx0E5" title="Acquired estimated useful lives"&gt;7&lt;/span&gt; years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zeDL1ibzQ7z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives of the Company&#x2019;s intangible assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B6_zmqGirkfDx9a" style="display: none"&gt;SCHEDULE
OF INTANGIBLE ASSETS ESTIMATED USEFUL LIVES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Intangible Assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Tradename and trademarks&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z1mZ6mNDzrm6" title="Intangible assets estimated useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zjYo3jL3DS15" title="Intangible assets estimated useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer list&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerListsMember_zCrx0h2UUOzc" title="Intangible assets estimated useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zsRY2AWv0zti" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2025-01-012025-09-30_srt_MinimumMember"
      id="Fact001047">P5Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="From2025-01-012025-09-30_srt_MaximumMember"
      id="Fact001049">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001051">&lt;p id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zeDL1ibzQ7z4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives of the Company&#x2019;s intangible assets are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B6_zmqGirkfDx9a" style="display: none"&gt;SCHEDULE
OF INTANGIBLE ASSETS ESTIMATED USEFUL LIVES&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: justify"&gt;Intangible Assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Tradename and trademarks&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_z1mZ6mNDzrm6" title="Intangible assets estimated useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TechnologyBasedIntangibleAssetsMember_zjYo3jL3DS15" title="Intangible assets estimated useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Customer list&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20250930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerListsMember_zCrx0h2UUOzc" title="Intangible assets estimated useful life"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2025-09-30_us-gaap_TrademarksAndTradeNamesMember"
      id="Fact001053">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2025-09-30_us-gaap_TechnologyBasedIntangibleAssetsMember"
      id="Fact001055">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="AsOf2025-09-30_us-gaap_CustomerListsMember"
      id="Fact001057">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001059">&lt;p id="xdx_842_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zz61XuURaS58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Property
and equipment, net&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are stated at cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the
estimated useful lives of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zupeJjcpHDl2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives of the Company&#x2019;s property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BC_z9kpncmxnod8" style="display: none"&gt;SCHEDULE
OF USEFUL LIVES OF THE COMPANY&#x2019;S PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Computers and peripheral equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zv6x20RY0Mj4" title="Estimated useful life"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zanrc1xvanPf" title="Estimated useful life"&gt;5&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_ze8dXDvWdAn" title="Estimated useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20250930_zQxMLDjHg8F" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23LeaseholdImprovementsMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1068"&gt;The shorter of term of the lease or the useful life of the asset&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zAsTAWI0K2h5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001061">&lt;p id="xdx_895_eus-gaap--PropertyPlantAndEquipmentTextBlock_zupeJjcpHDl2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
estimated useful lives of the Company&#x2019;s property and equipment are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BC_z9kpncmxnod8" style="display: none"&gt;SCHEDULE
OF USEFUL LIVES OF THE COMPANY&#x2019;S PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Years&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Computers and peripheral equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 18%; text-align: center"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zv6x20RY0Mj4" title="Estimated useful life"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MinimumMember_zanrc1xvanPf" title="Estimated useful life"&gt;5&lt;/span&gt;-&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20250930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember__srt--RangeAxis__srt--MaximumMember_ze8dXDvWdAn" title="Estimated useful life"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentDepreciationMethodExtensibleEnumeration_iI_dxL_c20250930_zQxMLDjHg8F" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2025%23LeaseholdImprovementsMember"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1068"&gt;The shorter of term of the lease or the useful life of the asset&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-09-30_us-gaap_ComputerEquipmentMember"
      id="Fact001063">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-09-30_us-gaap_OfficeEquipmentMember_srt_MinimumMember"
      id="Fact001065">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2025-09-30_us-gaap_OfficeEquipmentMember_srt_MaximumMember"
      id="Fact001067">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001070">&lt;p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z57YghytELv8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Impairment
of Long-Lived Assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
long-lived assets of the Company, including finite-lived intangible assets, are reviewed for impairment in accordance with ASC No. 360,
&#x201c;Property, Plant and Equipment&#x201d;, whenever events or changes in circumstances indicate that the carrying amount of an asset
may not be recoverable. The recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset
to the future undiscounted cash flows expected to be generated by the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of
the assets exceeds the fair value of the assets. During the three and nine months ended September 30, 2025 and 2024, &lt;span id="xdx_904_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_do_c20250701__20250930_zKyHu5Dv32w8" title="Impairment of long lived assets"&gt;&lt;span id="xdx_908_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_do_c20250101__20250930_z58c0BqGtNXa" title="Impairment of long lived assets"&gt;&lt;span id="xdx_90E_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_do_c20240701__20240930_zl7BEbqK85pl" title="Impairment of long lived assets"&gt;&lt;span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsToBeDisposedOf_pn3n3_do_c20240101__20240930_zeHhL8aMoIs1" title="Impairment of long lived assets"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; impairment was
recorded.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact001072"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001074"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001076"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact001078"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <NAOV:WarrantsPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001080">&lt;p id="xdx_849_ecustom--WarrantsPolicyTextBlock_z5fELiGYlOJ9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s
specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments,
meet the definition of a liability under ASC 480, and meet all of the requirements for equity classification, including whether the warrants
are indexed to the Company&#x2019;s own common stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d;
in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires
the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent reporting period end date while
the warrants are outstanding. Warrants that meet all the criteria for equity classification, are required to be recorded as a component
of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities
at their initial fair value on the date of issuance and remeasured to fair value at each balance sheet date thereafter. The liability-classified
warrants are recorded under non-current liabilities. Changes in the estimated fair value of the warrants are recognized in Financial
expenses or income in the unaudited interim condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued warrants in connection with the Series G Preferred financing and Series H Preferred financing, which were recorded as
liabilities. The rest of the Company&#x2019;s outstanding warrants are equity classified.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NAOV:WarrantsPolicyTextBlock>
    <NAOV:AccruedSeverancePayPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001082">&lt;p id="xdx_84D_ecustom--AccruedSeverancePayPolicyTextBlock_z8oYmgDVav89" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Accrued
severance pay&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s liability for severance pay is for its Israeli employees and is calculated pursuant to Israeli Severance Pay Law based
on the most recent salary of the employees multiplied by the number of years of employment as of the balance sheet date and is in large
part covered by regular deposits with recognized pension funds, deposits with severance pay funds and purchases of insurance policies.
The value of these deposits and policies is recorded as an asset in the Company&#x2019;s balance sheet. Accrued severance pay liability
on September 30, 2025, and December 31, 2024, was $&lt;span id="xdx_907_ecustom--AccruedSeverancePayLiability_pn3n3_c20250101__20250930_zbbcb1wQGDA2" title="Accrued severance pay liability"&gt;260&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--AccruedSeverancePayLiability_pn3n3_c20240101__20241231_zQ0y35yMDaZd" title="Accrued severance pay liability"&gt;216&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NAOV:AccruedSeverancePayPolicyTextBlock>
    <NAOV:AccruedSeverancePayLiability
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001084"
      unitRef="USD">260000</NAOV:AccruedSeverancePayLiability>
    <NAOV:AccruedSeverancePayLiability
      contextRef="From2024-01-012024-12-31"
      decimals="-3"
      id="Fact001086"
      unitRef="USD">216000</NAOV:AccruedSeverancePayLiability>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001088">&lt;p id="xdx_848_eus-gaap--LesseeLeasesPolicyTextBlock_z6xuZ0tNRhPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for its leases in accordance with ASU 2016-02, &#x201c;Leases&#x201d; (Topic 842). This topic requires that a lessee recognize
the assets and liabilities that arise from operating leases. The Company recognizes right-of-use assets and lease liabilities on the
consolidated balance sheet for all leases with a term longer than 12 months and classifies them as operating leases. For leases with
a term of 12 months or less, the Company elects not to recognize lease assets and lease liabilities on those leases. Lease liabilities
have been measured by the present value of the Company&#x2019;s remaining lease payments over the lease term using our incremental borrowing
rates or implicit rates, when readily determined.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company may sell its insertion systems to customers through bundled lease arrangements which typically include insertion systems and
nasoenteral tubes. Revenues under these bundled lease arrangements are allocated considering the relative standalone selling prices of
the lease and non-lease components included in the bundled arrangement. The primary accounting provision the Company uses to classify
transactions as sales-type or operating leases is whether the lease transfers ownership of the underlying asset to the lessee by the
end of the lease term. Systems included in arrangements meeting this condition are accounted for as sales-type leases and revenue is
recognized at lease commencement. When leases are determined to be operating leases, revenue is recognized over the term of the lease.
For the nine-month period ended September 30, 2025, there were no operating leases.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenue
from sales-type leases is presented on a gross basis when the Company enters into a lease to realize value from a product that it would
otherwise sell in its ordinary course of business&#x2014;see revenue recognition policy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Interest
income for the nine-month period ended September 30, 2025 was immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the commencement date of sales-type leases for the nine-month period ended September 30, 2025, the Company recognized $&lt;span id="xdx_908_eus-gaap--SalesTypeLeaseRevenue_pn3n3_c20250101__20250930_z4w9ioKeV08e" title="Sales-type lease revenue"&gt;43&lt;/span&gt;&#160;of revenue.
At the commencement date of sales-type leases nine-month period ended September 30, 2025, the Company recognized $&lt;span id="xdx_903_eus-gaap--CostOfGoodsSoldSalesTypeLease_pn3n3_c20250101__20250930_zDJjd2IO14cf" title="Sales-type lease. cost of revenue"&gt;36&lt;/span&gt;&#160;cost of revenue.
The Company&#x2019;s short -term net investment in a lease receivable as of September 30, 2025 was $&lt;span id="xdx_906_eus-gaap--SalesTypeLeaseLeaseReceivable_iI_pn3n3_c20250930_zceBCi8nzToi" title="Sales-type lease. lease receivable"&gt;20&lt;/span&gt;&#160;and is presented within trade
receivables in the interim consolidated balance sheets. The Company&#x2019;s long -term net investment in a lease receivable as of September
30, 2025 was $&lt;span id="xdx_907_ecustom--SalesTypeLeaseLeaseReceivableNoncurrent_iI_pn3n3_c20250930_zq1oAPtIUIAc" title="Sales-type lease. lease receivable"&gt;23&lt;/span&gt; and is presented within long-term trade receivables in the interim consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:SalesTypeLeaseRevenue
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001090"
      unitRef="USD">43000</us-gaap:SalesTypeLeaseRevenue>
    <us-gaap:CostOfGoodsSoldSalesTypeLease
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001092"
      unitRef="USD">36000</us-gaap:CostOfGoodsSoldSalesTypeLease>
    <us-gaap:SalesTypeLeaseLeaseReceivable
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001094"
      unitRef="USD">20000</us-gaap:SalesTypeLeaseLeaseReceivable>
    <NAOV:SalesTypeLeaseLeaseReceivableNoncurrent
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001096"
      unitRef="USD">23000</NAOV:SalesTypeLeaseLeaseReceivableNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001098">&lt;p id="xdx_841_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zICJTWjYLx0f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Revenue
recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Revenues
from product and services are recognized in accordance with ASC 606 &#x201c;Revenue Recognition.&#x201d; Five basic steps must be followed
before revenue can be recognized: (1) Identifying the contract(s) with a customer that create(s) enforceable rights and obligations;
(2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining
the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring
promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which
requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling
prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance
obligation by transferring a promised good or service to a customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company generates revenue from sales of products and services. Revenues from product sales is recorded at
the net sales price, or &#x201c;transaction price,&#x201d; which includes estimates of variable consideration that result from discounts
as well as allowances for returns. Revenue from product sales is recognized at a point in time when control of the product is transferred,
which is generally upon shipment to the customer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Regarding
its ENvue sales, the Company regularly sells its Systems and Nasoenteral tubes on a stand-alone basis and therefore concludes these products
are separate performance obligations. Revenue from product sales is recognized at a point in time when control of the product is transferred,
which is generally upon shipment to the customer. Revenue from training services is recognized over time, while the Company provides
the services, which are usually completed in under a week.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company also concluded that training services are capable of being distinct and separately identifiable and therefore should be accounted
for as a separate performance obligation. When a contract includes one of these products or services, the entire transaction price is
allocated to that product or service. When a contract includes a combination of products and services, the transaction price is allocated
to each performance obligation on a stand-alone selling price basis. The stand-alone selling prices are generally determined based on
the prices at which the Company separately sells the products and services. The Company&#x2019;s contracts with its ENvue customers generally
do not include rights of return.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Revenue from sales-type leases is presented
on a gross basis when the Company enters into a lease to realize value from a product that it would otherwise sell in its ordinary course
of business&#x2014;see lease policy.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The payments are typically due between 30 and 60 days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applied the practical expedient in ASC 606 and did not evaluate payment terms of one year or less for the existence of a significant
financing component. The related revenue is recognized net of any taxes collected from customers which are subsequently remitted to governmental
entities (e.g., sales tax and other indirect taxes). The Company elected to not disclose information about the remaining performance
obligations that have original expected durations of one year or less.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
some of its contracts, the Company provides assurance type warranty services to its customers, in accordance with legal provisions or
industry standards to ensure the quality of the products. As such, the Company recognizes a provision for warranties in its financial
statements as applicable. As of September 30, 2025, the Company&#x2019;s provision for warranty amounted to $&lt;span id="xdx_907_ecustom--ProvisionForWarranty_iI_pn3n3_c20250930_z2MAgafOopz2" title="Provision for warranty"&gt;75&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <NAOV:ProvisionForWarranty
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001100"
      unitRef="USD">75000</NAOV:ProvisionForWarranty>
    <us-gaap:DebtPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001102">&lt;p id="xdx_842_eus-gaap--DebtPolicyTextBlock_zlGru4hipGn5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Convertible
Debenture&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
permitted under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic
825, &lt;i&gt;Financial Instruments&lt;/i&gt; (&#x201c;ASC 825&#x201d;), the Company elects to account for its Debenture (as defined below), which
meets the required criteria, at fair value at inception and at each subsequent reporting date. Subsequent changes in fair value are recorded
as a component of non-operating loss in the consolidated statements of operations, except for adjustments related to instrument specific
credit risk, which are recorded as other comprehensive income. This election is made on an instrument-by-instrument basis as permitted
under ASC 825. As a result of electing the fair value option, direct costs and fees related to the Debenture are expensed as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates the fair value of the Debenture using a Monte Carlo simulation model, which uses as inputs the fair value of our common
stock and estimates for the equity volatility and volume volatility of our common stock, the time to expiration of the Debenture, the
risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, we estimate our
expected future volatility based on the actual volatility of our common stock and historical volatility of our common stock utilizing
a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date, giving consideration
to the voluntary, mandatory and potential accelerated redemption scenarios. The risk-free interest rate is determined by reference to
the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability
of default is estimated using our financial information to calculate a default risk specific to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s convertible debenture was repaid in May 2025. During the nine-month period ended September 30, 2025, the Company recorded
fair value adjustment of $&lt;span id="xdx_90F_ecustom--RepaymentOfIssuanceOfDebt_pn3n3_c20250101__20250930_zrjLDJn39tLl" title="Repayment of issuance of debt"&gt;23&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtPolicyTextBlock>
    <NAOV:RepaymentOfIssuanceOfDebt
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001104"
      unitRef="USD">23000</NAOV:RepaymentOfIssuanceOfDebt>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="From2025-01-01to2025-09-30" id="Fact001106">&lt;p id="xdx_843_eus-gaap--ConsolidationVariableInterestEntityPolicy_zQgzSQKFOG51" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Variable
interest entities &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluates its variable interests in variable interest entities (&#x201c;VIEs&#x201d;), and consolidates VIEs when the Company is
the primary beneficiary. The Company determines whether it is the primary beneficiary of a VIE based on its assessment of whether the
Company possesses both (i) the power to direct the activities that most significantly affect the VIE&#x2019;s economic performance and
(ii) the obligation to absorb losses that could be significant to the VIE or the right to receive benefits that could be significant
to the VIE. The Company reevaluates the accounting for its VIEs upon the occurrence of events that could change the primary beneficiary
conclusion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:BusinessCombinationsPolicy contextRef="From2025-01-01to2025-09-30" id="Fact001108">&lt;p id="xdx_84E_eus-gaap--BusinessCombinationsPolicy_zmXjSxLYQX07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Business
combination&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the provisions of ASC 805, &#x201c;Business Combination&#x201d; and allocates the fair value of purchase consideration
to the tangible assets acquired, liabilities assumed, and intangible assets acquired based on their estimated fair values. The excess
of the fair value of purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill.
Goodwill generated from a business combination is primarily attributable to synergies.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;When
determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially
with respect to intangible assets. Significant estimates in valuing certain intangible assets include but are not limited to future expected
cash flows from acquired technology and acquired customer relationships from a market participant perspective, useful lives and discount
rates. Management&#x2019;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain
and unpredictable and, as a result, actual results may differ from estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition-related
expenses are recognized separately from the business combination and are expensed as incurred (see also Note 4).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001110">&lt;p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zHx6IUPtqGLl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Recently
issued accounting standards&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
December 2023, the Financial Accounting Standard Board (&#x201c;FASB&#x201d;) issued ASU 2023-09, &lt;i&gt;Income Taxes (Topic 740), Improvements
to Income Tax Disclosures&lt;/i&gt;, which requires disaggregated information about the effective tax rate reconciliation as well as information
on income taxes paid. The guidance is effective for the Company for annual periods beginning January 1, 2025. The Company is currently
evaluating the impact on its financial statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
November 2024, the FASB issued ASU 2024-03, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosure
(Subtopic 220-40), Disaggregation of Income Statement Expenses&lt;/i&gt;, which requires disclosure of disaggregated information about certain
expense captions presented in the Consolidated Statements of Operations as well as disclosure about selling expense. The guidance will
be effective for the Company for annual periods beginning January 1, 2027 and interim periods beginning January 1, 2028, with early adoption
permitted. It could be applied either prospectively or retrospectively. The Company is currently evaluating the impact on its financial
statement disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
July 2025, the FASB issued Accounting Standards Update No. 2025-05, &#x201c;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement
of Credit Losses for Accounts Receivable and Contract Assets&#x201d; (&#x201c;ASU 2025-05&#x201d;), which provides a practical expedient
for estimating expected credit losses for current accounts receivable and current contract assets. ASU 2025-05 will be effective for
annual periods beginning after December 15, 2025 and interim periods within those annual reporting periods and should be applied prospectively.
The Company is currently evaluating the impact of ASU 2025-05 on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001112">&lt;p id="xdx_80E_eus-gaap--BusinessCombinationDisclosureTextBlock_zYKInK6cNBF7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
4 &#x2013; &lt;span id="xdx_825_z5SNmoMsdBrf"&gt;MERGER&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Agreement
and Plan of Merger&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2025, pursuant to the terms of that certain Agreement and Plan of Merger (as amended, restated, amended and restated, supplemented
or modified from time to time, the &#x201c;Merger Agreement&#x201d;), dated as of February 14, 2025, by and among us, NVEH Merger Sub I,
Inc., a Delaware corporation and a wholly-owned subsidiary of the Company (&#x201c;First Merger Sub&#x201d;), NVEH Merger Sub II, LLC,
a Delaware limited liability company and a wholly-owned subsidiary of the Company (&#x201c;Second Merger Sub&#x201d;), and ENvue Medical
Holdings, Corp. (&#x201c;Predecessor ENvue&#x201d; or &#x201c;ENvue&#x201d;), the Company and Predecessor ENvue effected (i) a merger of
First Merger Sub with and into Predecessor ENvue, with the First Merger Sub ceasing to exist and Predecessor ENvue becoming a wholly-owned
subsidiary the Company (the &#x201c;First Merger&#x201d;, and effective time of such First Merger, the &#x201c;First Effective Time&#x201d;)
and (ii) the merger of Predecessor ENvue with and into Second Merger Sub (the &#x201c;Second Merger&#x201d; and, together with the First
Merger, the &#x201c;Merger&#x201d;), with Second Merger Sub being the surviving entity of the Second Merger (&#x201c;Surviving Entity&#x201d;).
At the effective time of the Second Merger, the certificate of formation of the Surviving Entity was amended and restated to, among other
things, to change the name of the Surviving Entity to &#x201c;ENvue Medical Holdings LLC.&#x201d; In connection with the Merger Agreement,
we issued (i) &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zr1BpyyW1aW" title="Number of new share issued"&gt;3,318&lt;/span&gt; shares of common stock (the &#x201c;Merger Shares&#x201d;), which such number of shares represented no more than &lt;span id="xdx_90C_ecustom--PercentageForNumberOfOutstandingCommonStock_pid_dp_uPure_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zp3sOsImZe9b" title="Percentage for number of outstanding common stock"&gt;4.9&lt;/span&gt;%
(the &#x201c;Exchange Cap&#x201d;) of the outstanding shares of common stock as of immediately before the First Effective Time and (ii)
Pre-Funded Warrants to purchase up to &lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__srt--RangeAxis__srt--MaximumMember_zeEUx3b2bR3" title="Number of securities called by warrants or rights"&gt;12,526&lt;/span&gt; shares of our common stock (the &#x201c;Merger Pre-Funded Warrants&#x201d;) at an exercise
price of $&lt;span id="xdx_905_eus-gaap--WarrantExercisePriceIncrease_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zRE4JXV8svR2" title="Warrant exercise price"&gt;0.001&lt;/span&gt; per share, and (iii) &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zKbCHF6dZsUi" title="Convertible shares"&gt;57,720&lt;/span&gt; shares of Series X Non-Voting Convertible Preferred Stock (the &#x201c;Series X Preferred
Stock&#x201d;) in excess of the Exchange Cap to the holders of Predecessor ENvue in consideration for &lt;span id="xdx_906_ecustom--PercentageForExchangeCapitalForConsideration_pid_dp_uPure_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ7OB15z81tf" title="Percentage for exchange capital for consideration"&gt;100&lt;/span&gt;% of Predecessor ENvue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Given
that both companies operate in the medical device sector and demonstrate natural synergies and strategic alignment in their operations,
the merger was undertaken to combine and enhance their respective strengths. The Company concluded the merger resulted in the Company
obtaining a controlling financial interest in VIE in accordance with &lt;i&gt;ASC 810, Consolidation&lt;/i&gt;. The Company determined that ENvue
was considered to be a VIE as it did not have sufficient equity to finance its activities without additional subordinated financial support.
The Company acquired all of the outstanding shares of ENvue and, therefore, is the sole equity holder and primary beneficiary. The Company
has the obligation to the absorb losses and right to receive the benefits of ENvue, and the power to direct the activities that most
significantly affect the economic performance of ENvue. Therefore, the Company is the primary beneficiary. Further, the Company concluded
that ENvue qualified as a business and accounted for the transaction as the acquisition of a business in accordance with ASC 805. As
the primary beneficiary, the Company was the acquirer in the transaction. In the second quarter of 2025, during the measurement period,
the Company revised certain aspects of the purchase price allocation. As a result, goodwill and additional paid-in capital increased
to reflect updated information available within the measurement period, in accordance with ASC 805, &lt;i&gt;Business Combinations&lt;/i&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
additional details regarding the Series X Preferred Stock, refer to note 6 &#x2013; stockholders&#x2019; equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
acquisition date fair value of the consideration transferred amounted to $&lt;span id="xdx_90B_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember_z1nKKYn9PYs7" title="Fair value of consideration transferred amount"&gt;41,864&lt;/span&gt;, which included a combination of the Company ordinary
shares, Series X Preferred Stock and Pre-Funded Warrants. Issuance costs of Series X Preferred Stock were immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Acquisition-related
expenses of approximately $&lt;span id="xdx_906_eus-gaap--BusinessCombinationAcquisitionRelatedCosts_pn3n3_c20250101__20250930__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zeVzfnmVq6b5" title="Acquisition-related expenses"&gt;461&lt;/span&gt; were expensed by the Company in general and administrative expenses in its condensed consolidated statements
of comprehensive loss for the nine months ended September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
transaction was accounted for as a business combination in accordance with ASC No. 805, &#x201c;Business Combinations.&#x201d; The total
purchase price was preliminarily allocated using information currently available to the Company and may be subject to change as additional
information is received during the respective measurement period, up to one year from the acquisition date. Preliminary allocation of
the purchase price to the tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair
values as of the acquisition date is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zt0DECAuFIjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zmJbuuXZzaM4" style="display: none"&gt;SCHEDULE
OF INTANGIBLE ASSETS AND LIABILITIES ASSUMED BASED ON THEIR ESTIMATED FAIR
VALUES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Purchase price:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250101__20250930__us-gaap--BusinessAcquisitionAxis__custom--ENvueMedicalHoldingsCorpMember_zI1KZNWbRSk2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockAndPreFundedWarrantsMember_zsBCbDidELHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Common Stock and Pre-Funded Warrants consideration&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;179&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_hus-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zc1yh6mCJJHe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Series X Preferred Stock consideration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;41,685&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_zOx6gUIwKMY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold"&gt;Total purchase price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41,864&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Allocated tangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetWorkingCapital_iE_pn3n3_zKWxrM6qMtef" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net working capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,198&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iE_pn3n3_z2TgB4P6moy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iE_pn3n3_zsgpeYmwcaoc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofuseAssets_iE_pn3n3_zwgFCTp5bRhb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_iNE_pn3n3_di_zO6jM7hW3Zl6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iNE_pn3n3_di_zRDUL9HH75ma" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left"&gt;Total allocated tangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,647&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Purchase price allocated to intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Goodwill_iE_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zsatX1oaHpe3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tradename and trademarks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;560&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Goodwill_iE_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ProprietaryTechnologyMember_zDJi1GTqYOXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Proprietary technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--Goodwill_iE_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxdeZgF7FJh7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Customer relationships&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,820&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Goodwill_iE_pn3n3_zuHjBGMnFqGc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left"&gt;Goodwill (unallocated intangible value)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zy8TuznzXfZ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
excess purchase price has been recorded as &#x201c;goodwill&#x201d; in the amount of $&lt;span id="xdx_90D_eus-gaap--Goodwill_iI_pn3n3_c20250930_zFMAllx9gtA3" title="Goodwill"&gt;38,631&lt;/span&gt;. The estimated useful life of the identifiable
intangible assets is five to seven years. Goodwill is not expected to be tax deductible.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Supplemental
Unaudited Pro Forma Information&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zvH5XM3b9Xfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
are the supplemental consolidated financial results of the Company, NanoVibronix and ENvue on an unaudited pro forma basis, as if the
acquisitions had been consummated as of the beginning of the fiscal year 2025 (i.e., January 1, 2025).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zj1ajKuZjgNf" style="display: none"&gt;SCHEDULE OF SUPPLEMENTAL CONSOLIDATED FINANCIAL RESULT OF THE COMPANY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20250930__us-gaap--BusinessAcquisitionAxis__custom--ENvueMedicalHoldingsCorpMember_zIoIjeMr90n7" style="font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--Revenues_zDYkvwBi7BUg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_z4dZImqv47Z7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,113&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_ziTaDLIt4IY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited pro forma financial information below combines the historical results of the Company with the historical results of ENvue for
the nine months ended September 30, 2025, as if the Merger had occurred on January 1, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
unaudited pro forma financial information presented is for informational purposes only and is not necessarily indicative of the results
of operations that would have been achieved had the Merger been completed at the beginning of fiscal year 2025, nor is it indicative
of the future operating results of the combined company. The pro forma results includes and adjustment related to purchase accounting,
primarily amortization of acquisition-related intangible assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001114"
      unitRef="Shares">3318</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <NAOV:PercentageForNumberOfOutstandingCommonStock
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001116"
      unitRef="Pure">0.049</NAOV:PercentageForNumberOfOutstandingCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-02-14_custom_MergerAgreementMember_custom_PreFundedWarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001118"
      unitRef="Shares">12526</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001120"
      unitRef="USDPShares">0.001</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact001122"
      unitRef="Shares">57720</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <NAOV:PercentageForExchangeCapitalForConsideration
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001124"
      unitRef="Pure">1</NAOV:PercentageForExchangeCapitalForConsideration>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember"
      decimals="-3"
      id="Fact001126"
      unitRef="USD">41864000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="From2025-01-012025-09-30_custom_MergerAgreementMember_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="-3"
      id="Fact001128"
      unitRef="USD">461000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001130">&lt;p id="xdx_89D_eus-gaap--ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_zt0DECAuFIjk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BB_zmJbuuXZzaM4" style="display: none"&gt;SCHEDULE
OF INTANGIBLE ASSETS AND LIABILITIES ASSUMED BASED ON THEIR ESTIMATED FAIR
VALUES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold"&gt;Purchase price:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250101__20250930__us-gaap--BusinessAcquisitionAxis__custom--ENvueMedicalHoldingsCorpMember_zI1KZNWbRSk2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_hus-gaap--StatementEquityComponentsAxis__custom--CommonStockAndPreFundedWarrantsMember_zsBCbDidELHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Common Stock and Pre-Funded Warrants consideration&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;179&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_hus-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zc1yh6mCJJHe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Series X Preferred Stock consideration&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;41,685&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--BusinessCombinationConsiderationTransferred1_pn3n3_zOx6gUIwKMY2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold"&gt;Total purchase price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;41,864&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Allocated tangible assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetWorkingCapital_iE_pn3n3_zKWxrM6qMtef" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Net working capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,198&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_iE_pn3n3_z2TgB4P6moy3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iE_pn3n3_zsgpeYmwcaoc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofuseAssets_iE_pn3n3_zwgFCTp5bRhb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Right-of-use assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation_iNE_pn3n3_di_zO6jM7hW3Zl6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(14&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_iNE_pn3n3_di_zRDUL9HH75ma" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left"&gt;Total allocated tangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,647&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Purchase price allocated to intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--Goodwill_iE_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksAndTradeNamesMember_zsatX1oaHpe3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Tradename and trademarks&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;560&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Goodwill_iE_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ProprietaryTechnologyMember_zDJi1GTqYOXj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Proprietary technology&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--Goodwill_iE_pn3n3_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--CustomerRelationshipsMember_zxdeZgF7FJh7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Customer relationships&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,820&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Goodwill_iE_pn3n3_zuHjBGMnFqGc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left"&gt;Goodwill (unallocated intangible value)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;38,631&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2025-01-012025-09-30_custom_ENvueMedicalHoldingsCorpMember_custom_CommonStockAndPreFundedWarrantsMember"
      decimals="-3"
      id="Fact001132"
      unitRef="USD">179000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2025-01-012025-09-30_custom_ENvueMedicalHoldingsCorpMember_custom_SeriesXPreferredStockMember"
      decimals="-3"
      id="Fact001134"
      unitRef="USD">41685000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="From2025-01-012025-09-30_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001136"
      unitRef="USD">41864000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <NAOV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetWorkingCapital
      contextRef="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001138"
      unitRef="USD">-3198000</NAOV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetWorkingCapital>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
      contextRef="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001140"
      unitRef="USD">395000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001142"
      unitRef="USD">112000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <NAOV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofuseAssets
      contextRef="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001144"
      unitRef="USD">58000</NAOV:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRightofuseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation
      contextRef="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001146"
      unitRef="USD">14000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCapitalLeaseObligation>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001148"
      unitRef="USD">2647000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:Goodwill
      contextRef="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember_us-gaap_TrademarksAndTradeNamesMember"
      decimals="-3"
      id="Fact001150"
      unitRef="USD">560000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember_custom_ProprietaryTechnologyMember"
      decimals="-3"
      id="Fact001152"
      unitRef="USD">3500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember_us-gaap_CustomerRelationshipsMember"
      decimals="-3"
      id="Fact001154"
      unitRef="USD">1820000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-09-30_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001156"
      unitRef="USD">38631000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001158"
      unitRef="USD">38631000</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001160">&lt;p id="xdx_89C_eus-gaap--BusinessAcquisitionProFormaInformationTextBlock_zvH5XM3b9Xfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Following
are the supplemental consolidated financial results of the Company, NanoVibronix and ENvue on an unaudited pro forma basis, as if the
acquisitions had been consummated as of the beginning of the fiscal year 2025 (i.e., January 1, 2025).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zj1ajKuZjgNf" style="display: none"&gt;SCHEDULE OF SUPPLEMENTAL CONSOLIDATED FINANCIAL RESULT OF THE COMPANY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20250930__us-gaap--BusinessAcquisitionAxis__custom--ENvueMedicalHoldingsCorpMember_zIoIjeMr90n7" style="font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--Revenues_zDYkvwBi7BUg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Net revenue&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,296&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--NetIncomeLoss_z4dZImqv47Z7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Net loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,113&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-09-30_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001162"
      unitRef="USD">2296000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-012025-09-30_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001164"
      unitRef="USD">-5113000</us-gaap:NetIncomeLoss>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001166">&lt;p id="xdx_805_eus-gaap--InventoryDisclosureTextBlock_zvGcPbdaPize" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
5 &#x2013; &lt;span id="xdx_824_z2xOec9dMgq9"&gt;INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLMKYcSTX1Fc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of the following components:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zb2iPWpCJHij" style="display: none"&gt;SCHEDULE OF INVENTORY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250930_z8tIcjtExOe8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September
    30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzmOi_zfF4Srfh6lu9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,702&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 14%"&gt;391&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzmOi_z8tACWESVNJb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;541&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,800&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryNet_iTI_pn3n3_mtINzmOi_zsRYgcmemDyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total inventory&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,243&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;2,191&lt;/p&gt;


&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_z2AvOhdfUrp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
write-down charged to the cost of sales amounted to $&lt;span id="xdx_90C_eus-gaap--InventoryWriteDown_pn3n3_c20250101__20250930_zqDOhKtI1Ss8"&gt;119&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for
the nine months ended September 30, 2025, respectively, to reduce inventory to its net realizable value and for any excess
or obsolete inventory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;The Company identified certain inaccuracies in its 510(k) application for the PainShield MD Plus product and on August
19, 2025 submitted a request to the U.S. Food and Drug Administration (FDA) to withdraw the clearance. While the Company is unaware of
any safety issues related to the PainShield MD Plus product, it has decided to halt future sales. An appropriate inventory allowance was
recorded for the impact of halt in sales in the amount of $&lt;span id="xdx_90C_eus-gaap--InventoryAdjustments_iI_pn3n3_c20250930_zdGivo0tfRzj" title="Inventory allowance"&gt;119&lt;/span&gt;.&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001168">&lt;p id="xdx_890_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zLMKYcSTX1Fc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventory
consists of the following components:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zb2iPWpCJHij" style="display: none"&gt;SCHEDULE OF INVENTORY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250930_z8tIcjtExOe8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September
    30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2025&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzmOi_zfF4Srfh6lu9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,702&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;$&lt;/td&gt;
    &lt;td style="text-align: right; width: 14%"&gt;391&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzmOi_z8tACWESVNJb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;541&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,800&lt;/td&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--InventoryNet_iTI_pn3n3_mtINzmOi_zsRYgcmemDyi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total inventory&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,243&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;p style="margin: 0"&gt;2,191&lt;/p&gt;


&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001170"
      unitRef="USD">1702000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryFinishedGoods
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001172"
      unitRef="USD">541000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001174"
      unitRef="USD">2243000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001175"
      unitRef="USD">119000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryAdjustments
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001177"
      unitRef="USD">119000</us-gaap:InventoryAdjustments>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001179">&lt;p id="xdx_804_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zwENUWdVRvY2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
6 - &lt;span id="xdx_829_zZ8GUkpysPTl"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
common stock confers upon the holders the right to receive notice to participate and vote in general meetings of the Company, and the
right to receive dividends, if declared, and to participate in the distribution of the surplus assets and funds of the Company in the
event of liquidation, dissolution or winding up of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Reverse
stock splits&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 13, 2025, the Company effected a &lt;span id="xdx_90D_eus-gaap--StockholdersEquityReverseStockSplit_c20250313__20250313_zaNiCPFmCeNj" title="Reverse stock split"&gt;1-for-11 reverse stock split&lt;/span&gt; (the &#x201c;March 2025 Reverse Stock Split&#x201d;). On August 11,
2025, the Company effected a &lt;span id="xdx_901_eus-gaap--StockholdersEquityReverseStockSplit_c20250811__20250811_z3suATNWEF2h" title="Reverse stock split"&gt;1-for-10 reverse stock split&lt;/span&gt; (the &#x201c;August 2025 Reverse Stock Split&#x201d; and together with the March
2025 Reverse Stock Split, the &#x201c;Reverse Stock Splits&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the March 2025 Reverse Stock Split, every eleven (&lt;span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_pid_c20250313_z648YMPedNR7" title="Common stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250313_zGu0AWqzV6mg" title="Common stock, shares outstanding"&gt;11&lt;/span&gt;&lt;/span&gt;)
shares of issued and outstanding Common Stock were automatically combined into one (1) issued and outstanding share of Common Stock,
without any change in the par value per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
a result of the August 2025 Reverse Stock Split, every ten (&lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_iI_pid_c20250811_zRFpfz4C6BKd" title="Common stock, shares issued"&gt;&lt;span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_pid_c20250811_zfXcctRoUdne" title="Common stock, shares outstanding"&gt;10&lt;/span&gt;&lt;/span&gt;) shares of issued and outstanding Common Stock were automatically combined
into one (1) issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares were issued
as a result of the Reverse Stock Splits. In connection with the August 2025 Reverse Stock Split, the Company issued an aggregate of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250811__20250811_zAcXqDjKCitl" title="Number of share issued"&gt;6,618&lt;/span&gt; additional shares
to round up fractional shares to whole shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Any
fractional shares that would otherwise have resulted from the Reverse Stock Splits were rounded up to the next whole number. The number
of authorized shares of common stock under the Company&#x2019;s Amended and Restated Certificate of Incorporation, as amended, remained
unchanged at &lt;span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20250313_zpWDprsHPPkc"&gt;40,000,000&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;All
references in this Quarterly Report to the number of shares, price per share and weighted average number of shares of common stock outstanding
prior to the Reverse Stock Splits have been adjusted to reflect the Reverse Stock Splits on a retroactive basis, unless otherwise noted.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Underwritten
Public Offering, Series G Convertible Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 15, 2025, the Company announced the closing of an underwritten public offering (the &#x201c;2025 Underwritten Offering&#x201d;) of
&lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250515__20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zuJPmCF62R9h" title="Number of shares issued"&gt;400,000&lt;/span&gt; shares of the Company&#x2019;s Series G Convertible Preferred Stock (&#x201c;Series G Preferred Stock&#x201d;), with a par value
$&lt;span id="xdx_907_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zabBNa01LcD7" title="Preferred stock, par value"&gt;0.001&lt;/span&gt; per share, and liability classified warrants to purchase up to &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_z4RXpX3BDZk1" title="Warrants outstanding"&gt;490,198&lt;/span&gt; shares of common stock, par value $&lt;span id="xdx_900_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zqAD3SGO6Iec" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share of the
Company at an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zTEnGfOOBk6k" title="Warrants exercise price"&gt;20.40&lt;/span&gt; per share (the &#x201c;May 2025 Warrants&#x201d;). The combined public offering price of each share
of Series G Preferred Stock together with an accompanying May 2025 Warrant was $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_pn3n3_c20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zwx9DRDXh2x7" title="Price per share"&gt;25&lt;/span&gt;. The May 2025 Warrants have a term of five years from
the initial issuance date and are exercisable immediately upon issuance. The Company also issued liability classified warrants (the &#x201c;May
2025 Representative&#x2019;s Warrants&#x201d;) to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zyTfNPVFMFd8" title="Warrants"&gt;24,510&lt;/span&gt; shares of common stock, as issuance costs with substantially the
same terms as the May 2025 Warrants except that the May 2025 Representative&#x2019;s Warrants expire &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zQOyaeZrMPz4" title="Warrants expire"&gt;five years&lt;/span&gt; from the date of commencement
of sales in the 2025 Underwritten Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 15, 2025, prior to the closing of the 2025 Underwritten Offering, the Company filed the Certificate of Preferences, Rights and Limitations
of the Series G Convertible Preferred Stock (the &#x201c;Series G Certificate of Designations&#x201d;) with the Secretary of State of the
State of Delaware, which became effective upon filing. Pursuant to the terms of the Series G Certificate of Designations, the holders
of the Series G Preferred Stock are entitled to receive cumulative dividends at the rate per share of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250515__20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zjltVgXQljeh" title="Dividend rate"&gt;9&lt;/span&gt;% per annum of the stated value
per share until the fifth anniversary of the date of issuance of the Series G Preferred Stock, which such dividends may be paid, at the
Company&#x2019;s option, in up to an aggregate of &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesDividendReinvestmentPlan_c20250515__20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zrf1wUBXJ55i" title="Dividend shares"&gt;220,588&lt;/span&gt; shares of common stock. In addition, in accordance with the Series G Certificate
of Designations, accrued and unpaid dividends are payable upon the conversion of the Series G Preferred Stock prior to the fifth anniversary
of issuance, upon any liquidation, dissolution, or winding up of the Company, and in connection with certain fundamental transactions.
The five year &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250515__20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zcjVd6Ukl3C9" title="Dividend rate"&gt;9&lt;/span&gt;% per annum dividend will be paid upon conversion of the Series G Preferred Stock irrespective of the timing of conversion
such that upon conversion, the conversion price will incorporate the five-year &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20250515__20250515__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zDT6d5dXjuPj" title="Dividend rate"&gt;9&lt;/span&gt;% dividend.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate net proceeds of the 2025 Underwritten Offering were approximately $&lt;span id="xdx_904_eus-gaap--PaymentsForProceedsFromInvestments_pn5n6_c20250515__20250515_zEKwUwrk53G1" title="Net proceeds"&gt;8.2&lt;/span&gt; million, after deducting approximately $&lt;span id="xdx_908_eus-gaap--PaymentsForProceedsFromLoansReceivable_pn5n6_c20250515__20250515_zCnkL66d7ZGi" title="Underwriting discounts, commissions and other offering costs and expenses"&gt;1.8&lt;/span&gt; million
of underwriting discounts, commissions and other offering costs and expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;i&gt;Conversion of Series G Convertible Preferred
Stock&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;Between May 16, 2025, and July 1, 2025, a majority of the Series G Preferred Stockholders exercised their optional
conversion right, converting &lt;span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250516__20250702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zaP2JJNwk49h" title="Number of common stock issued"&gt;399,180&lt;/span&gt; shares of Series G Preferred Stock into &lt;span id="xdx_907_eus-gaap--PreferredStockConvertibleSharesIssuable_iI_pid_c20250702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zM5mGGJ1QOZe" title="Number of common stock issued"&gt;488,987&lt;/span&gt; shares of Common Stock and an additional &lt;span id="xdx_905_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250516__20250702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeR7rWNjV4H5" title="Number of common stock issued"&gt;220,432&lt;/span&gt;
shares of Common Stock for the make-whole dividend. As of September 30, 2025, there were &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesGPreferredStockMember_zguiptKH5Gn4" title="Preferred stock, shares outstanding"&gt;820&lt;/span&gt; outstanding shares of Series G Preferred
Stock.&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Series
X Non-Voting Convertible Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2025, in connection with the Merger (see Note 4), the Company issued &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zWEgckDABCmc" title="Convertible shares"&gt;57,720&lt;/span&gt; shares of Series X Non-Voting Convertible Preferred
Stock (the &#x201c;Series X Preferred Stock&#x201d;) to the holders of Predecessor ENvue. In addition, the Company issued &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_pid_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_z60jtBHILiVl" title="Shares issued for service"&gt;3,626&lt;/span&gt; shares
of Series X Preferred Stock to a consulting firm for services rendered in facilitating the Merger, resulting in a total of &lt;span id="xdx_903_eus-gaap--SharesOutstanding_iI_pid_c20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zaHlNHSHf798" title="Shares outstanding"&gt;61,346&lt;/span&gt; shares
of Series X Preferred Stock outstanding after the Merger.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Merger was consummated and completed on February 14, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;After
giving effect to the Merger, pursuant to the terms and conditions of the Merger Agreement: (i) &lt;span id="xdx_905_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20250214__20250214__us-gaap--TypeOfArrangementAxis__custom--MergerAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zAqUzb38V2Pg" title="Convertible description"&gt;the holders of the outstanding equity
of Predecessor ENvue immediately prior to the effective time of the First Merger (&#x201c;First Effective Time&#x201d;) own 19.9% of the
common stock of the Company and 85.0% of the outstanding equity of the Company (assuming the Series X Preferred Stock is converting at
a ratio of 100:1) immediately following the First Effective Time, which following stockholder approval will allow the Series X Preferred
Stock to convert to common stock of the Company which may result in the holders of Predecessor ENvue to own 85% of the common stock of
the Company, and (ii) the holders of our outstanding equity immediately prior to the First Effective Time own 80.1% of the common stock
of the Company and 15.0% of the outstanding equity of the Company (assuming the Series X Preferred Stock is converting at a ratio of
100:1) immediately following the First Effective Time, which following stockholder approval which will allow the Series X Preferred Stock
to convert to common stock of the Company which may result in our holders owning 15% of common stock of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Each
share of Series X Preferred Stock has a stated value of $&lt;span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250214__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zB0xghJyUeF8" title="Preferred stock stated value"&gt;606.38&lt;/span&gt; and ranks senior to the Company&#x2019;s common stock with respect to
dividend rights and rights upon liquidation, dissolution or winding up. The Series X Preferred Stock is not subject to mandatory redemption
and may not be redeemed at the option of the Company or the holder.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
shall be entitled to receive, and the Company shall pay, dividends on shares of Series X Preferred Stock, based on the Stated Value,
at a rate of eight percent (8%) per annum, commencing on the three (3) month anniversary of the Original Issue Date (as defined in the
Series X Certificate of Designations) until the date the Company obtains the Stockholder Approval. Such dividends can be paid in the
form of cash or additional issuances of shares of Series X Preferred Stock based on the Stated Value, with such type of payment determined
in the sole discretion of the Company, and accrue and be compounded daily on the basis of a 360-day year and twelve (12) 30-day months
and shall be paid the earlier of: (i) promptly after conversion of the Series X Preferred Stock or (ii) quarterly starting on the six
(6) month anniversary of the Original Issue Date. For the three and nine-month period ended September 30, 2025, the Company recorded
$&lt;span id="xdx_90C_eus-gaap--PaymentsOfDividends_pn3n3_c20250701__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesXAmendmentAgreementMember_zvUuiEc5hqG3" title="Potential dividend"&gt;344&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--PaymentsOfDividends_pn3n3_c20250101__20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesXAmendmentAgreementMember_zIIjgNcSHolj" title="Potential dividend"&gt;1,102&lt;/span&gt; of dividends attributable to Series X Preferred stockholders, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 12, 2025, the Company filed the Series X Certificate of Amendment with the Secretary of State of the State of Delaware, thereby amending
the Series X Certificate of Designations. The Series X Certificate of Amendment became effective with the Secretary of State of the State
of Delaware upon filing. The amendment decreased the Series X Preferred Stock conversion price from $&lt;span id="xdx_900_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250512__srt--RangeAxis__srt--MinimumMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesXAmendmentAgreementMember_zrUql5yTKMFl" title="Preferred stock conversion price"&gt;66.69&lt;/span&gt; to $&lt;span id="xdx_90A_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250512__srt--RangeAxis__srt--MaximumMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesXAmendmentAgreementMember_z0DmlKV0w6G9" title="Preferred stock conversion price"&gt;20.40&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company concluded that the modification of the Series X Preferred stock should be accounted for as an extinguishment. As such, the difference
between the fair value of the modified Series X Preferred Stock and their carrying amount was accounted for as a deemed contribution
in the amount of $&lt;span id="xdx_90E_eus-gaap--PreferredStockDividendsAndOtherAdjustments_pn3n3_c20250512__20250512__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--SeriesXAmendmentAgreementMember_zQhLiNOpC4zg" title="Deemed contribution"&gt;3,815&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
conjunction with the July Purchase Agreement (as defined below), on July 22, 2025, the Company repurchased &lt;span id="xdx_908_eus-gaap--SharesOutstanding_iI_pid_c20250722__us-gaap--TypeOfArrangementAxis__custom--JulyPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zeekzh6VVyMb" title="Shares outstanding"&gt;8,246&lt;/span&gt;
outstanding shares of its Series X Preferred Stock from one investor for $&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_pn6n6_c20250722__20250722__us-gaap--TypeOfArrangementAxis__custom--JulyPurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyPrivatePlacementMember_zxju86IbzCJ8" title="Net proceeds"&gt;5&lt;/span&gt;
million from the use of proceeds from the July 2025 Private Placement. As of September 30, 2025, &lt;span id="xdx_903_eus-gaap--PreferredStockSharesIssued_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zEi09yytLJt6" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_pid_c20250930__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zmaG2wtTyTcf" title="Preferred stock, shares outstanding"&gt;53,100&lt;/span&gt;&lt;/span&gt;
shares of Series X Preferred Stock were issued and outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Private
Placement, Series H Convertible Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 18, 2025, the Company entered into a Securities Purchase Agreement (the &#x201c;July 2025 Purchase Agreement&#x201d;) with a certain
institutional investor (the &#x201c;July 2025 Investor&#x201d;), pursuant to which it agreed to sell to the Investor (i) an aggregate of
&lt;span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250718__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_zs4KTHvqSYc6" title="Preferred stock, shares authorized"&gt;8,889&lt;/span&gt; shares of the Company&#x2019;s newly-designated Series H Convertible Preferred Stock (&#x201c;Series H Preferred Stock&#x201d;), and
(ii) warrants to acquire up to an aggregate of &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250718__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_zpYy11zT4UQb" title="Warrant outstanding"&gt;467,836&lt;/span&gt; shares of common stock (the &#x201c;July 2025 Warrants&#x201d;) at an exercise price
of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250718__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_zbz4c3RE06c9" title="Warrant exercise price"&gt;22.50&lt;/span&gt; (the &#x201c;July 2025 Private Placement&#x201d; and such closing, the &#x201c;Initial Closing&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the terms of the July 2025 Purchase Agreement, the Company also agreed to issue &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250718__20250718__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_z9Ime6B5lqg4" title="Issuance of shares"&gt;2,222&lt;/span&gt; shares of Series H Preferred Stock and warrants
to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250718__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_z7xhQk4jaXsk" title="Issuance of warrants outstanding"&gt;116,960&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250718__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_zajctPiJAMkl" title="Warrant exercise price"&gt;22.50&lt;/span&gt; in a second closing (the &#x201c;Second Closing&#x201d;),
subject to the satisfaction of customary closing conditions. Additionally, pursuant to the terms of the July 2025 Purchase Agreement,
the Company has agreed that during the period ending 36 months from the effective date of the registration statement (the &#x201c;Resale
Registration Statement&#x201d;) registering the resale of the shares of common stock underlying the Series H Preferred Stock and the July
2025 Warrants, the July 2025 Investor shall have the right to purchase up to &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250718__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zbUFFtHISNsl"&gt;44,000&lt;/span&gt; additional shares of Series H Preferred Stock, which
shall have identical terms to the Series H Preferred Stock issued at the Initial Closing, except that the initial conversion price of
such additional shares of Series H Preferred Stock shall be equal to 85% of the arithmetic average of the three (3) lowest VWAPs during
the ten trading days prior to the date of such investor&#x2019;s exercise of such right.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Initial Closing and occurred on July 22, 2025, and the Second Closing occurred October 30, 2025. The aggregate net proceeds from the
July 2025 Private Placement were $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_pn6n6_c20250722__20250722__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFivePrivatePlacementMember_zT3EMhAldaJk" title="Aggregatte net proceeds"&gt;9&lt;/span&gt; million, after deducting placement agent fees and other offering expenses payable by the Company
of $&lt;span id="xdx_90E_eus-gaap--NoninterestExpenseOfferingCost_pn3n3_c20250722__20250722__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFivePrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zmXhfNvtRNXb" title="Offering expenses payable"&gt;958&lt;/span&gt;. The Series H Preferred Stock and the option to purchase additional &lt;span&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_c20250722__20250722__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFivePrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zhL8xT1CISi4" title="Options to purchase shares"&gt;44,000&lt;/span&gt;&lt;/span&gt; shares of Series H Preferred Stock
were classified as equity, while the warrants and the obligation to issue additional warrants and Series H Preferred Stock were classified
as liability. The Company allocated the financing proceeds to the freestanding financial instruments. Thus, the Company allocated $&lt;span id="xdx_90E_eus-gaap--StockholdersEquity_iI_pn3n3_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFivePrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zp2lPZx7Y9Zg" title="Warrant liability"&gt;4,601&lt;/span&gt;
to equity, $&lt;span id="xdx_901_ecustom--WarrantLiability_iI_pn3n3_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFivePrivatePlacementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zM4jrMy27KRc" title="Warrant liability"&gt;2,772&lt;/span&gt; to warrant liability and $&lt;span id="xdx_90E_ecustom--TrancheFinancingLiabilityCurrent_iI_pn3n3_c20250930__us-gaap--SubsidiarySaleOfStockAxis__custom--JulyTwoThousandTwentyFivePrivatePlacementMember_zMwLmCgtkIR9" title="Tranche financing liability"&gt;2,000&lt;/span&gt; to the tranche financing liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Holders
of the Series H Preferred Stock shall be entitled to receive cumulative dividends at the rate per share (as a percentage of the stated
value per share) of &lt;span id="xdx_900_eus-gaap--PreferredStockDividendRatePercentage_pid_dp_uPure_c20250722__20250722__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zoMYaRhULjLa" title="Preferred stock dividend rate"&gt;9&lt;/span&gt;% per annum, payable on each conversion date of the Series H Preferred Stock in duly authorized, validly issued,
fully paid and non-assessable shares of common stock at the conversion price then in effect. The stated value of the Series H Preferred
Stock is $&lt;span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20250722__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zxw6M5hFmA9c" title="Preferred stock stated value per share"&gt;1,000&lt;/span&gt; per share. The Company recorded $&lt;span id="xdx_902_eus-gaap--DividendsPreferredStock_pn3n3_c20250701__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zqLs0iKdrUak" title="Preferred stock dividend"&gt;&lt;span id="xdx_906_eus-gaap--DividendsPreferredStock_pn3n3_c20250101__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zc5AXamJkeg3" title="Preferred stock dividend"&gt;223&lt;/span&gt;&lt;/span&gt; of dividends attributable to Series H Preferred stockholders for the three and nine-month
periods ended September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;As a result of the September 2025 registered
direct offering (see below), the conversion price of the Series H Preferred Stock was reduced to $&lt;span id="xdx_909_eus-gaap--PreferredStockConvertibleConversionPriceDecrease_pid_c20250101__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zHGWjVwJp3sc" title="Conversion price per share reduced"&gt;7.01&lt;/span&gt;, resulting in a deemed dividend
of $&lt;span id="xdx_900_ecustom--DeemedDividend_pn3n3_c20250101__20250930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember_zfLu6ZabK6y" title="Deemed dividend"&gt;399&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;September
2025 Registered Direct Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 16, 2025, the Company entered into a securities purchase agreement with a single institutional investor, pursuant to which
the Company issued and sold (i) &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250916__20250916__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbS64PJpvjUk" title="Number of shares issued"&gt;74,114&lt;/span&gt; shares of common stock and (ii) prefunded warrants to purchase up to &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250916__20250916__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zeQmde49VIke" title="Number of warrants issued"&gt;217,090&lt;/span&gt; shares of common
stock (the &#x201c;September 2025 Pre-Funded Warrants&#x201d;) pursuant to an effective shelf registration statement on Form S-3 (the &#x201c;September
2025 Offering&#x201d;). The offering price was $&lt;span id="xdx_90B_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250916__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKkDuJyo9oNb" title="Offering price"&gt;7.01&lt;/span&gt; per share of common stock and $&lt;span id="xdx_904_eus-gaap--SaleOfStockPricePerShare_iI_pid_c20250916__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zxroED6k7Ct" title="Offering price"&gt;7.009&lt;/span&gt; per September 2025 Pre-Funded Warrant, which
is the price of each share of common stock sold in the September 2025 Offering, minus the $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250916__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantMember_zIk2a8rVKvPd" title="Exercise price"&gt;0.001&lt;/span&gt; exercise price per September 2025 Pre-Funded
Warrant. The net proceeds from the September 2025 Offering were approximately $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn4n6_c20250916__20250916__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zwQHsziXtuA1" title="Net proceeds"&gt;1.88&lt;/span&gt; million, after deducting placement agent fees and
other offering expenses of $&lt;span id="xdx_90B_eus-gaap--NoninterestExpenseOfferingCost_pn3n3_c20250916__20250916__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zAGxpijcjHE3" title="Offering expenses"&gt;163&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Share-based
compensation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 19, 2024, stockholders approved the NanoVibronix, Inc. 2024 Long-Term Incentive Plan (the &#x201c;2024 Plan&#x201d;), as a successor
to the Nanovibronix 2014 Long-Term Incentive Plan, which was adopted by the Board on November 6, 2023. As of December 31, 2024, under
the 2024 Plan, &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pid_c20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember_zUGMwZ91d974" title="Stock reserved for future issuance"&gt;60,000&lt;/span&gt; shares of our common stock were reserved for issuance. On March 14, 2025, the Company effected the 2025 Reverse
Stock Split. Consequently, the number of shares of common stock of the Company reserved for issuance pursuant to awards under the 2024
Plan was reduced to &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20250314__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJ7QOMZNaxsj" title="Number of common stock reserved for issuance for awards"&gt;5,455&lt;/span&gt; shares. As of September 30, 2025, there were &lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250101__20250930__us-gaap--PlanNameAxis__custom--TwoThousandAndTwentyFourLongTermIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrmTs75W8ILf" title="Number of share issued"&gt;1,043&lt;/span&gt; shares of common stock available to be issued under the
plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
the three- and nine-month periods ended September 30, 2025, &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_dxL_c20250701__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zgPm9Bxw1Uu3" title="Number of options, exercised::XDX::-"&gt;&lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_dxL_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z1vRxdwUSzOb" title="Number of options, exercised::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1317"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1319"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; employee options were exercised, &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_do_c20250701__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zznzVDhtC3I9" title="Number of employee options granted"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_pid_do_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zL82rs0oPhC5" title="Number of employee options granted"&gt;no&lt;/span&gt;&lt;/span&gt; options were granted and &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_c20250701__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zHrXpHOKB2af" title="Number of employee options expired"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zOmsFyYCv7dj" title="Number of employee options expired"&gt;95&lt;/span&gt;&lt;/span&gt; options
expired.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
options granted during the nine months ended September 30, 2024, vested immediately and were recorded at fair values of approximately
$&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWvoBojjWGYi" title="Fair values"&gt;71&lt;/span&gt;. The contractual term for granted options is &lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod_dtY_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zaV9x2OHqXuj" title="Contractual term for granted options"&gt;10&lt;/span&gt; years. During the three- and nine-month periods ended September 30, 2024, stock-based
compensation expense related to these options were approximately $&lt;span id="xdx_90D_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20240701__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWapQWxhqVvl" title="Stock-based compensation expense"&gt;28&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pn3n3_c20240101__20240930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zWgt4qTWGkbi" title="Stock-based compensation expense"&gt;135&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zLjZ4cGY7a2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of options activity is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zwrVD0kI9PXk" style="display: none"&gt;SCHEDULE OF OPTIONS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares Under&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding &#x2013; December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjNaWuuPaUC5" style="width: 12%; text-align: right" title="Options, Outstanding - balance"&gt;4,506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztp684N82XCh" style="width: 12%; text-align: right" title="Weighted Average Exercise Price per Share, Exercisable - balance"&gt;35.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpDnoDVLgoa7" title="Weighted Average Remaining Life (Years), Outstanding"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrVnSlbKjVcb" style="text-align: right" title="Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z0ht25FNxoM8" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTerkyjdiNH9" style="text-align: right" title="Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1349"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPpFFKYCqhm8" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1351"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcEXHtkOrL3" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJLSpw5ecjcc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Expired"&gt;514.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding &#x2013; September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zaZ4BRrBbkAe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding - balance"&gt;4,411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpQ214hnqn4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Exercisable - balance"&gt;272.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZh1JBLcIdH5" title="Weighted Average Remaining Life (Years), Outstanding"&gt;8.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zXQMxtvLdyIj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 30, 2023, the Company issued (a) Pre-Funded Warrants to purchase up to &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z5JAqV26QKn8" title="Warrants issued to purchase common stock"&gt;16,227&lt;/span&gt; shares of Common Stock with an exercise price of
$&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za4iGiqsLRrc" title="Class of warrant or right exercise price"&gt;0.001&lt;/span&gt; per share, (b) Series A-1 Warrants to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--SeriesA1WarrantsMember_zdIfTlwuuVec" title="Warrants issued to purchase common stock"&gt;26,427&lt;/span&gt; shares of Common Stock with an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--SeriesA1WarrantsMember_zlrRHCSQlECb" title="Warrant exercise price"&gt;161.70&lt;/span&gt; per share
(the &#x201c;Series A-1 Warrants&#x201d;) and (c) Series A-2 Warrants to purchase up to &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--SeriesA2WarrantsMember_zWs6zZINCi6j" title="Warrants issued to purchase common stock"&gt;26,427&lt;/span&gt; shares of Common Stock with an exercise
price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__us-gaap--StatementEquityComponentsAxis__custom--SeriesA2WarrantsMember_zoy815jYsZz8" title="Warrant exercise price"&gt;161.70&lt;/span&gt; per share (the &#x201c;Series A-2 Warrants&#x201d;), or a total of &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830_zvmVjdWGpgJj" title="Warrants issued to purchase common stock"&gt;77,644&lt;/span&gt; warrants, in conjunction with a private placement
by and between the Company and an institutional investor, pursuant to a securities purchase agreement dated August 30, 2023 (the &#x201c;August
2023 Private Placement&#x201d;). The Series A-1 Warrants are exercisable immediately upon issuance and expire on March 1, 2029. The Series
A-2 Warrants have expired on October 1, 2024&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with the August 2023 Private Placement, the Company issued placement agent warrants to H.C. Wainwright &amp;amp; Co., LLC, or
its designees, as compensation in connection with the Private Placement, to purchase up to an aggregate of &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zI9H9bm8dfDb" title="Warrants issued to purchase common stock"&gt;1,982&lt;/span&gt; shares of common stock
at an exercise price equal to $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_ztScctTJ3fY8" title="Share price"&gt;236.50&lt;/span&gt; per share (the &#x201c;August 2023 Placement Agent Warrants&#x201d;). The August 2023 Placement Agent
Warrants are exercisable immediately upon issuance and expire &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20230830__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zzlpWhQvkpJl" title="Class of warrant or right expire date"&gt;March 1, 2029&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Warrant
Exchange Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 7, 2025, the Company entered into a securities exchange agreement (the &#x201c;Exchange Agreement&#x201d;) with a certain institutional
investor pursuant to which the Company agreed to issue an aggregate of (i) &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20250107__20250107__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember_zhHsW5GWbH0k" title="Number of new share issued"&gt;4,149&lt;/span&gt; shares of common stock (the &#x201c;3(a)(9) Shares&#x201d;),
(ii) a warrant to purchase up to &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--TypeOfArrangementAxis__custom--PrefundedWarrantMember_zQ8EFlKrAnX6" title="Warrant to purchase common stock"&gt;15,856&lt;/span&gt; shares of common stock (the &#x201c;January 2025 Warrant&#x201d;), and (iii) a pre-funded warrant
to purchase up to &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250107__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember_zSlt4PGCHZR9" title="Warrant to purchase common stock"&gt;17,813&lt;/span&gt; shares of common stock (the &#x201c;January 2025 Pre-Funded Warrant&#x201d;), in exchange for the Series A-1 Warrant
held by the Holder to purchase up to &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesA1WarrantsMember_zY1ANif7fICg" title="Warrant to purchase common stock"&gt;26,427&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--WarrantExercisePriceIncrease_c20250107__20250107__us-gaap--TypeOfArrangementAxis__custom--SecuritiesExchangeAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--SeriesA1WarrantsMember_zG79EL5vA6l4" title="Warrant exercise price"&gt;161.70&lt;/span&gt; per share (the &#x201c;Exchange&#x201d;).
The Company cancelled the Series A-1 Warrant reacquired in the Exchange and the Series A-1 Warrant will not be reissued. The January
2025 Warrant has substantially the same terms as the Series A-1 Warrant, except that the shares of common stock issuable upon exercise
of the January 2025 Warrant were subject to stockholder approval pursuant to the applicable rules and regulations of the Nasdaq (which
such stockholder approval was obtained on February 24, 2025, at a special meeting of stockholders), is exercisable for a term of five
and one half years from the date such stockholder approval is received and deemed effective under Delaware law, and has an exercise price
of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20250224__us-gaap--TypeOfArrangementAxis__custom--PrefundedWarrantMember_zIf7wOepeTNi" title="Exercise price per share"&gt;68.296&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subsequent
to the Exchange, the holder of the January 2025 Pre-Funded Warrant (i) exercised the January 2025 Pre-Funded Warrant in full on a cashless
basis for an aggregate of &lt;span id="xdx_903_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20250101__us-gaap--TypeOfArrangementAxis__custom--PrefundedWarrantMember_z6cRzhpmxila" title="Conversion warrant, shares"&gt;22,835&lt;/span&gt; shares of common stock and (ii) exercised the January 2025 Warrant in full on a cashless basis for an
aggregate of &lt;span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20250101__20250101__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqk8y3m11id" title="Conversion warrant, shares"&gt;9,151&lt;/span&gt; shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, a total of &lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250930_zLF9CO6TeCIg" title="Warrants outstanding"&gt;1,071,463&lt;/span&gt; warrants were outstanding, including &lt;span id="xdx_903_ecustom--PrefundedWarrants_iI_pid_c20250930_z9m0CY1dGDh8" title="Pre-funded warrants"&gt;89,616&lt;/span&gt; of pre-funded warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&#160;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-03-132025-03-13" id="Fact001181">1-for-11 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="From2025-08-112025-08-11" id="Fact001183">1-for-10 reverse stock split</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-03-13"
      decimals="INF"
      id="Fact001185"
      unitRef="Shares">11</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-03-13"
      decimals="INF"
      id="Fact001187"
      unitRef="Shares">11</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2025-08-11"
      decimals="INF"
      id="Fact001189"
      unitRef="Shares">10</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2025-08-11"
      decimals="INF"
      id="Fact001191"
      unitRef="Shares">10</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-08-112025-08-11"
      decimals="INF"
      id="Fact001193"
      unitRef="Shares">6618</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2025-03-13"
      decimals="INF"
      id="Fact001194"
      unitRef="Shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-05-152025-05-15_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001196"
      unitRef="Shares">400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-05-15_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001198"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-05-15_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001200"
      unitRef="Shares">490198</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2025-05-15_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001202"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-05-15_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001204"
      unitRef="USDPShares">20.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2025-05-15_us-gaap_SeriesGPreferredStockMember"
      decimals="-3"
      id="Fact001206"
      unitRef="USDPShares">25000</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-05-15_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001208"
      unitRef="Shares">24510</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-05-15_us-gaap_SeriesGPreferredStockMember"
      id="Fact001210">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-05-152025-05-15_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001212"
      unitRef="Pure">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan
      contextRef="From2025-05-152025-05-15_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001214"
      unitRef="Shares">220588</us-gaap:StockIssuedDuringPeriodSharesDividendReinvestmentPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-05-152025-05-15_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001216"
      unitRef="Pure">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2025-05-152025-05-15_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001218"
      unitRef="Pure">0.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:PaymentsForProceedsFromInvestments
      contextRef="From2025-05-152025-05-15"
      decimals="-5"
      id="Fact001220"
      unitRef="USD">8200000</us-gaap:PaymentsForProceedsFromInvestments>
    <us-gaap:PaymentsForProceedsFromLoansReceivable
      contextRef="From2025-05-152025-05-15"
      decimals="-5"
      id="Fact001222"
      unitRef="USD">1800000</us-gaap:PaymentsForProceedsFromLoansReceivable>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-05-162025-07-02_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001224"
      unitRef="Shares">399180</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="AsOf2025-07-02_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001226"
      unitRef="Shares">488987</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-05-162025-07-02_us-gaap_SeriesGPreferredStockMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001228"
      unitRef="Shares">220432</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_us-gaap_SeriesGPreferredStockMember"
      decimals="INF"
      id="Fact001230"
      unitRef="Shares">820</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact001232"
      unitRef="Shares">57720</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact001234"
      unitRef="Shares">3626</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact001236"
      unitRef="Shares">61346</us-gaap:SharesOutstanding>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="From2025-02-142025-02-14_custom_MergerAgreementMember_custom_SeriesXPreferredStockMember"
      id="Fact001238">the holders of the outstanding equity
of Predecessor ENvue immediately prior to the effective time of the First Merger (&#x201c;First Effective Time&#x201d;) own 19.9% of the
common stock of the Company and 85.0% of the outstanding equity of the Company (assuming the Series X Preferred Stock is converting at
a ratio of 100:1) immediately following the First Effective Time, which following stockholder approval will allow the Series X Preferred
Stock to convert to common stock of the Company which may result in the holders of Predecessor ENvue to own 85% of the common stock of
the Company, and (ii) the holders of our outstanding equity immediately prior to the First Effective Time own 80.1% of the common stock
of the Company and 15.0% of the outstanding equity of the Company (assuming the Series X Preferred Stock is converting at a ratio of
100:1) immediately following the First Effective Time, which following stockholder approval which will allow the Series X Preferred Stock
to convert to common stock of the Company which may result in our holders owning 15% of common stock of the Company.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-02-14_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact001240"
      unitRef="USDPShares">606.38</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PaymentsOfDividends
      contextRef="From2025-07-012025-09-30_custom_SeriesXPreferredStockMember_custom_SeriesXAmendmentAgreementMember"
      decimals="-3"
      id="Fact001242"
      unitRef="USD">344000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="From2025-01-012025-09-30_custom_SeriesXPreferredStockMember_custom_SeriesXAmendmentAgreementMember"
      decimals="-3"
      id="Fact001244"
      unitRef="USD">1102000</us-gaap:PaymentsOfDividends>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-05-12_srt_MinimumMember_custom_SeriesXPreferredStockMember_custom_SeriesXAmendmentAgreementMember"
      decimals="INF"
      id="Fact001246"
      unitRef="USDPShares">66.69</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-05-12_srt_MaximumMember_custom_SeriesXPreferredStockMember_custom_SeriesXAmendmentAgreementMember"
      decimals="INF"
      id="Fact001248"
      unitRef="USDPShares">20.40</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2025-05-122025-05-12_custom_SeriesXPreferredStockMember_custom_SeriesXAmendmentAgreementMember"
      decimals="-3"
      id="Fact001250"
      unitRef="USD">3815000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2025-07-22_custom_JulyPurchaseAgreementMember_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact001252"
      unitRef="Shares">8246</us-gaap:SharesOutstanding>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="From2025-07-222025-07-22_custom_JulyPurchaseAgreementMember_custom_SeriesXPreferredStockMember_custom_JulyPrivatePlacementMember"
      decimals="-6"
      id="Fact001254"
      unitRef="USD">5000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2025-09-30_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact001256"
      unitRef="Shares">53100</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2025-09-30_custom_SeriesXPreferredStockMember"
      decimals="INF"
      id="Fact001258"
      unitRef="Shares">53100</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-07-18_us-gaap_SeriesHPreferredStockMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001260"
      unitRef="Shares">8889</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-07-18_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001262"
      unitRef="Shares">467836</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-18_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001264"
      unitRef="USDPShares">22.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-182025-07-18_us-gaap_SeriesHPreferredStockMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001266"
      unitRef="Shares">2222</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-07-18_us-gaap_WarrantMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001268"
      unitRef="Shares">116960</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-18_us-gaap_WarrantMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001270"
      unitRef="USDPShares">22.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-07-18_us-gaap_SeriesHPreferredStockMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001271"
      unitRef="Shares">44000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2025-07-222025-07-22_custom_JulyTwoThousandTwentyFivePrivatePlacementMember"
      decimals="-6"
      id="Fact001273"
      unitRef="USD">9000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2025-07-222025-07-22_custom_JulyTwoThousandTwentyFivePrivatePlacementMember_us-gaap_SeriesHPreferredStockMember"
      decimals="-3"
      id="Fact001275"
      unitRef="USD">958000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-07-222025-07-22_custom_JulyTwoThousandTwentyFivePrivatePlacementMember_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact001277"
      unitRef="Shares">44000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2025-09-30_custom_JulyTwoThousandTwentyFivePrivatePlacementMember_us-gaap_SeriesHPreferredStockMember"
      decimals="-3"
      id="Fact001279"
      unitRef="USD">4601000</us-gaap:StockholdersEquity>
    <NAOV:WarrantLiability
      contextRef="AsOf2025-09-30_custom_JulyTwoThousandTwentyFivePrivatePlacementMember_us-gaap_SeriesHPreferredStockMember"
      decimals="-3"
      id="Fact001281"
      unitRef="USD">2772000</NAOV:WarrantLiability>
    <NAOV:TrancheFinancingLiabilityCurrent
      contextRef="AsOf2025-09-30_custom_JulyTwoThousandTwentyFivePrivatePlacementMember"
      decimals="-3"
      id="Fact001283"
      unitRef="USD">2000000</NAOV:TrancheFinancingLiabilityCurrent>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2025-07-222025-07-22_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact001285"
      unitRef="Pure">0.09</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2025-07-22_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact001287"
      unitRef="USDPShares">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-07-012025-09-30_us-gaap_SeriesHPreferredStockMember"
      decimals="-3"
      id="Fact001289"
      unitRef="USD">223000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2025-01-012025-09-30_us-gaap_SeriesHPreferredStockMember"
      decimals="-3"
      id="Fact001291"
      unitRef="USD">223000</us-gaap:DividendsPreferredStock>
    <us-gaap:PreferredStockConvertibleConversionPriceDecrease
      contextRef="From2025-01-012025-09-30_us-gaap_SeriesHPreferredStockMember"
      decimals="INF"
      id="Fact001293"
      unitRef="USDPShares">7.01</us-gaap:PreferredStockConvertibleConversionPriceDecrease>
    <NAOV:DeemedDividend
      contextRef="From2025-01-012025-09-30_us-gaap_SeriesHPreferredStockMember"
      decimals="-3"
      id="Fact001295"
      unitRef="USD">399000</NAOV:DeemedDividend>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-09-162025-09-16_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001297"
      unitRef="Shares">74114</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-09-162025-09-16_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001299"
      unitRef="Shares">217090</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-09-16_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001301"
      unitRef="USDPShares">7.01</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2025-09-16_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact001303"
      unitRef="USDPShares">7.009</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-09-16_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact001305"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2025-09-162025-09-16_custom_SecuritiesPurchaseAgreementMember"
      decimals="-4"
      id="Fact001307"
      unitRef="USD">1880000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:NoninterestExpenseOfferingCost
      contextRef="From2025-09-162025-09-16_custom_SecuritiesPurchaseAgreementMember"
      decimals="-3"
      id="Fact001309"
      unitRef="USD">163000</us-gaap:NoninterestExpenseOfferingCost>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2024-12-31_us-gaap_StockOptionMember_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember"
      decimals="INF"
      id="Fact001311"
      unitRef="Shares">60000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2025-03-14_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001313"
      unitRef="Shares">5455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-012025-09-30_custom_TwoThousandAndTwentyFourLongTermIncentivePlanMember_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001315"
      unitRef="Shares">1043</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-07-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001321"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2025-01-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001323"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2025-07-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001325"
      unitRef="Shares">95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2025-01-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001327"
      unitRef="Shares">95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="From2024-01-012024-09-30_us-gaap_StockOptionMember"
      decimals="-3"
      id="Fact001329"
      unitRef="USD">71000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <NAOV:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod
      contextRef="From2024-01-012024-09-30_us-gaap_StockOptionMember"
      id="Fact001331">P10Y</NAOV:ShareBasedCompensationArrangementByShareBasedPaymentAwardContractualPeriod>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-07-012024-09-30_us-gaap_StockOptionMember"
      decimals="-3"
      id="Fact001333"
      unitRef="USD">28000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="From2024-01-012024-09-30_us-gaap_StockOptionMember"
      decimals="-3"
      id="Fact001335"
      unitRef="USD">135000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001337">&lt;p id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zLjZ4cGY7a2i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
summary of options activity is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B3_zwrVD0kI9PXk" style="display: none"&gt;SCHEDULE OF OPTIONS ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Shares Under&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Exercise Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;per Share&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%"&gt;Outstanding &#x2013; December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zjNaWuuPaUC5" style="width: 12%; text-align: right" title="Options, Outstanding - balance"&gt;4,506&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztp684N82XCh" style="width: 12%; text-align: right" title="Weighted Average Exercise Price per Share, Exercisable - balance"&gt;35.00&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20240101__20241231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpDnoDVLgoa7" title="Weighted Average Remaining Life (Years), Outstanding"&gt;9.24&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zrVnSlbKjVcb" style="text-align: right" title="Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1345"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z0ht25FNxoM8" style="text-align: right" title="Weighted Average Exercise Price per Share, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1347"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zTerkyjdiNH9" style="text-align: right" title="Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1349"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPpFFKYCqhm8" style="text-align: right" title="Weighted Average Exercise Price per Share, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1351"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zcEXHtkOrL3" style="border-bottom: Black 1pt solid; text-align: right" title="Options, Expired"&gt;(95&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zJLSpw5ecjcc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price per Share, Expired"&gt;514.00&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Outstanding &#x2013; September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zaZ4BRrBbkAe" style="border-bottom: Black 2.5pt double; text-align: right" title="Options, Outstanding - balance"&gt;4,411&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zpQ214hnqn4" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price per Share, Exercisable - balance"&gt;272.00&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20250930__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zZh1JBLcIdH5" title="Weighted Average Remaining Life (Years), Outstanding"&gt;8.75&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001339"
      unitRef="Shares">4506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-12-31_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001341"
      unitRef="USDPShares">35.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2024-01-012024-12-31_us-gaap_StockOptionMember"
      id="Fact001343">P9Y2M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2025-01-012025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001353"
      unitRef="Shares">95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2025-01-012025-09-30_us-gaap_StockOptionMember"
      decimals="-3"
      id="Fact001355"
      unitRef="USDPShares">514000.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001357"
      unitRef="Shares">4411</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2025-09-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact001359"
      unitRef="USDPShares">272.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2025-01-012025-09-30_us-gaap_StockOptionMember"
      id="Fact001361">P8Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001363"
      unitRef="Shares">16227</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001365"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_SeriesA1WarrantsMember"
      decimals="INF"
      id="Fact001367"
      unitRef="Shares">26427</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_SeriesA1WarrantsMember"
      decimals="INF"
      id="Fact001369"
      unitRef="USDPShares">161.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_SeriesA2WarrantsMember"
      decimals="INF"
      id="Fact001371"
      unitRef="Shares">26427</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_SeriesA2WarrantsMember"
      decimals="INF"
      id="Fact001373"
      unitRef="USDPShares">161.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30"
      decimals="INF"
      id="Fact001375"
      unitRef="Shares">77644</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember"
      decimals="INF"
      id="Fact001377"
      unitRef="Shares">1982</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember"
      decimals="INF"
      id="Fact001379"
      unitRef="USDPShares">236.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-08-30_custom_HCWainwrightAndCoLLCMember"
      id="Fact001381">2029-03-01</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-01-072025-01-07_us-gaap_CommonStockMember_custom_SecuritiesExchangeAgreementMember"
      decimals="INF"
      id="Fact001383"
      unitRef="Shares">4149</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-07_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact001385"
      unitRef="Shares">15856</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-07_custom_PreFundedWarrantsMember_custom_SecuritiesExchangeAgreementMember"
      decimals="INF"
      id="Fact001387"
      unitRef="Shares">17813</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2025-01-07_custom_SecuritiesExchangeAgreementMember_custom_SeriesA1WarrantsMember"
      decimals="INF"
      id="Fact001389"
      unitRef="Shares">26427</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantExercisePriceIncrease
      contextRef="From2025-01-072025-01-07_custom_SecuritiesExchangeAgreementMember_custom_SeriesA1WarrantsMember"
      decimals="INF"
      id="Fact001391"
      unitRef="USDPShares">161.70</us-gaap:WarrantExercisePriceIncrease>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-02-24_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact001393"
      unitRef="USDPShares">68.296</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-01-012025-01-01_custom_PrefundedWarrantMember"
      decimals="INF"
      id="Fact001395"
      unitRef="Shares">22835</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2025-01-012025-01-01_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001397"
      unitRef="Shares">9151</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001399"
      unitRef="Shares">1071463</us-gaap:ClassOfWarrantOrRightOutstanding>
    <NAOV:PrefundedWarrants
      contextRef="AsOf2025-09-30"
      decimals="INF"
      id="Fact001401"
      unitRef="Shares">89616</NAOV:PrefundedWarrants>
    <NAOV:WarrantLiabilityDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001403">&lt;p id="xdx_804_ecustom--WarrantLiabilityDisclosureTextBlock_zMGi1fm6dCoa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_829_zvlRylxgTjLj"&gt;WARRANT LIABILITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on an evaluation, pursuant to ASC 815-40, the May 2025 Warrants and July 2025 Warrants (see note 6) do not meet all the equity classification
criteria and therefore were determined to be classified as liabilities measured at fair value through earnings. The Company utilized
the Black Scholes Model to calculate the value of the May 2025 Warrants and July 2025 Warrants issued during the three months ended September
30, 2025. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the May 2025 Warrants and Representative&#x2019;s Warrants of $&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyFiveWarrantsMember_zqfXsKeZLbwg" title="Fair value of warrants"&gt;5,306&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__custom--RepresentativeWarrantsMember_zJhgH7S76dQe" title="Fair value of warrants"&gt;265&lt;/span&gt;, respectively, was estimated at the date of
issuance using the following assumptions: dividend yield &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember_zQhEgPGbKPw6" title="Warrant oustanding input"&gt;0&lt;/span&gt;%; expected term of &lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zB0mRAeUNXq2" title="Warrant term"&gt;5.0&lt;/span&gt; years; equity volatility of &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember_zTx6aZjHDBr5" title="Warrant oustanding input"&gt;145.65&lt;/span&gt;%; and a risk-free
interest rate of &lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember_zxEcvetXMll9" title="Warrant oustanding input"&gt;4.06&lt;/span&gt;%. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value of the July 2025 Warrants of $&lt;span id="xdx_909_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20250101__20250930__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFiveWarrantsMember_zI3J5TWdwcWi" title="Fair value of warrants"&gt;2,772&lt;/span&gt; was estimated at the date of issuance using the following assumptions: dividend yield
&lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFiveWarrantsMember_zlCRROxRl8Xa" title="Warrant oustanding input"&gt;0&lt;/span&gt;%; expected term of &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFiveWarrantsMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zNJs2DAfdq3c" title="Warrant term"&gt;1.5&lt;/span&gt; years; equity volatility of &lt;span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFiveWarrantsMember_zecmQCwl5dN4" title="Warrant oustanding input"&gt;170.97&lt;/span&gt;%; and a risk-free interest rate of &lt;span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--ClassOfWarrantOrRightAxis__custom--JulyTwoThousandTwentyFiveWarrantsMember_zo3AGYBrGum7" title="Warrant oustanding input"&gt;3.94&lt;/span&gt;%. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognized changes in the fair value of the warrant liability of $&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20250701__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherIncomeMember_zpIiFJ81mqJb" title="Fair value of warrants liability"&gt;3,203&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pn3n3_c20250101__20250930__us-gaap--IncomeStatementLocationAxis__us-gaap--OtherIncomeMember_zMEqlIwLkWPf" title="Fair value of warrants liability"&gt;4,613&lt;/span&gt; during the three and nine months ended September
30, 2025, respectively, as financial income on the consolidated statement of operations. The aggregate fair value of the Warrants of
$&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstanding_iI_pn3n3_c20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSHw3GSWSIG7" title="Fair value of warrants"&gt;3,730&lt;/span&gt; was estimated on September 30, 2025 utilizing the Black Scholes Model and using the following assumptions: stock price $&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zG5U3li6s1Va" title="Warrant oustanding input"&gt;5.64&lt;/span&gt;,
exercise price $&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MinimumMember_z8ia5gpnNm0l" title="Warrant oustanding input"&gt;20.40&lt;/span&gt; &#x2013; $&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExercisePriceMember__srt--RangeAxis__srt--MaximumMember_zmbTh4a9ZkQj" title="Warrant oustanding input"&gt;22.50&lt;/span&gt;, dividend yield &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_za4ttLTSNPwg" title="Warrant oustanding input"&gt;0&lt;/span&gt;%; remaining term of &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zOWgS00mMImd" title="Warrant term"&gt;1.50&lt;/span&gt; &#x2013; &lt;span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zTI3cV8ICJ06" title="Warrant term"&gt;4.63&lt;/span&gt; years; equity volatility of &lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_zhsptAYfjn7a" title="Warrant oustanding input"&gt;149.90&lt;/span&gt;% - &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_za3gxfgQMJ1e" title="Warrant oustanding input"&gt;178.58&lt;/span&gt;%;
and a risk-free interest rate of &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zmfJPfMecafd" title="Warrant oustanding input"&gt;3.74&lt;/span&gt;% - &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20250930__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zkuGLvUnIZWf" title="Warrant oustanding input"&gt;3.94&lt;/span&gt;%. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Changes
in the warrant liability balance&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfChangeInWarrantLiabilityTableTextBlock_z3qT78SLpG5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Below
is the change in the warrant liability balance for the nine months ended September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zg0zM3JRHZWf" style="display: none"&gt;SCHEDULE
OF CHANGE IN WARRANT LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjja6AEWPVi8" style="width: 16%; text-align: right" title="Warrant outstanding balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1455"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSIGfeoKASeb" style="text-align: right" title="Issuance"&gt;8,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_iN_pn3n3_di_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZWUsemupiB4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(4,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance as of September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOHUn5oYKSb7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant outstanding balance"&gt;3,730&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zbajKSGuFiyc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;See
note 12 for assets and liabilities which are measured at fair value on a recurring basis by level within the fair value hierarchy.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NAOV:WarrantLiabilityDisclosureTextBlock>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-09-30_custom_MayTwoThousandTwentyFiveWarrantsMember"
      decimals="-3"
      id="Fact001405"
      unitRef="USD">5306000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-09-30_custom_RepresentativeWarrantsMember"
      decimals="-3"
      id="Fact001407"
      unitRef="USD">265000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember"
      decimals="INF"
      id="Fact001409"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-09-30_custom_MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001411">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember"
      decimals="INF"
      id="Fact001413"
      unitRef="Pure">1.4565</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_MayTwoThousandTwentyFiveWarrantsAndRepresentativesWarrantsMember"
      decimals="INF"
      id="Fact001415"
      unitRef="Pure">0.0406</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-09-30_custom_JulyTwoThousandTwentyFiveWarrantsMember"
      decimals="-3"
      id="Fact001417"
      unitRef="USD">2772000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember_custom_JulyTwoThousandTwentyFiveWarrantsMember"
      decimals="INF"
      id="Fact001419"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-09-30_custom_JulyTwoThousandTwentyFiveWarrantsMember_us-gaap_MeasurementInputExpectedTermMember"
      id="Fact001421">P1Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_custom_JulyTwoThousandTwentyFiveWarrantsMember"
      decimals="INF"
      id="Fact001423"
      unitRef="Pure">1.7097</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_custom_JulyTwoThousandTwentyFiveWarrantsMember"
      decimals="INF"
      id="Fact001425"
      unitRef="Pure">0.0394</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-07-012025-09-30_us-gaap_OtherIncomeMember"
      decimals="-3"
      id="Fact001427"
      unitRef="USD">3203000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_OtherIncomeMember"
      decimals="-3"
      id="Fact001429"
      unitRef="USD">4613000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact001431"
      unitRef="USD">3730000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001433"
      unitRef="Pure">5.64</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExercisePriceMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001435"
      unitRef="Pure">20.40</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExercisePriceMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001437"
      unitRef="Pure">22.50</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001439"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember"
      id="Fact001441">P1Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember"
      id="Fact001443">P4Y7M17D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001445"
      unitRef="Pure">1.4990</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001447"
      unitRef="Pure">1.7858</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001449"
      unitRef="Pure">0.0374</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2025-09-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001451"
      unitRef="Pure">0.0394</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <NAOV:ScheduleOfChangeInWarrantLiabilityTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001453">&lt;p id="xdx_899_ecustom--ScheduleOfChangeInWarrantLiabilityTableTextBlock_z3qT78SLpG5h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Below
is the change in the warrant liability balance for the nine months ended September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B6_zg0zM3JRHZWf" style="display: none"&gt;SCHEDULE
OF CHANGE IN WARRANT LIABILITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Balance as of December 31, 2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iS_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zjja6AEWPVi8" style="width: 16%; text-align: right" title="Warrant outstanding balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1455"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Issuance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSIGfeoKASeb" style="text-align: right" title="Issuance"&gt;8,343&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Change in fair value&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueAdjustmentOfWarrants_iN_pn3n3_di_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zZWUsemupiB4" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(4,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance as of September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WarrantsAndRightsOutstanding_iE_pn3n3_c20250101__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOHUn5oYKSb7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrant outstanding balance"&gt;3,730&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</NAOV:ScheduleOfChangeInWarrantLiabilityTableTextBlock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact001457"
      unitRef="USD">8343000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact001459"
      unitRef="USD">4613000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2025-09-30_us-gaap_WarrantMember"
      decimals="-3"
      id="Fact001461"
      unitRef="USD">3730000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001463">&lt;p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zJDo180AJA58" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
8 &#x2013; &lt;span id="xdx_825_znL0aLBVBgqc"&gt;CONVERTIBLE DEBENTURE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 13, 2025, the Company entered into a Securities Purchase Agreement (the &#x201c;PIPE Purchase Agreement&#x201d;) with an institutional
investor (the &#x201c;February 2025 Investor&#x201d;), pursuant to which the Company sold in a private placement senior convertible debenture
(the &#x201c;Debenture&#x201d;) due the earlier of (i) the date that is the 30-day anniversary of the effective date of stockholder approval
of the issuance of the shares of common stock upon the conversion of the debentures and (ii) November 13, 2025 (the date that is nine
months following the date of issuance of the Debenture) (&#x201c;Maturity Date&#x201d;), having an aggregate principal amount (the &#x201c;Principal
Amount&#x201d;) of $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20250213_z3iL8dqHoovj" title="Principal amount"&gt;500&lt;/span&gt; (the &#x201c;Debenture Transaction&#x201d;). The closing of the Debenture Transaction occurred on February 14, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 26, 2025, the Company amended and restated the Debenture (the &#x201c;A&amp;amp;R Debenture&#x201d;) to increase the Principal Amount
to $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20250326__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zezR6afsKxqf" title="Principal amount"&gt;1,300&lt;/span&gt; to provide for the funding by the February 2025 Investor to ENvue (i) an aggregate of $&lt;span id="xdx_908_eus-gaap--Investments_iI_pn3n3_c20250206__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zRT4KN3sD1A" title="Investments"&gt;250&lt;/span&gt; by the February 2025 Investor to
ENvue on February 6, 2025, (ii) an aggregate of $&lt;span id="xdx_906_eus-gaap--Investments_iI_pn3n3_c20250304__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zSYdxU2X0Yea" title="Investments"&gt;250&lt;/span&gt; by the Investor to ENvue on March 4, 2025, and (iii) and an aggregate of $&lt;span id="xdx_90B_eus-gaap--Investments_iI_pn3n3_c20250326__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zn93Y1zuA2e7" title="Investments"&gt;300&lt;/span&gt; by
the Investor to ENvue on March 26, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
the Maturity Date, the Company shall pay the February 2025 Investor in cash or, at the option of the February 2025 Investor, in the
form of conversion shares, or a combination thereof, the entire outstanding Principal Amount of the A&amp;amp;R Debenture, together with
accrued and unpaid interest thereon, the applicable exit fee and any other amounts due thereunder. Following the receipt of
Debenture Stockholder Approval, the A&amp;amp;R Debenture shall be convertible, in whole or in part, into shares of common stock, at the
option of the Investor, at the initial conversion price of $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20250326__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zocaP9FDkZxa" title="Conversion price"&gt;48.906&lt;/span&gt;
(the &#x201c;Conversion Price&#x201d;), which is subject to customary anti-dilution adjustments, and which such Conversion Price shall
not be lower than the floor price of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250326__srt--RangeAxis__srt--MinimumMember_zH8ZNqiAr1q2" title="Conversion price"&gt;9.7812&lt;/span&gt;.
The A&amp;amp;R Debenture bears interest at the rate of &lt;span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20250326__dei--LegalEntityAxis__custom--ENvueMedicalHoldingsCorpMember_zoP5iJ7gFQQ" title="Debt interest rate"&gt;8.0&lt;/span&gt;%
per annum, payable on the Maturity Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Due
to certain embedded features within the A&amp;amp;R Debenture, the Company elected to account for the A&amp;amp;R Debenture and all the embedded
features at fair value at inception. Subsequent changes in fair value are recorded in financial income (expense), net in the consolidated
statements of operations. As a result of electing the fair value option, direct costs and fees related to the Debenture were expensed
as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and nine months ended September 30, 2025, the Company recorded a loss of $&lt;span id="xdx_909_ecustom--ChangeInFairValueOfDebenture_pn3n3_c20250701__20250930_zeK5v5CRGAe8" title="Change in fair value of debenture"&gt;9&lt;/span&gt; and $&lt;span id="xdx_907_ecustom--ChangeInFairValueOfDebenture_pn3n3_c20250101__20250930_z43kDmVarAxl" title="Change in fair value of debenture"&gt;23&lt;/span&gt;, respectively, related to the change in
fair value of the A&amp;amp;R Debenture which was recognized in other income (expense) in the consolidated statements of operations. On May
19, 2025, the Company repaid the A&amp;amp;R Debenture in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfDebtTableTextBlock_zRxeFyAKCLUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the change in the balance of the A&amp;amp;R Debenture for periods identified:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zeQIrSCQlxvh" style="display: none"&gt;SCHEDULE
OF A&amp;amp;R DEBENTURE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250930_zFqR5N42iX2c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;br/&gt; September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LongTermDebt_iS_pn3n3_z2AtoXHWSpGb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1487"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DebentureIssued_pn3n3_zU5Fx7otHxcg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Debenture issued&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_zxBZ12RSC7e6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Mark to market&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PaymentsForLoans_iN_pn3n3_di_zgi6wVDPj032" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Payments on debenture&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,322&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebt_iE_pn3n3_zTMc16Ho2gE1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1495"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zpETBpBexafi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-02-13"
      decimals="-3"
      id="Fact001465"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-03-26_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001467"
      unitRef="USD">1300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:Investments
      contextRef="AsOf2025-02-06_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001469"
      unitRef="USD">250000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2025-03-04_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001471"
      unitRef="USD">250000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="AsOf2025-03-26_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001473"
      unitRef="USD">300000</us-gaap:Investments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-03-26_custom_ENvueMedicalHoldingsCorpMember"
      decimals="INF"
      id="Fact001475"
      unitRef="USDPShares">48.906</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2025-03-26_srt_MinimumMember"
      decimals="INF"
      id="Fact001477"
      unitRef="USDPShares">9.7812</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2025-03-26_custom_ENvueMedicalHoldingsCorpMember"
      decimals="INF"
      id="Fact001479"
      unitRef="Pure">0.080</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <NAOV:ChangeInFairValueOfDebenture
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact001481"
      unitRef="USD">9000</NAOV:ChangeInFairValueOfDebenture>
    <NAOV:ChangeInFairValueOfDebenture
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001483"
      unitRef="USD">23000</NAOV:ChangeInFairValueOfDebenture>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001485">&lt;p id="xdx_890_eus-gaap--ScheduleOfDebtTableTextBlock_zRxeFyAKCLUh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents the change in the balance of the A&amp;amp;R Debenture for periods identified:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B0_zeQIrSCQlxvh" style="display: none"&gt;SCHEDULE
OF A&amp;amp;R DEBENTURE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250930_zFqR5N42iX2c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;br/&gt; September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LongTermDebt_iS_pn3n3_z2AtoXHWSpGb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1487"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DebentureIssued_pn3n3_zU5Fx7otHxcg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Debenture issued&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DebtInstrumentIncreaseAccruedInterest_pn3n3_zxBZ12RSC7e6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Mark to market&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PaymentsForLoans_iN_pn3n3_di_zgi6wVDPj032" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Payments on debenture&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,322&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebt_iE_pn3n3_zTMc16Ho2gE1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1495"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <NAOV:DebentureIssued
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001489"
      unitRef="USD">1300000</NAOV:DebentureIssued>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001491"
      unitRef="USD">22000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:PaymentsForLoans
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001493"
      unitRef="USD">1322000</us-gaap:PaymentsForLoans>
    <us-gaap:ShortTermDebtTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001497">&lt;p id="xdx_801_eus-gaap--ShortTermDebtTextBlock_zKcJGH2rYVji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
9 &#x2013; &lt;span id="xdx_824_zLp9yOy1RH4i"&gt;LOANS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;ENvue
Consolidated Secured Note&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 17, 2025, ENvue issued a Consolidated Secured Note (as amended, the &#x201c;Alpha Note&#x201d;) in the aggregate principal amount
of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20250117__us-gaap--DebtInstrumentAxis__custom--ENvueConsolidatedSecuredNoteMember_zsXwrRnXXcf2" title="Principal amount"&gt;2,497&lt;/span&gt; to Alpha Capital Anstalt (&#x201c;Alpha&#x201d;), which such Alpha Note was funded in several tranches. The Alpha Note does not
bear interest and is secured by Collateral (as defined in the ENvue Note). The aggregate principal amount owed under the Alpha Note shall
be due and payable on the earlier of (i) the receipt of shareholder approval by the Company of the Parent Stockholder Matters (as defined
in that certain Merger Agreement) and (ii) December 31, 2025. As part of the acquisition accounting, the Company recorded the loan at
its fair value of $&lt;span id="xdx_908_eus-gaap--BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_pn3n3_c20251231__20251231__us-gaap--DebtInstrumentAxis__custom--ENvueConsolidatedSecuredNoteMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember__us-gaap--BusinessAcquisitionAxis__custom--ENvueMedicalHoldingsCorpMember_zEhAXMBQo544" title="Fair value of loan"&gt;2,258&lt;/span&gt;. The difference between the face value and the fair value will be recognized as interest expense over the life
of the note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the nine months ended September 30, 2025, the Company recognized $&lt;span id="xdx_905_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20250101__20250930_z0Ev0lVqSMV5" title="Amortized discount"&gt;202&lt;/span&gt; of amortized interest expense related to the note. During the period
ended September 30, 2025, the Company paid $&lt;span id="xdx_90A_eus-gaap--RepaymentsOfShortTermDebt_pn3n3_c20250101__20250930_z6RvbgXxOm4b" title="Payments on note"&gt;1,417&lt;/span&gt; toward redeeming the Alpha Note, leaving a balance of $&lt;span id="xdx_900_eus-gaap--LoansPayable_iI_pn3n3_c20250930_zsuq8UtjzpF6" title="Loans"&gt;1,043&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfShortTermDebtTextBlock_zdHssTXARhg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zykDd2T7TRvi" style="display: none"&gt;SCHEDULE OF LOANS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250101__20250930_zz8OfFkXp6gk" style="font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LoansPayable_iS_pn3n3_z9QVO4tf10Y7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,258&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_zvj2hpO6UlMg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Amortized discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--RepaymentsOfShortTermDebt_iN_pn3n3_di_zZb08AbbRm96" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Payments on note&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,417&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LoansPayable_iE_pn3n3_znpdwScTQ3Zb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zrda5h9qXSXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;April
2025 Promissory Note and Guaranty&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 11, 2025, ENvue issued a promissory note (the &#x201c;April Note&#x201d;) to Alpha (the &#x201c;Lender&#x201d;) in the principal amount
of $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20250411__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyFivePromissoryNoteMember_zmcchmXr4KNg" title="Principal amount"&gt;360&lt;/span&gt; (the &#x201c;April Note Principal Amount&#x201d;), together with all accrued interest thereon. The April Note has a maturity date
of &lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20250411__20250411__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyFivePromissoryNoteMember_zGYhQ81jJMg2" title="Maturity date"&gt;June 11, 2025&lt;/span&gt; (the &#x201c;April Note Maturity Date&#x201d;) and on the April Note Maturity Date, the aggregate unpaid April Note Principal
Amount, all accrued and unpaid interest and all other amounts payable under the April Note shall be due and payable. The April Note bears
interest at an annual rate equal to &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20250411__20250411__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyFivePromissoryNoteMember_zdCda4PawWPj" title="Interest rate"&gt;8.0&lt;/span&gt;% and is payable &#x201c;in kind&#x201d; by adding such accrued interest to the April Note Principal
Amount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the terms of the April Note, commencing on the date of the issuance and sale of any shares common stock or Common Stock Equivalents
(as defined in the April Note) by us, the Lender may require ENvue to redeem all or a portion of the April Note with the proceeds of
such issuance and sale (the &#x201c;Redemption Right&#x201d;). The Redemption Right may be redeemed at any time after date of such issuance
and sale by the Lender providing to ENvue written notice specifying the principal amount of the Note to be redeemed (the &#x201c;Redemption
Amount&#x201d;), and the Redemption Amount shall be due and payable by ENvue on the second business day after the date of such notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
April Note additionally provides for certain customary events of default which upon occurrence, the Lender may, at its option, declare
the entire April Note Principal Amount together with all accrued interest and all other amounts payable under the April Note immediately
due and payable, provided however, that if a bankruptcy event occurs, the April Note Principal Amount and accrued interest on the April
Note shall become immediately due and payable without any notice, declaration or other act on the part of the Lender.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with ENvue&#x2019;s issuance of the April Note, on April 11, 2025, we entered into that certain Guaranty (the &#x201c;Guaranty&#x201d;)
in favor of the Lender, pursuant to which we have agreed to guarantee to the Lender the payment of all obligations and liabilities of
ENvue under the April Note, including, without limitation, for principal, interest and any other amounts due and payable by ENvue under
the April Note (the &#x201c;Guaranteed Obligations&#x201d;). Upon the occurrence of an Event of Default (as defined in the April Note),
the Guaranteed Obligations shall be deemed immediately due and payable at the election of Lender and we shall pay on demand the Guaranteed
Obligations to Lender.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 19, 2025, the Company paid the April Note in full using proceeds from the 2025 Underwritten Offering, pursuant to the terms of the
April Note.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShortTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-01-17_custom_ENvueConsolidatedSecuredNoteMember"
      decimals="-3"
      id="Fact001499"
      unitRef="USD">2497000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="From2025-12-312025-12-31_custom_ENvueConsolidatedSecuredNoteMember_srt_ScenarioForecastMember_custom_ENvueMedicalHoldingsCorpMember"
      decimals="-3"
      id="Fact001501"
      unitRef="USD">2258000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001503"
      unitRef="USD">202000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001505"
      unitRef="USD">1417000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:LoansPayable
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001507"
      unitRef="USD">1043000</us-gaap:LoansPayable>
    <us-gaap:ScheduleOfShortTermDebtTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001509">&lt;p id="xdx_895_eus-gaap--ScheduleOfShortTermDebtTextBlock_zdHssTXARhg8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zykDd2T7TRvi" style="display: none"&gt;SCHEDULE OF LOANS&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20250101__20250930_zz8OfFkXp6gk" style="font-weight: bold; text-align: center"&gt;Nine Months Ended&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LoansPayable_iS_pn3n3_z9QVO4tf10Y7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;2,258&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_zvj2hpO6UlMg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Amortized discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--RepaymentsOfShortTermDebt_iN_pn3n3_di_zZb08AbbRm96" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Payments on note&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,417&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LoansPayable_iE_pn3n3_znpdwScTQ3Zb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: justify"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,043&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:LoansPayable
      contextRef="AsOf2024-12-31"
      decimals="-3"
      id="Fact001511"
      unitRef="USD">2258000</us-gaap:LoansPayable>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001513"
      unitRef="USD">202000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001515"
      unitRef="USD">1417000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:LoansPayable
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001517"
      unitRef="USD">1043000</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-04-11_custom_AprilTwoThousandTwentyFivePromissoryNoteMember"
      decimals="-3"
      id="Fact001519"
      unitRef="USD">360000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2025-04-112025-04-11_custom_AprilTwoThousandTwentyFivePromissoryNoteMember"
      id="Fact001521">2025-06-11</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2025-04-112025-04-11_custom_AprilTwoThousandTwentyFivePromissoryNoteMember"
      decimals="INF"
      id="Fact001523"
      unitRef="Pure">0.080</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001525">&lt;p id="xdx_80F_eus-gaap--EarningsPerShareTextBlock_zkyLUHZz3Xdk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
10 - &lt;span id="xdx_82D_zgJkGaNL2dob"&gt;LOSS PER SHARE APPLICABLE TO COMMON STOCKHOLDERS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per common share (&#x201c;Basic EPS&#x201d;) is computed by dividing net loss available to common stockholders by the
weighted average number of common shares outstanding during the period. All outstanding stock options and warrants for the three and
nine months ended September 30, 2025, and 2024 have been excluded from the calculation of the diluted net loss per share because all
such securities are anti-dilutive for all periods presented, except for prefunded warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zhIYrbrXYTN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the computation of the net loss per share for the period presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zJoeo34PIBKk" style="display: none"&gt;SCHEDULE OF NET LOSS PER SHARE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250701__20250930_zdaY2C8gT4E9" style="font-weight: bold; text-align: center"&gt;Three Months Ended September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240701__20240930_zdJI0UedNOP8" style="font-weight: bold; text-align: center"&gt;Three Months Ended September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250930_zSx0Gx4kf7v7" style="font-weight: bold; text-align: center"&gt;Nine Months Ended September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930_zGQ5vkJCGGV6" style="font-weight: bold; text-align: center"&gt;Nine Months Ended September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_z3cLd3QNqYSh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Net income (loss)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;510&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(5,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(2,274&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DividendsPreferredStockStock_iN_di_zTyldecTKAml" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend on Series X Convertible Preferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(758&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1535"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,102&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1537"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DividendsPreferredStockStockOne_iN_di_zUE8O2qatGub" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend on Series H Convertible Preferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(223&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1540"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(223&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1542"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeemedDividend_iN_di_zItlXwMkIg88" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deemed dividend for down round on Series H (See note 6)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(399&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1545"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(399&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1547"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DividendsPreferredStockStockTwo_iN_di_zCHzEBEP5ujf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deemed contribution on repurchase of Preferred Series X&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1552"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PreferredStockDividendsAndOtherAdjustments_iN_di_znV7B9wjJ7Ya" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Deemed contribution (See note 6)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1554"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1555"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,815&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1557"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zPYs0UOCSLm8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Net loss available to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(780&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(998&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,152&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zR2LZPClqWa6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z94cNQOpSaRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s securities, in common stock equivalents, which have been excluded from the calculation
of dilutive loss per share as their effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zurfsTsRul74" style="display: none"&gt;SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250101__20250930_zEAbc3DqylW1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240930_zUuQrTjxOhwj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_zWIlyCMp9aI" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Stock options &#x2013; employee and non-employee&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,411&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;202,650&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zjekQ407GJBi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,071,463&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,623,229&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zgezQgLHJN67" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,075,874&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,828,879&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zltoIFLPxSVd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
diluted loss per share equals basic loss per share in the three and nine months ended September 30, 2025, and 2024 because the Company
had a net loss and the impact of the assumed exercise of stock options and the vesting of restricted stock would have been anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001527">&lt;p id="xdx_895_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zhIYrbrXYTN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the computation of the net loss per share for the period presented:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zJoeo34PIBKk" style="display: none"&gt;SCHEDULE OF NET LOSS PER SHARE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250701__20250930_zdaY2C8gT4E9" style="font-weight: bold; text-align: center"&gt;Three Months Ended September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240701__20240930_zdJI0UedNOP8" style="font-weight: bold; text-align: center"&gt;Three Months Ended September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20250101__20250930_zSx0Gx4kf7v7" style="font-weight: bold; text-align: center"&gt;Nine Months Ended September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930_zGQ5vkJCGGV6" style="font-weight: bold; text-align: center"&gt;Nine Months Ended September 30,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Numerator:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--NetIncomeLoss_z3cLd3QNqYSh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Net income (loss)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;510&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(998&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(5,333&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;(2,274&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DividendsPreferredStockStock_iN_di_zTyldecTKAml" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend on Series X Convertible Preferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(758&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1535"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,102&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1537"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DividendsPreferredStockStockOne_iN_di_zUE8O2qatGub" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Dividend on Series H Convertible Preferred&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(223&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1540"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(223&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1542"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--DeemedDividend_iN_di_zItlXwMkIg88" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deemed dividend for down round on Series H (See note 6)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(399&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1545"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(399&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1547"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--DividendsPreferredStockStockTwo_iN_di_zCHzEBEP5ujf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Deemed contribution on repurchase of Preferred Series X&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1550"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1552"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PreferredStockDividendsAndOtherAdjustments_iN_di_znV7B9wjJ7Ya" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;Deemed contribution (See note 6)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1554"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1555"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;3,815&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1557"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zPYs0UOCSLm8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"&gt;Net loss available to common stockholders&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(780&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(998&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,152&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,274&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact001529"
      unitRef="USD">510000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001530"
      unitRef="USD">-998000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001531"
      unitRef="USD">-5333000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact001532"
      unitRef="USD">-2274000</us-gaap:NetIncomeLoss>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact001534"
      unitRef="USD">758000</us-gaap:DividendsPreferredStockStock>
    <us-gaap:DividendsPreferredStockStock
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001536"
      unitRef="USD">1102000</us-gaap:DividendsPreferredStockStock>
    <NAOV:DividendsPreferredStockStockOne
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact001539"
      unitRef="USD">223000</NAOV:DividendsPreferredStockStockOne>
    <NAOV:DividendsPreferredStockStockOne
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001541"
      unitRef="USD">223000</NAOV:DividendsPreferredStockStockOne>
    <NAOV:DeemedDividend
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact001544"
      unitRef="USD">399000</NAOV:DeemedDividend>
    <NAOV:DeemedDividend
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001546"
      unitRef="USD">399000</NAOV:DeemedDividend>
    <NAOV:DividendsPreferredStockStockTwo
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact001549"
      unitRef="USD">-90000</NAOV:DividendsPreferredStockStockTwo>
    <NAOV:DividendsPreferredStockStockTwo
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001551"
      unitRef="USD">-90000</NAOV:DividendsPreferredStockStockTwo>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001556"
      unitRef="USD">-3815000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact001559"
      unitRef="USD">-780000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001560"
      unitRef="USD">-998000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001561"
      unitRef="USD">-3152000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact001562"
      unitRef="USD">-2274000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001564">&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z94cNQOpSaRi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s securities, in common stock equivalents, which have been excluded from the calculation
of dilutive loss per share as their effect would be anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8B4_zurfsTsRul74" style="display: none"&gt;SUMMARY OF COMMON SHARE EQUIVALENTS BEEN EXCLUDED FROM DILUTIVE LOSS PER SHARE AS ANTI-DILUTIVE&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20250101__20250930_zEAbc3DqylW1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240930_zUuQrTjxOhwj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;September 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--StockOptionsEmployeeAndNonEmployeeMember_zWIlyCMp9aI" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Stock options &#x2013; employee and non-employee&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;4,411&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;202,650&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zjekQ407GJBi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,071,463&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;7,623,229&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_zgezQgLHJN67" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,075,874&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;7,828,879&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember"
      decimals="INF"
      id="Fact001566"
      unitRef="Shares">4411</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_custom_StockOptionsEmployeeAndNonEmployeeMember"
      decimals="INF"
      id="Fact001567"
      unitRef="Shares">202650</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-012025-09-30_us-gaap_WarrantMember2482609"
      decimals="INF"
      id="Fact001569"
      unitRef="Shares">1071463</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001570"
      unitRef="Shares">7623229</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001572"
      unitRef="Shares">1075874</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2024-01-012024-09-30"
      decimals="INF"
      id="Fact001573"
      unitRef="Shares">7828879</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001575">&lt;p id="xdx_802_eus-gaap--SegmentReportingDisclosureTextBlock_zVBqclx62eMa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
11 &#x2013; &lt;span id="xdx_82F_zW5r63dcCR57"&gt;SEGMENT INFORMATION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
segments are defined as components of an entity for which separate financial information is available and that is regularly provided
to the Chief Operating Decision Maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources to an individual segment and in assessing
performance. The Company&#x2019;s Chief Executive Officer is the Company&#x2019;s CODM. The CODM reviews financial information presented
by operating segment in making operating decisions, allocating resources, and evaluating financial performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company conducted the business through &lt;span id="xdx_904_eus-gaap--NumberOfReportableSegments_dc_uInteger_c20250101__20250930_zus1t62p51C" title="Number of segments"&gt;two&lt;/span&gt; primary operating segments: NanoVibronix and ENvue. NanoVibronix derives revenues from selling
its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral
tubes and related services. Non-allocated administrative and other expenses are reflected in Corporate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s chief executive officer is its chief operating decision maker (CODM), who allocates resources to and assesses the performance
of each operating segment using information about the operating segment&#x2019;s loss from operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zFNNTnj6vqqc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_z4Tq038Av7i1" style="display: none"&gt;SCHEDULE
OF SEGMENT INFORMATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Goodwill
and Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NanoVibronix&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;ENvue&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;Balance sheet at September 30, 2025:&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%"&gt;Goodwill&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Goodwill_iI_pn3n3_c20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zNVsMTL0USr" style="width: 10%; text-align: right" title="Goodwill"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1581"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Goodwill_iI_pn3n3_c20250930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zCIrSbii7xM2" style="width: 10%; text-align: right" title="Goodwill"&gt;38,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;-&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Goodwill_iI_pn3n3_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zEQ9bhCkroYk" style="width: 10%; text-align: right" title="Goodwill"&gt;38,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Assets_iI_pn3n3_c20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zZa3ulbtDoHa" style="text-align: right" title="Assets"&gt;2,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Assets_iI_pn3n3_c20250930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zZk0A2rRkmOg" style="text-align: right" title="Assets"&gt;51,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_z7dOKfLeS7re" style="text-align: right" title="Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1591"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0frrulprAy1" style="text-align: right" title="Assets"&gt;54,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;b&gt;Balance sheet at December 31, 2024:&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Goodwill_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zBVjjlOwnEfe" style="text-align: right" title="Goodwill"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1595"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Goodwill_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zw07J8f8pJx8" style="text-align: right" title="Goodwill"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1597"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Goodwill_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zfLiyjtXSsPd" style="text-align: right" title="Goodwill"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1599"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zLAjsQOYWclh" style="text-align: right" title="Assets"&gt;3,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zPKuFOjeE46b" style="text-align: right" title="Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1603"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zChSNouegf1e" style="text-align: right" title="Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1605"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJ7tbjjEBwYl" style="text-align: right" title="Assets"&gt;3,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Segment
operating results&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Nine months ended September 30, 2025:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zt2DjFjzKH6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NanoVibronix&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_z5iVdKOIX9jg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;ENvue&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zGNealyoK52d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zb8b0lfFmzde" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--Revenues_zlCfK12onI5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,738&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;503&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1611"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,241&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_zQT7bf3nQE0g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,062&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1616"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_zjQ4m6EpeFdh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,723&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--SellingAndMarketingExpense_zggvk7zdN5q3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1626"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherGeneralAndAdministrativeExpense_zKMA4wC5y3kd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,550&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,379&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,068&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,997&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_zQQu9u35KXjl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total operating loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,857&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,068&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,075&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Nine months ended September 30, 2024:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zW8JcLycFpyl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NanoVibronix&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zoDc6rrp4o18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;ENvue&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_z0SRQIK6lYeh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z9uPsH3cXhfc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_zgXJBqQgqR1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,114&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1641"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,114&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CostOfRevenue_znLea3Qfoap" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1645"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_z44IRSCeqiTi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1651"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--SellingAndMarketingExpense_zNVVn4zPPe77" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1656"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OtherGeneralAndAdministrativeExpense_zeRoaFB3cvEf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,335&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1660"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1661"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,335&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_zGtI2tunYGp7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,212&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1665"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1666"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,212&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Three months ended September 30, 2025:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zqDH2BY67S6j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NanoVibronix&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zevASowaJV25" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;ENvue&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zDxgeXWdH5ob" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zEl8ER7qyX4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Revenues_zYgdmXZGolUe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;371&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;351&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1671"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;722&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CostOfRevenue_ztWKPF3graO9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1676"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zgbJ5jSylKA8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1681"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--SellingAndMarketingExpense_zCZLKecWOqZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1686"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherGeneralAndAdministrativeExpense_zGW8xqts1Jxl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;323&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;577&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;503&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,403&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingIncomeLoss_zC3HSBpKEDk7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(614&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(503&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,247&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Three months ended September 30, 2024:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zcyRQifSO1Dh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NanoVibronix&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zHGE4TWvBqV1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;ENvue&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zNU6ALIJrvZh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zENhIYKy75d6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--Revenues_zeoKUv1Jk5Uk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1700"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1701"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CostOfRevenue_zKXscXL3c0xc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1705"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1706"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_zxe7wNN1LQD5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1710"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1711"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--SellingAndMarketingExpense_zejGiwVnQMz5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1715"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1716"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherGeneralAndAdministrativeExpense_zppeAolaAlU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;673&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1720"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1721"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;673&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingIncomeLoss_zBAyW44sXQv9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(970&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1725"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1726"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(970&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AC_zJLWXtxulpkf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Geographic
Information and Major Customer Data&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zns9TkTsUoc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of revenues within geographic areas:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BD_zpQw9yIvQOL5" style="display: none"&gt;SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250701__20250930_zWv4maZYo3Zf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240701__20240930_zcc7qALzzC0f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20250930_zmRBOPpK1SY8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240930_zc4cMILotwa4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended &lt;br/&gt;
September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--US_zkrIcABJ5WO1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;694&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;349&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__srt--EuropeMember_zUHn0KHa9zql" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__custom--AustraliaNewZealandMember_zMBHYlRpoBRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Australia/New Zealand&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_z2x2RwpWhff5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1746"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zkLOlGfavwG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;376&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,241&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,114&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zhD0h9Ka4i4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the three and nine months ended September 30, 2025, the Company generated approximately $&lt;span id="xdx_906_eus-gaap--Revenues_pn3n3_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zyBl7S06GjS6" title="Revenues"&gt;219&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--Revenues_pn3n3_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zxsVcvh3HiMe" title="Revenues"&gt;616&lt;/span&gt;, respectively, in revenue from
its largest customer, representing about &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250701__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zEjq0tp7yHBd" title="Concentration risk, percentage"&gt;59&lt;/span&gt;% and &lt;span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20250101__20250930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_z4w4TaH4WfM6" title="Concentration risk, percentage"&gt;35&lt;/span&gt;% of total revenue for those periods. For the same periods in 2024, the Company&#x2019;s
largest customer accounted for approximately &lt;span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zwNjJkf0i8Il" title="Concentration risk, percentage"&gt;24&lt;/span&gt;% and &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_znrh2pqnNLr8" title="Concentration risk, percentage"&gt;38&lt;/span&gt;% of total revenue, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="From2025-01-01to2025-09-30"
      decimals="INF"
      id="Fact001577"
      unitRef="Integer">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001579">&lt;p id="xdx_89F_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zFNNTnj6vqqc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span id="xdx_8BC_z4Tq038Av7i1" style="display: none"&gt;SCHEDULE
OF SEGMENT INFORMATION&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Goodwill
and Assets&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NanoVibronix&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;ENvue&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;b&gt;Balance sheet at September 30, 2025:&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 44%"&gt;Goodwill&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Goodwill_iI_pn3n3_c20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zNVsMTL0USr" style="width: 10%; text-align: right" title="Goodwill"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1581"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Goodwill_iI_pn3n3_c20250930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zCIrSbii7xM2" style="width: 10%; text-align: right" title="Goodwill"&gt;38,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;-&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Goodwill_iI_pn3n3_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zEQ9bhCkroYk" style="width: 10%; text-align: right" title="Goodwill"&gt;38,631&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--Assets_iI_pn3n3_c20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zZa3ulbtDoHa" style="text-align: right" title="Assets"&gt;2,413&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Assets_iI_pn3n3_c20250930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zZk0A2rRkmOg" style="text-align: right" title="Assets"&gt;51,970&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_z7dOKfLeS7re" style="text-align: right" title="Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1591"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z0frrulprAy1" style="text-align: right" title="Assets"&gt;54,383&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;b&gt;Balance sheet at December 31, 2024:&lt;/b&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Goodwill&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Goodwill_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zBVjjlOwnEfe" style="text-align: right" title="Goodwill"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1595"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Goodwill_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zw07J8f8pJx8" style="text-align: right" title="Goodwill"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1597"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Goodwill_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zfLiyjtXSsPd" style="text-align: right" title="Goodwill"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1599"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zLAjsQOYWclh" style="text-align: right" title="Assets"&gt;3,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zPKuFOjeE46b" style="text-align: right" title="Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1603"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zChSNouegf1e" style="text-align: right" title="Assets"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1605"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Assets_iI_pn3n3_c20241231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zJ7tbjjEBwYl" style="text-align: right" title="Assets"&gt;3,629&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;i&gt;Segment
operating results&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Nine months ended September 30, 2025:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zt2DjFjzKH6c" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NanoVibronix&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_z5iVdKOIX9jg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;ENvue&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250101__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zGNealyoK52d" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20250101__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zb8b0lfFmzde" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--Revenues_zlCfK12onI5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;1,738&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;503&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1611"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,241&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--CostOfRevenue_zQT7bf3nQE0g" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,062&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;656&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1616"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,718&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ResearchAndDevelopmentExpense_zjQ4m6EpeFdh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,227&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1621"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,723&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--SellingAndMarketingExpense_zggvk7zdN5q3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;756&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,122&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1626"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,878&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OtherGeneralAndAdministrativeExpense_zKMA4wC5y3kd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,550&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,379&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,068&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,997&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_zQQu9u35KXjl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Total operating loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,857&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,068&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,075&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Nine months ended September 30, 2024:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zW8JcLycFpyl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NanoVibronix&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zoDc6rrp4o18" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;ENvue&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20240101__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_z0SRQIK6lYeh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z9uPsH3cXhfc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--Revenues_zgXJBqQgqR1k" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: justify"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,114&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1640"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1641"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,114&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--CostOfRevenue_znLea3Qfoap" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1645"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1646"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;889&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_z44IRSCeqiTi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1650"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1651"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;557&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--SellingAndMarketingExpense_zNVVn4zPPe77" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1655"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1656"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;545&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OtherGeneralAndAdministrativeExpense_zeRoaFB3cvEf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,335&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1660"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1661"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,335&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_zGtI2tunYGp7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,212&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1665"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1666"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,212&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Three months ended September 30, 2025:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zqDH2BY67S6j" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NanoVibronix&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zevASowaJV25" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;ENvue&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20250701__20250930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zDxgeXWdH5ob" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20250701__20250930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zEl8ER7qyX4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--Revenues_zYgdmXZGolUe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;371&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;351&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1671"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;722&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--CostOfRevenue_ztWKPF3graO9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;346&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1676"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;533&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_zgbJ5jSylKA8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;177&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1681"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;221&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--SellingAndMarketingExpense_zCZLKecWOqZd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;431&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;381&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1686"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;812&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherGeneralAndAdministrativeExpense_zGW8xqts1Jxl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;323&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;577&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;503&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;1,403&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--OperatingIncomeLoss_zC3HSBpKEDk7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(614&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(1,131&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(503&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(2,247&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;Three months ended September 30, 2024:&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--NanoVibronixMember_zcyRQifSO1Dh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;NanoVibronix&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__custom--EnvueMember_zHGE4TWvBqV1" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;ENvue&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20240701__20240930__us-gaap--StatementBusinessSegmentsAxis__us-gaap--CorporateMember_zNU6ALIJrvZh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Corporate&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240701__20240930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zENhIYKy75d6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--Revenues_zeoKUv1Jk5Uk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%"&gt;Revenues&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1700"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl1701"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;376&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CostOfRevenue_zKXscXL3c0xc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Cost of revenues&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1705"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1706"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;243&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_zxe7wNN1LQD5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1710"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1711"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--SellingAndMarketingExpense_zejGiwVnQMz5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling and marketing&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1715"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1716"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;181&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--OtherGeneralAndAdministrativeExpense_zppeAolaAlU9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;673&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1720"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1721"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;673&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingIncomeLoss_zBAyW44sXQv9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Total operating loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(970&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1725"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1726"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(970&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Goodwill
      contextRef="AsOf2025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001583"
      unitRef="USD">38631000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001585"
      unitRef="USD">38631000</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001587"
      unitRef="USD">2413000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001589"
      unitRef="USD">51970000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001593"
      unitRef="USD">54383000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001601"
      unitRef="USD">3629000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2024-12-31_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001607"
      unitRef="USD">3629000</us-gaap:Assets>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001609"
      unitRef="USD">1738000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001610"
      unitRef="USD">503000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001612"
      unitRef="USD">2241000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001614"
      unitRef="USD">1062000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001615"
      unitRef="USD">656000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-01-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001617"
      unitRef="USD">1718000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001619"
      unitRef="USD">1227000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001620"
      unitRef="USD">496000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-01-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001622"
      unitRef="USD">1723000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001624"
      unitRef="USD">756000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001625"
      unitRef="USD">1122000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-01-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001627"
      unitRef="USD">1878000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001629"
      unitRef="USD">1550000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001630"
      unitRef="USD">1379000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_CorporateMember"
      decimals="-3"
      id="Fact001631"
      unitRef="USD">2068000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-01-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001632"
      unitRef="USD">4997000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001634"
      unitRef="USD">-2857000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001635"
      unitRef="USD">-3150000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_CorporateMember"
      decimals="-3"
      id="Fact001636"
      unitRef="USD">-2068000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-01-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001637"
      unitRef="USD">-8075000</us-gaap:OperatingIncomeLoss>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001639"
      unitRef="USD">2114000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001642"
      unitRef="USD">2114000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001644"
      unitRef="USD">889000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001647"
      unitRef="USD">889000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001649"
      unitRef="USD">557000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001652"
      unitRef="USD">557000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001654"
      unitRef="USD">545000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001657"
      unitRef="USD">545000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001659"
      unitRef="USD">2335000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001662"
      unitRef="USD">2335000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001664"
      unitRef="USD">-2212000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-01-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001667"
      unitRef="USD">-2212000</us-gaap:OperatingIncomeLoss>
    <us-gaap:Revenues
      contextRef="From2025-07-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001669"
      unitRef="USD">371000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001670"
      unitRef="USD">351000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-07-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001672"
      unitRef="USD">722000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001674"
      unitRef="USD">187000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001675"
      unitRef="USD">346000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2025-07-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001677"
      unitRef="USD">533000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001679"
      unitRef="USD">44000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001680"
      unitRef="USD">177000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2025-07-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001682"
      unitRef="USD">221000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-07-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001684"
      unitRef="USD">431000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-07-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001685"
      unitRef="USD">381000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2025-07-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001687"
      unitRef="USD">812000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001689"
      unitRef="USD">323000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001690"
      unitRef="USD">577000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_CorporateMember"
      decimals="-3"
      id="Fact001691"
      unitRef="USD">503000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2025-07-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001692"
      unitRef="USD">1403000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001694"
      unitRef="USD">-614000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30_custom_EnvueMember"
      decimals="-3"
      id="Fact001695"
      unitRef="USD">-1131000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_CorporateMember"
      decimals="-3"
      id="Fact001696"
      unitRef="USD">-503000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2025-07-012025-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001697"
      unitRef="USD">-2247000</us-gaap:OperatingIncomeLoss>
    <us-gaap:Revenues
      contextRef="From2024-07-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001699"
      unitRef="USD">376000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001702"
      unitRef="USD">376000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001704"
      unitRef="USD">243000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001707"
      unitRef="USD">243000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001709"
      unitRef="USD">249000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001712"
      unitRef="USD">249000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-07-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001714"
      unitRef="USD">181000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001717"
      unitRef="USD">181000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001719"
      unitRef="USD">673000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense
      contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001722"
      unitRef="USD">673000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30_custom_NanoVibronixMember"
      decimals="-3"
      id="Fact001724"
      unitRef="USD">-970000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2024-07-012024-09-30_us-gaap_RelatedPartyMember"
      decimals="-3"
      id="Fact001727"
      unitRef="USD">-970000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001729">&lt;p id="xdx_891_eus-gaap--RevenueFromExternalCustomersByGeographicAreasTableTextBlock_zns9TkTsUoc3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of revenues within geographic areas:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span id="xdx_8BD_zpQw9yIvQOL5" style="display: none"&gt;SUMMARY
OF REVENUE WITHIN GEOGRAPHIC AREAS&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20250701__20250930_zWv4maZYo3Zf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20240701__20240930_zcc7qALzzC0f" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250101__20250930_zmRBOPpK1SY8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240101__20240930_zc4cMILotwa4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;September 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Nine Months Ended &lt;br/&gt;
September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__country--US_zkrIcABJ5WO1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;United States&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;694&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;349&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,133&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;2,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__srt--EuropeMember_zUHn0KHa9zql" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Europe&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__custom--AustraliaNewZealandMember_zMBHYlRpoBRc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Australia/New Zealand&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--StatementGeographicalAxis__custom--OtherCountryMember_z2x2RwpWhff5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1746"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;12&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;24&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;38&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zkLOlGfavwG1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;722&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;376&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,241&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,114&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_country_US"
      decimals="-3"
      id="Fact001731"
      unitRef="USD">694000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30_country_US"
      decimals="-3"
      id="Fact001732"
      unitRef="USD">349000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_country_US"
      decimals="-3"
      id="Fact001733"
      unitRef="USD">2133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30_country_US"
      decimals="-3"
      id="Fact001734"
      unitRef="USD">2047000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_srt_EuropeMember"
      decimals="-3"
      id="Fact001736"
      unitRef="USD">8000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30_srt_EuropeMember"
      decimals="-3"
      id="Fact001737"
      unitRef="USD">8000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_srt_EuropeMember"
      decimals="-3"
      id="Fact001738"
      unitRef="USD">25000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30_srt_EuropeMember"
      decimals="-3"
      id="Fact001739"
      unitRef="USD">8000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30_custom_AustraliaNewZealandMember"
      decimals="-3"
      id="Fact001741"
      unitRef="USD">20000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30_custom_AustraliaNewZealandMember"
      decimals="-3"
      id="Fact001742"
      unitRef="USD">7000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_AustraliaNewZealandMember"
      decimals="-3"
      id="Fact001743"
      unitRef="USD">59000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30_custom_AustraliaNewZealandMember"
      decimals="-3"
      id="Fact001744"
      unitRef="USD">21000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30_custom_OtherCountryMember"
      decimals="-3"
      id="Fact001747"
      unitRef="USD">12000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-012025-09-30_custom_OtherCountryMember"
      decimals="-3"
      id="Fact001748"
      unitRef="USD">24000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30_custom_OtherCountryMember"
      decimals="-3"
      id="Fact001749"
      unitRef="USD">38000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-07-012025-09-30"
      decimals="-3"
      id="Fact001751"
      unitRef="USD">722000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-07-012024-09-30"
      decimals="-3"
      id="Fact001752"
      unitRef="USD">376000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2025-01-01to2025-09-30"
      decimals="-3"
      id="Fact001753"
      unitRef="USD">2241000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2024-01-012024-09-30"
      decimals="-3"
      id="Fact001754"
      unitRef="USD">2114000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="From2025-07-012025-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember"
      decimals="-3"
      id="Fact001756"
      unitRef="USD">219000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2025-01-012025-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember"
      decimals="-3"
      id="Fact001758"
      unitRef="USD">616000</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-07-012025-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember"
      decimals="INF"
      id="Fact001760"
      unitRef="Pure">0.59</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2025-01-012025-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember"
      decimals="INF"
      id="Fact001762"
      unitRef="Pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-07-012024-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember"
      decimals="INF"
      id="Fact001764"
      unitRef="Pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2024-01-012024-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_custom_CustomerMember"
      decimals="INF"
      id="Fact001766"
      unitRef="Pure">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001768">&lt;p id="xdx_806_eus-gaap--FairValueDisclosuresTextBlock_zpDbNfXjsEe4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
12 &#x2013; &lt;span id="xdx_82B_zjgrkA6EWyVf"&gt;FAIR VALUE&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Financial
Liabilities Measured at Fair Value on a Recurring Basis&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
fair value accounting standards define fair value as the amount that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants. As such, fair value is determined based upon assumptions that market participants
would use in pricing an asset or liability. Fair value measurements are rated on a three-tier hierarchy as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 1 inputs: Quoted
    prices (unadjusted) for identical assets or liabilities in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 2 inputs: Inputs,
    other than quoted prices included in Level 1, that are observable either directly or indirectly; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level 3 inputs: Unobservable
    inputs for which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between Level 3 during the nine months ended September 30, 2025, and 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zjIM9yeZWM83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents changes in Level 3 asset and liability measured at fair value for the nine months ended September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zFFMTGlURVbl" style="display: none"&gt;SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--WarrantLiabilityFairValueDisclosure_iS_pn3n3_c20250101__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSm9zBLiS3d7" style="text-align: right" title="Warrant liability balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1772"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left; padding-bottom: 1pt"&gt;Issuance &#x2013; warrant liability&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_c20250101__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7hPK4M8G7l6" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Issuance"&gt;8,343&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair Value adjustments &#x2013; warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_iN_pn3n3_di_c20250101__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zR0PFsEkM5Il" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(4,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance &#x2013; September 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantLiabilityFairValueDisclosure_iE_pn3n3_c20250101__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHy3MizijsUa" style="text-align: right" title="Warrant liability balance"&gt;3,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A1_zeQjIKjoR4Ka" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zZGTKFO4FoYd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the Company&#x2019;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zMtf4l7f4Zd3" style="display: none"&gt;SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeOG1aEc8Dv5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdoWH5vxMip3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsDiVZVPjojf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250930_zJBklqEFN958" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--WarrantLiabilityFairValueDisclosure_iI_zK4FHDnvklE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1782"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1783"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zHbxqLZpvLtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001770">&lt;p id="xdx_897_eus-gaap--FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_zjIM9yeZWM83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents changes in Level 3 asset and liability measured at fair value for the nine months ended September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zFFMTGlURVbl" style="display: none"&gt;SCHEDULE
OF CHANGES IN LEVEL 3 AND LIABILITY MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Warrants Liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance &#x2013; December 31, 2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--WarrantLiabilityFairValueDisclosure_iS_pn3n3_c20250101__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zSm9zBLiS3d7" style="text-align: right" title="Warrant liability balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1772"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left; padding-bottom: 1pt"&gt;Issuance &#x2013; warrant liability&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_c20250101__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z7hPK4M8G7l6" style="border-bottom: Black 1pt solid; width: 16%; text-align: right" title="Issuance"&gt;8,343&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1pt"&gt;Fair Value adjustments &#x2013; warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueAdjustmentOfWarrants_iN_pn3n3_di_c20250101__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zR0PFsEkM5Il" style="border-bottom: Black 1pt solid; text-align: right" title="Change in fair value"&gt;(4,613&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance &#x2013; September 30, 2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--WarrantLiabilityFairValueDisclosure_iE_pn3n3_c20250101__20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zHy3MizijsUa" style="text-align: right" title="Warrant liability balance"&gt;3,730&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001774"
      unitRef="USD">8343000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2025-01-012025-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001776"
      unitRef="USD">4613000</us-gaap:FairValueAdjustmentOfWarrants>
    <NAOV:WarrantLiabilityFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001778"
      unitRef="USD">3730000</NAOV:WarrantLiabilityFairValueDisclosure>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001780">&lt;p id="xdx_899_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zZGTKFO4FoYd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table sets forth the Company&#x2019;s assets and liabilities which are measured at fair value on a recurring basis by level
within the fair value hierarchy:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BA_zMtf4l7f4Zd3" style="display: none"&gt;SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeOG1aEc8Dv5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zdoWH5vxMip3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_490_20250930__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zsDiVZVPjojf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20250930_zJBklqEFN958" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Fair Value Measurements as of September 30, 2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level I&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level II&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Level III&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--WarrantLiabilityFairValueDisclosure_iI_zK4FHDnvklE3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1782"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1783"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;3,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <NAOV:WarrantLiabilityFairValueDisclosure
      contextRef="AsOf2025-09-30_us-gaap_FairValueInputsLevel3Member"
      decimals="-3"
      id="Fact001784"
      unitRef="USD">3730000</NAOV:WarrantLiabilityFairValueDisclosure>
    <NAOV:WarrantLiabilityFairValueDisclosure
      contextRef="AsOf2025-09-30"
      decimals="-3"
      id="Fact001785"
      unitRef="USD">3730000</NAOV:WarrantLiabilityFairValueDisclosure>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001787">&lt;p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z4ZktpHooV2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
13 - &lt;span id="xdx_829_zMUXDDNo0ZRa"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;i&gt;Pending
and settled litigation&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 26, 2021, Protrade Systems, Inc. (&#x201c;Protrade&#x201d;) filed a Request for Arbitration (the &#x201c;Request&#x201d;) with the
International Court of Arbitration (the &#x201c;ICA&#x201d;) of the International Chamber of Commerce alleging the Company is in breach
of an Exclusive Distribution Agreement dated March 7, 2019 (the &#x201c;Exclusive Distribution Agreement&#x201d;) between Protrade and
the Company. Protrade alleges, in part, that the Company has breached the Exclusive Distribution Agreement by discontinuing the manufacture
of the DV0057 Painshield MD device in favor of an updated 10-100-001 Painshield MD device. Protrade claims damages estimated at $&lt;span id="xdx_90B_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20210225__20210226_zNXqLQH9NK07" title="Litigation damages sought value"&gt;3&lt;/span&gt; million.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
March 15, 2022, the arbitrator issued a final award which determined that (i) the Company had the right to terminate the Exclusive Distribution
Agreement; (ii) the Company did not breach the duty of good faith and fair dealing with regard to the Exclusive Distribution Agreement;
and (iii) the Company did not breach any confidentiality obligations to Protrade. Nevertheless, the arbitrator determined that the Company
did not comply with the obligation to supply Protrade with a year&#x2019;s supply of patches, and awarded Protrade $&lt;span id="xdx_90D_eus-gaap--LossContingencyDamagesSoughtValue_pn3n3_c20220314__20220315_zhWtO3ajxWX3" title="Loss contingency damages sought value"&gt;1,500&lt;/span&gt;, which consists
of $&lt;span id="xdx_908_eus-gaap--LossContingencyDamagesAwardedValue_pn3n3_c20220314__20220315_zl4TpcZVQEB3" title="Loss contingency damages sought value"&gt;1,432&lt;/span&gt; for &#x201c;lost profits&#x201d; and $&lt;span id="xdx_902_eus-gaap--LossContingencyDamagesPaidValue_pn3n3_c20220314__20220315_znyv5gvXyKN4" title="Loss contingency damages paid value"&gt;68&lt;/span&gt; as reimbursement of arbitration costs, on the grounds that the Company allegedly failed
to supply Protrade with certain patches utilized by users of DV0057 Painshield MD device. The arbitrator based the decision on the testimony
of Protrade&#x2019;s president who asserted that a user would use in excess of 33 patches per each device. The Company believes that the
number of patches per device alleged by Protrade is grossly inflated, and that these claims were not properly raised before the arbitrator.
Accordingly, on April 13, 2022, the Company submitted an application for the correction of the award which the arbitrator denied on June
22, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 22, 2022, the Company filed a cross-motion seeking to vacate arbitration award on the grounds that the arbitrator exceeded her authority,
that the award was procured by fraud, and that the arbitrator failed to follow procedures established by New York law. In particular,
the Company averred in its motion that Protrade&#x2019;s witness made false statements in arbitration, and that the arbitrator resolved
a claim that was never raised by Protrade and that has no factual basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 3, 2022, the court issued a decision granting Protrade its petition to confirm the award and denying the cross-motion.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
November 9, 2022, the Company filed a motion to re-argue and renew its cross-motion to vacate the arbitration decision based on newer
information that was not available during the initial hearing. On the same day, the Company also filed a notice of appeal with the Appellate
Division, Second Department. On March 21, 2023, the court denied the motion to re-argue and renew.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 10, 2023, the Company filed its appeal with the Appellate Division, Second Department. That appeal is now fully briefed. In February
2025, the Second Department informed counsel for the Company that the Second Department was beginning to process the appeal for calendaring
with oral arguments to start by the end of May 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
May 30, 2025, the oral arguments were presented to the Appellate Court. A decision is expected at undetermined date later this year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of September 30, 2025, the Company accrued the amount of the arbitration award to Protrade of approximately $&lt;span id="xdx_908_eus-gaap--LossContingencyDamagesAwardedValue_pn5n6_c20250101__20250930__srt--TitleOfIndividualAxis__custom--ArbitratorMember_zgxbrLtp62t2" title="Damages awarded value"&gt;2.2&lt;/span&gt; million, respectively,
including interest which is classified in &#x201c;Other accounts payable and accrued expenses&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2021-02-252021-02-26"
      decimals="-6"
      id="Fact001789"
      unitRef="USD">3000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2022-03-142022-03-15"
      decimals="-3"
      id="Fact001791"
      unitRef="USD">1500000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2022-03-142022-03-15"
      decimals="-3"
      id="Fact001793"
      unitRef="USD">1432000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesPaidValue
      contextRef="From2022-03-142022-03-15"
      decimals="-3"
      id="Fact001795"
      unitRef="USD">68000</us-gaap:LossContingencyDamagesPaidValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="From2025-01-012025-09-30_custom_ArbitratorMember"
      decimals="-5"
      id="Fact001797"
      unitRef="USD">2200000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001799">&lt;p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zU9w3r145Lx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
14 &#x2013; &lt;span id="xdx_82D_z2f0K64eQTT"&gt;RELATED PARTY TRANSACTION&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Aurora
Cassirer served as a member of the Company&#x2019;s board of directors until her resignation effective April 1, 2025. During her
tenure, Ms. Cassirer also served on the Audit Committee, the Nominating and Corporate Governance Committee, and the Compensation
Committee. Her resignation was not in connection with any disagreement with the Company on any matter relating to the
Company&#x2019;s operations, policies, or practices, or any other matter. Ms. Cassirer is an attorney but did not provide any legal
services or legal advice to the Company during the period that she was a member of the board&lt;b&gt;.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
firm FisherBroyles LLP handled all of the Company&#x2019;s Protrade litigation and appeals through December 31, 2024. For the year ended
December 31, 2024, the Company was not billed and did not pay any legal fees to FisherBroyles. On January 1, 2024, Ms. Cassirer and the
lawyers responsible for handling the Company&#x2019;s Protrade litigation left FisherBroyles to join the firm Pierson Ferdinand LLP, which
since that date has currently been the sole firm handling all of the Company&#x2019;s Protrade litigation and appeals. For the nine months
ended September 30, 2025, and 2024, Pierson Ferdinand was paid $&lt;span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20250101__20250930__srt--TitleOfIndividualAxis__custom--PiersonFerdinandMember_zjkBDMtFckCh" title="Payments"&gt;58&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20240101__20240930__srt--TitleOfIndividualAxis__custom--PiersonFerdinandMember_z9tsXRhTA8q3" title="Payments"&gt;0&lt;/span&gt;, respectively, while Ms. Cassirer was a member of the board.
As in prior years, Ms. Cassirer has not provided any legal services or legal advice to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 17, 2025, ENvue issued the Alpha Note in the aggregate principal amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20250117__us-gaap--DebtInstrumentAxis__custom--ENvueConsolidatedSecuredNoteMember_z3LA2G2flrqj" title="Principal amount"&gt;2,497&lt;/span&gt;, to Alpha, which such Alpha Note was funded
in several tranches, see note 9.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 13, 2025, the Company entered into a PIPE Purchase Agreement with Alpha, pursuant to which the Company sold in a private placement
Debenture due the earlier of (i) the date that is the 30-day anniversary of the effective date of stockholder approval of the issuance
of the shares of common stock upon the conversion of the debentures and (ii) November 13, 2025 (the date that is nine months following
the date of issuance of the Debenture), having the Principal Amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20250213_zaCKA8BOoL2a" title="Principal amount"&gt;500&lt;/span&gt;. The closing of the Debenture Transaction occurred on February
14, 2025&#x2014;see note 8.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 14, 2025, pursuant to the terms of the Merger Agreement and in connection with the Merger and the appointment of Doron Besser
and Zeev Rotstein (together, the &#x201c;Indemnitees&#x201d;) to the Board of Directors, the Company and each of the Indemnitees entered
into the Company&#x2019;s standard form of indemnification agreement, which such indemnification agreements provide that the Company shall
indemnify the Indemnitees to the fullest extent of permitted by applicable law in effect on the date hereof or as amended to increase
the scope of permitted indemnification, against expenses, losses, liabilities, judgments, fines, penalties and amounts paid in settlement
(including all interest, taxes, assessments and other charges in connection therewith) incurred by Indemnitee or on Indemnitee&#x2019;s
behalf in connection with any proceeding in any way connected with, resulting from or relating to Indemnitee&#x2019;s corporate status.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
April 11, 2025, ENvue issued the April Note to Alpha in the principal amount of $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pn3n3_c20250411__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyFivePromissoryNoteMember_zRaP8YXFhLml" title="Principal amount"&gt;360&lt;/span&gt;, together with all accrued interest thereon. The
April Note has a maturity date of &lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20250411__20250411__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyFivePromissoryNoteMember_zKKZjw708Fdd" title="Maturity date"&gt;June 11, 2025&lt;/span&gt;, and on the April Note Maturity Date, the aggregate unpaid April Note Principal Amount,
all accrued and unpaid interest and all other amounts payable under the April Note shall be due and payable. The April Note bears interest
at an annual rate equal to &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20250411__20250411__us-gaap--DebtInstrumentAxis__custom--AprilTwoThousandTwentyFivePromissoryNoteMember_zvIax4bT2X13" title="Interest rate"&gt;8.0&lt;/span&gt;% and is payable &#x201c;in kind&#x201d; by adding such accrued interest to the April Note Principal Amount&#x2014;see
note 9.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
July 18, 2025, the Company entered into the July 2025 Purchase Agreement pursuant to which it agreed to sell to the July 2025 Investor
(i) an aggregate of &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20250718__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_z3lfoQFLOaFj" title="Preferred stock, shares authorized"&gt;8,889&lt;/span&gt; shares of the Company&#x2019;s newly-designated Series H Preferred Stock, initially convertible into up to &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20250718__20250718__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_zC0rTUAruAO6" title="Conversion of shares"&gt;880,099&lt;/span&gt;
shares of common stock at an adjusted conversion price of $&lt;span id="xdx_908_eus-gaap--PreferredStockConvertibleConversionPrice_iI_pid_c20250718__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_zga8AK9EEj82" title="Conversion price"&gt;7.01&lt;/span&gt; per share and the July 2025 Warrants to acquire up to an aggregate of
&lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250718__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_zeNExXPRc9Oh" title="Warrant outstanding"&gt;467,836&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250718__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_z3mlSbwhrXp2" title="Warrant exercise price"&gt;22.50&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Pursuant
to the terms of the July 2025 Purchase Agreement, the Company has also issued &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20250718__20250718__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_zBkUEJ82az1b" title="Issuance of shares"&gt;2,222&lt;/span&gt; shares of Series H Preferred Stock with a total stated
value of $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn3n3_c20250718__20250718__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesHPreferredStockMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_zux3zWKvqXm3" title="Issuance of shares, value"&gt;2,222&lt;/span&gt; and warrants to purchase up to &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20250718__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_zFymB81bZ4o" title="Issuance of warrants outstanding"&gt;116,960&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20250718__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--JulyTwoThousandTwentyFivePurchaseAgreementMember_zzcmoAYR5Uf4" title="Warrant exercise price"&gt;22.50&lt;/span&gt; in a second closing&#x2014;see
note 6.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
September 16, 2025, the Company entered into a securities purchase agreement with a single institutional investor, pursuant to which
the Company agreed to issue and sell (i) &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250916__20250916__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7z5QO4tXNW9" title="Number of shares issued"&gt;74,114&lt;/span&gt; shares of the Company&#x2019;s common stock, and (ii) the September 2025 Pre-Funded Warrants
to purchase up to &lt;span id="xdx_903_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20250916__20250916__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PreFundedWarrantsMember_zZxpHvCwVRX8" title="Number of warrants issued"&gt;217,090&lt;/span&gt; shares of common stock in the September 2025 Offering &#x2014;see note 6.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2025-01-012025-09-30_custom_PiersonFerdinandMember"
      decimals="-3"
      id="Fact001801"
      unitRef="USD">58000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-01-012024-09-30_custom_PiersonFerdinandMember"
      decimals="-3"
      id="Fact001803"
      unitRef="USD">0</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-01-17_custom_ENvueConsolidatedSecuredNoteMember"
      decimals="-3"
      id="Fact001805"
      unitRef="USD">2497000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-02-13"
      decimals="-3"
      id="Fact001807"
      unitRef="USD">500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2025-04-11_custom_AprilTwoThousandTwentyFivePromissoryNoteMember"
      decimals="-3"
      id="Fact001809"
      unitRef="USD">360000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="From2025-04-112025-04-11_custom_AprilTwoThousandTwentyFivePromissoryNoteMember"
      id="Fact001811">2025-06-11</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2025-04-112025-04-11_custom_AprilTwoThousandTwentyFivePromissoryNoteMember"
      decimals="INF"
      id="Fact001813"
      unitRef="Pure">0.080</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2025-07-18_us-gaap_SeriesHPreferredStockMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001815"
      unitRef="Shares">8889</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2025-07-182025-07-18_us-gaap_SeriesHPreferredStockMember_srt_MaximumMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001817"
      unitRef="Shares">880099</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="AsOf2025-07-18_us-gaap_SeriesHPreferredStockMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001819"
      unitRef="USDPShares">7.01</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-07-18_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001821"
      unitRef="Shares">467836</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-18_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001823"
      unitRef="USDPShares">22.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2025-07-182025-07-18_us-gaap_SeriesHPreferredStockMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001825"
      unitRef="Shares">2222</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2025-07-182025-07-18_us-gaap_SeriesHPreferredStockMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="-3"
      id="Fact001827"
      unitRef="USD">2222000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2025-07-18_us-gaap_WarrantMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001829"
      unitRef="Shares">116960</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2025-07-18_us-gaap_WarrantMember_custom_JulyTwoThousandTwentyFivePurchaseAgreementMember"
      decimals="INF"
      id="Fact001831"
      unitRef="USDPShares">22.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-09-162025-09-16_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001833"
      unitRef="Shares">74114</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2025-09-162025-09-16_custom_SecuritiesPurchaseAgreementMember_custom_PreFundedWarrantsMember"
      decimals="INF"
      id="Fact001835"
      unitRef="Shares">217090</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2025-01-01to2025-09-30" id="Fact001837">&lt;p id="xdx_80D_eus-gaap--SubsequentEventsTextBlock_zn0OXT22izV6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NOTE
15 - &lt;span id="xdx_826_zD9ov2aKc8Ul"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 30, 2025, the Second Closing of the July 2025 Private Placement was consummated&#x2014;see note 6.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#xdx2ixbrl0139"
          xlink:label="xdx2ixbrl0139"
          xlink:type="locator"/>
        <link:footnote id="Footnote000232" xlink:label="Footnote000232" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Adjusted
    to reflect the reverse stock splits (see note 6).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0139"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0140"
          xlink:label="xdx2ixbrl0140"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0140"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0158"
          xlink:label="xdx2ixbrl0158"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0158"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0159"
          xlink:label="xdx2ixbrl0159"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0159"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0196"
          xlink:label="xdx2ixbrl0196"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0196"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0197"
          xlink:label="xdx2ixbrl0197"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0197"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000199"
          xlink:label="Fact000199"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000199"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000200"
          xlink:label="Fact000200"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000200"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000218"
          xlink:label="Fact000218"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000218"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000219"
          xlink:label="Fact000219"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000219"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000221"
          xlink:label="Fact000221"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000221"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000222"
          xlink:label="Fact000222"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000222"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000224"
          xlink:label="Fact000224"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000224"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000225"
          xlink:label="Fact000225"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000225"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000227"
          xlink:label="Fact000227"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000227"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000228"
          xlink:label="Fact000228"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000228"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000230"
          xlink:label="Fact000230"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000230"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000231"
          xlink:label="Fact000231"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000231"
          xlink:to="Footnote000232"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000339"
          xlink:label="Fact000339"
          xlink:type="locator"/>
        <link:footnote id="Footnote000390" xlink:label="Footnote000390" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Adjusted
    to reflect the reverse stock splits (see note 6).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000339"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000341"
          xlink:label="Fact000341"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000341"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000343"
          xlink:label="Fact000343"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000343"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000345"
          xlink:label="Fact000345"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000345"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000347"
          xlink:label="Fact000347"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000347"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000349"
          xlink:label="Fact000349"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000349"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000351"
          xlink:label="Fact000351"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000351"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000353"
          xlink:label="Fact000353"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000353"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000355"
          xlink:label="Fact000355"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000355"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000357"
          xlink:label="Fact000357"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000357"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000359"
          xlink:label="Fact000359"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000359"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000361"
          xlink:label="Fact000361"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000361"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000363"
          xlink:label="Fact000363"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000363"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000365"
          xlink:label="Fact000365"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000365"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000367"
          xlink:label="Fact000367"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000367"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000369"
          xlink:label="Fact000369"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000369"
          xlink:to="Footnote000390"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000395"
          xlink:label="Fact000395"
          xlink:type="locator"/>
        <link:footnote id="Footnote000878" xlink:label="Footnote000878" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Adjusted
    to reflect the reverse stock splits (see note 6).</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000395"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000396"
          xlink:label="Fact000396"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000396"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000407"
          xlink:label="Fact000407"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000407"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0412"
          xlink:label="xdx2ixbrl0412"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0412"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000413"
          xlink:label="Fact000413"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000413"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000418"
          xlink:label="Fact000418"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000418"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0423"
          xlink:label="xdx2ixbrl0423"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0423"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0424"
          xlink:label="xdx2ixbrl0424"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0424"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000429"
          xlink:label="Fact000429"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000429"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0434"
          xlink:label="xdx2ixbrl0434"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0434"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0435"
          xlink:label="xdx2ixbrl0435"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0435"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000442"
          xlink:label="Fact000442"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000442"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0447"
          xlink:label="xdx2ixbrl0447"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0447"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000448"
          xlink:label="Fact000448"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000448"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0458"
          xlink:label="xdx2ixbrl0458"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0458"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000459"
          xlink:label="Fact000459"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000459"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0467"
          xlink:label="xdx2ixbrl0467"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0467"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000468"
          xlink:label="Fact000468"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000468"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0476"
          xlink:label="xdx2ixbrl0476"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0476"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000477"
          xlink:label="Fact000477"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000477"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0487"
          xlink:label="xdx2ixbrl0487"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0487"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000488"
          xlink:label="Fact000488"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000488"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0496"
          xlink:label="xdx2ixbrl0496"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0496"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0497"
          xlink:label="xdx2ixbrl0497"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0497"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0505"
          xlink:label="xdx2ixbrl0505"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0505"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0506"
          xlink:label="xdx2ixbrl0506"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0506"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000514"
          xlink:label="Fact000514"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000514"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000515"
          xlink:label="Fact000515"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000515"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000526"
          xlink:label="Fact000526"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000526"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000531"
          xlink:label="Fact000531"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000531"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000532"
          xlink:label="Fact000532"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000532"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000539"
          xlink:label="Fact000539"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000539"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0544"
          xlink:label="xdx2ixbrl0544"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0544"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000545"
          xlink:label="Fact000545"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000545"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000550"
          xlink:label="Fact000550"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000550"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0555"
          xlink:label="xdx2ixbrl0555"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0555"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000556"
          xlink:label="Fact000556"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000556"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000560"
          xlink:label="Fact000560"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000560"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0565"
          xlink:label="xdx2ixbrl0565"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0565"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0566"
          xlink:label="xdx2ixbrl0566"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0566"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000570"
          xlink:label="Fact000570"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000570"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0575"
          xlink:label="xdx2ixbrl0575"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0575"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0576"
          xlink:label="xdx2ixbrl0576"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0576"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000580"
          xlink:label="Fact000580"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000580"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0585"
          xlink:label="xdx2ixbrl0585"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0585"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000586"
          xlink:label="Fact000586"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000586"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0595"
          xlink:label="xdx2ixbrl0595"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0595"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0596"
          xlink:label="xdx2ixbrl0596"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0596"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000601"
          xlink:label="Fact000601"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000601"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0606"
          xlink:label="xdx2ixbrl0606"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0606"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000607"
          xlink:label="Fact000607"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000607"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0616"
          xlink:label="xdx2ixbrl0616"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0616"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000617"
          xlink:label="Fact000617"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000617"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0625"
          xlink:label="xdx2ixbrl0625"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0625"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000626"
          xlink:label="Fact000626"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000626"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0635"
          xlink:label="xdx2ixbrl0635"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0635"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000636"
          xlink:label="Fact000636"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000636"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0644"
          xlink:label="xdx2ixbrl0644"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0644"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000645"
          xlink:label="Fact000645"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000645"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000649"
          xlink:label="Fact000649"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000649"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0654"
          xlink:label="xdx2ixbrl0654"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0654"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000655"
          xlink:label="Fact000655"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000655"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0663"
          xlink:label="xdx2ixbrl0663"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0663"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0664"
          xlink:label="xdx2ixbrl0664"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0664"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000668"
          xlink:label="Fact000668"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000668"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0673"
          xlink:label="xdx2ixbrl0673"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0673"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0674"
          xlink:label="xdx2ixbrl0674"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0674"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0682"
          xlink:label="xdx2ixbrl0682"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0682"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0683"
          xlink:label="xdx2ixbrl0683"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0683"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000691"
          xlink:label="Fact000691"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000691"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000692"
          xlink:label="Fact000692"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000692"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000699"
          xlink:label="Fact000699"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000699"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000704"
          xlink:label="Fact000704"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000704"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000705"
          xlink:label="Fact000705"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000705"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000716"
          xlink:label="Fact000716"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000716"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0721"
          xlink:label="xdx2ixbrl0721"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0721"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000722"
          xlink:label="Fact000722"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000722"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0730"
          xlink:label="xdx2ixbrl0730"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0730"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0731"
          xlink:label="xdx2ixbrl0731"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0731"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000739"
          xlink:label="Fact000739"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000739"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0740"
          xlink:label="xdx2ixbrl0740"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0740"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000745"
          xlink:label="Fact000745"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000745"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0750"
          xlink:label="xdx2ixbrl0750"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0750"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0751"
          xlink:label="xdx2ixbrl0751"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0751"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000759"
          xlink:label="Fact000759"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000759"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000760"
          xlink:label="Fact000760"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000760"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000771"
          xlink:label="Fact000771"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000771"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000776"
          xlink:label="Fact000776"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000776"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000777"
          xlink:label="Fact000777"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000777"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000788"
          xlink:label="Fact000788"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000788"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000793"
          xlink:label="Fact000793"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000793"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000794"
          xlink:label="Fact000794"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000794"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000805"
          xlink:label="Fact000805"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000805"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0810"
          xlink:label="xdx2ixbrl0810"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0810"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000811"
          xlink:label="Fact000811"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000811"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000819"
          xlink:label="Fact000819"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000819"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0820"
          xlink:label="xdx2ixbrl0820"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0820"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000825"
          xlink:label="Fact000825"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000825"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0830"
          xlink:label="xdx2ixbrl0830"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0830"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0831"
          xlink:label="xdx2ixbrl0831"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0831"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0839"
          xlink:label="xdx2ixbrl0839"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0839"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0840"
          xlink:label="xdx2ixbrl0840"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0840"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000848"
          xlink:label="Fact000848"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000848"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000849"
          xlink:label="Fact000849"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000849"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000860"
          xlink:label="Fact000860"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000860"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000865"
          xlink:label="Fact000865"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000865"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000866"
          xlink:label="Fact000866"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000866"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000877"
          xlink:label="Fact000877"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000877"
          xlink:to="Footnote000878"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
